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Abstract 
Pseudomonas aeruginosa is a Gram-negative bacterium responsible for a wide 
range of opportunistic hospital-acquired infections. However metallo-β-lactamases 
(MBLs) encoding resistance to carbapenems and other β-lactam antibiotics – which 
are important agents for the treatment of P. aeruginosa infections – are 
increasingly reported in the species worldwide. This study aimed to characterise a 
comprehensive collection of MBL-producing P. aeruginosa referred to the UK 
national reference laboratory from 267 patients between 2003 and 2012. VIM-type 
MBLs predominated (91%) but a few IMP- and NDM-type enzymes were also 
identified. Diverse types were identified amongst these isolates using nine-locus 
variable number tandem-repeat (VNTR) analysis, but the majority (85%) belonged 
to six major complexes, corresponding to sequence types (STs) 111, 233, 235, 357, 
654/964 and 773, respectively, by multi-locus sequence typing (MLST). These are all 
‘high-risk clones’ frequently reported internationally as hosts of MBLs. blaVIM- and 
blaIMP-MBL genes were carried in diverse class 1 integron structures; the six most 
common integron structures (I-VI) carried blaVIM-2 (n=5) or blaVIM-6 (n=1) genes; four 
were associated with single STs (I, ST111; III, ST773; IV, ST654/964; V,ST357) while 
two integrons types (II,VI) were seen in multiple STs. Five of these six integrons 
were located on the P. aeruginosa chromosome, while one (VI) was located on a 
plasmid. VIM-encoding genomic islands were characterised in representatives of 
STs 111, 233 and 235 using whole genome sequencing (WGS) methods. SNP analysis 
achieved greater discrimination among MBL-producing representatives of STs 111 
and 235. CRISPR-Cas bacterial defence systems were absent from all sequenced 
representatives of STs 111 and 235 but were present in single representatives of STs 
233, 357, 654 and 773. Overall, ‘high-risk clones’ are important in the spread of 
MBL-producing P. aeruginosa in the UK. Future work should focus on further 
elucidating the reasons for the success of these clones, to better understand how to 
limit the spread of these multi-drug resistant organisms.   
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1 Introduction 
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1.1 Pseudomonas genus 
The genus Pseudomonas was first proposed by Migula in 1894 as a bacterial group 
of “cells with polar organs of motility”.1 Over the next 70 years a large number of 
diverse strictly aerobic Gram-negative rods that were motile by one or several polar 
flagella, were placed in the genus.2 DNA and RNA hybridisation studies in the 1960s 
and 70s, identified at least five main sub-divisions sharing little sequence 
homology.1,2 This diversity was confirmed by sequencing of 16S rRNA, and 
housekeeping genes such as rpoB and, consequently, since the 1980s many former 
Pseudomonas species were moved into other new or existing genera, including 
Burkholderia, Comamonas, Pandoraea, Ralstonia, and Stenotrophomonas.2  
Despite these reclassifications, there are still some 225 species in the genus 
Pseudomonas according to the List of Prokaryotic Names with Standing in 
Nomenclature3 (http://www.bacterio.net/pseudomonas.html; last accessed 20th 
November 2015). They predominantly occupy soil- and water-associated 
environments and are noted for their metabolic and physiological flexibility.4  
Phenotypic features of these Pseudomonas spp. are described in the current edition 
of the Bergey’s Manual of Bacteriology, and include cell morphology, cell wall 
composition, pigment types, nutritional and metabolic characteristics, and 
susceptibility to different compounds.2,5 However, these phenotypic features do not 
discriminate absolutely between Pseudomonas spp. and those of other genera, and 
so genotypic methods including 16S and rpoB gene sequencing are increasingly 
necessary to identify new species.2,5  
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Seven main subgroups were identified in the genus, namely the Pseudomonas 
aeruginosa, Pseudomonas chlororaphis, Pseudomonas fluorescens, Pseudomonas 
pertucinogena, Pseudomonas putida, Pseudomonas stutzeri and Pseudomonas 
syringae groups.2 P. aeruginosa, the type species, and common opportunistic 
human pathogen, is in an important member of the genus and is discussed in more 
detail later in this chapter. Other well-studied species are the plant pathogen P. 
syringae, of which there are many different pathovars each infecting different plant 
species, the saprotrophic organism P. putida, and the insect pathogen  
Pseudomonas entomophilia, which is lethal to Drosophila melanogaster.4  
Members of the genus have diverse applications in industry. Some are used as 
biocontrol agents in agriculture (e.g. P. fluorescens and P. putida),4,6 or as plant 
growth promoters (e.g. P. fluorescens and P. stutzeri).4 Several are being 
investigated for their ability to produce insecticides, for example, the Fit toxin 
identified in strains of P. fluorescens, and P. chlororaphis is active against insect 
pests including the tobacco budworm Heliothis virescens and the greater wax moth 
Galleria mellonela.7 Members of the genus are also useful bioremediation agents 
due to their ability to degrade aromatic hydrocarbons; for example, P. putida can 
degrade benzene, toluene and ethylbenzene8 and P. aeruginosa strains have been 
isolated from soil and groundwater contaminated with petroleum by-products.4 
1.2 Pseudomonas aeruginosa general biology 
P. aeruginosa infection (though not the organism) was recognised in the clinical 
setting as early as 1850, by Sedillot, as a result of the blue-green discolouration of 
wound dressings that it causes.9  Pyocyanin, the pigment responsible for this colour 
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was first extracted by Fordos in 1860,9 while the earliest description of the culture 
of the organism was by Gessard in 1882.10 The species was referred to by several 
different names, including Bacillus pyocyaneus and Bacterium aeruginosa, before 
finally being classified as P. aeruginosa.1,11 
P. aeruginosa grows well in a variety of conditions including  at temperatures up to 
42oC, and is noted for its sweet grape-like odour, as well as the pyocyanin (blue-
green) and pyoverdin (yellow-green) pigments, produced by most, but not all 
strains.12 Other distinguishing features include the species inability to ferment 
lactose and positive oxidase and catalase test results.12 Colonies are often large and 
round, although their morphology can vary; some representatives, particularly from 
cystic fibrosis patients with chronic lung infections, display a mucoid colony 
phenotype.12 The species has minimal nutritional requirements and utilises a wide 
range of organic compounds as energy and carbon sources. As with other 
Pseudomonas spp., P. aeruginosa is tolerant of many environmental conditions, 
grows particularly well in moist environments, and interacts with a wide range of 
hosts, including plants, nematodes, fruit flies and mammals.4,13 It is well known as 
an opportunistic human pathogen, as discussed below. 
The P. aeruginosa genome is large in size, compared to other Gram-negative 
bacteria, varying between 6-7 Mb and having a high GC content (~67%).14 Like other 
members of its genus, the species is noted for its high level of recombination, and 
the acquisition of genes is thought to have played an important part in its evolution, 
conferring the ability to thrive in diverse environments.4  P. aeruginosa genomes 
have a mosaic structure including a conserved core interspersed with blocks of 
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accessory genes. A recent estimate, based on available genome sequences, suggest 
there are around 5233 core genes, accounting for around 88% of the average 
genome.14 
1.3 P. aeruginosa as an opportunistic pathogen 
P. aeruginosa infections are rare in healthy individuals, but the species is an 
important human opportunistic pathogen, and infections are particularly prevalent 
in hospital settings. P. aeruginosa was the second most-frequently-isolated Gram-
negative species, after Escherichia coli, in a recent point prevalence survey of 
health-care-associated infections in Europe, by the European Centre for Disease 
Prevention and Control (ECDC), where it accounted for 8.3% of infections.15 P. 
aeruginosa infections are less common in community settings but can include 
keratitis, dermatitis, folliculitis, otitis externa, osteomyelitis and septic arthritis.16  
 Common P. aeruginosa infections in the hospital setting 1.3.1
Hospital-acquired P. aeruginosa infections are largely seen in the most vulnerable 
patients such as the immunocompromised, critically ill, or injured. While infections 
can affect almost any part of the body, the respiratory tract is the most common 
site, while urinary tract, blood, and wound infections are often seen. Frequent 
examples include ventilator-associated pneumonia in intensive care patients, 
wound infections in burns patients, urinary tract infections associated with 
indwelling devices such as catheters, and bacteraemias.13,16 The species is also one 
of the principal causes of chronic lung infection in cystic fibrosis patients and of 
those with bronchiectasis and chronic obstructive pulmonary disease. 
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 P. aeruginosa hospital outbreaks 1.3.2
P. aeruginosa can colonise many surfaces in hospitals such as taps, showers, 
ventilators and catheters. This colonisation can be an important source of infection 
in a clinical setting.16 There are many reports of P. aeruginosa hospital outbreaks, 
often associated with contaminated water outlets;  other environmental sources 
(e.g. ventilators, bronchoscopes) and, occasionally, colonised health-care workers 
are implicated.16,17 The exact routes of transmission between these sources and 
patients are not always apparent.17 A variety of infection prevention and control 
measures are usually implemented to bring outbreaks under control including 
improved hand hygiene, screening and isolation of affected patients, and 
decontamination of potential environmental sources.16  
Recent examples of UK outbreaks include those that occurred in several neo-natal 
critical care units in Northern Ireland in late 2011 and early 2012, resulting in four 
deaths.18 Investigations found that tap components from the affected hospitals 
were contaminated with the same P. aeruginosa strain seen in patients at each site 
suggesting that these water outlets could have acted as an environmental sources 
of the infections, although the presence of other sources could not be ruled out.18  
 Virulence factors 1.3.3
P. aeruginosa produces a wide variety of virulence factors that help it to evade 
human host defences.13,19 These include flagella and pili, which are involved in 
motility and adhesion and can also elicit an inflammatory response; a type 3 
secretion system, which is involved with the injection of toxic proteins into host 
cells; secreted proteases, which can contribute to tissue damage; and 
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lipopolysaccharide (LPS), which is a major component of the outer membrane (as in 
other Gram-negative bacteria) and is inherently toxic.19  Like many other bacteria, P. 
aeruginosa has a quorum sensing mechanism which co-ordinates adaptation to its 
environment;13 this mechanism can regulate many virulence factors and also 
contributes to the formation of biofilms. These biofilms are complex communities 
of bacteria that enable attachment and persistence in the environment. They are 
also important for the establishment of chronic infections in the lungs in cystic 
fibrosis patients.20 Biofilms are hard to eradicate due to a variety of factors 
including (i) the poor penetration of disinfectants, antibiotics and effectors of the 
host’s immune system, and (ii) the presence of slow-growing bacteria that are not 
killed by antibiotics.19,21 
1.4 General resistance mechanisms of P. aeruginosa 
 Commonly used antibiotics 1.4.1
P. aeruginosa is intrinsically resistant to many antimicrobial agents, due to 
interactions between several underlying mechanisms. One of the principal 
mechanisms is the organisms low outer membrane permeability compared with 
other Gram-negative species, thus reducing transport of many antibiotics across the 
membrane.22 P. aeruginosa also expresses several efflux pumps including the 
MexAB-OprM system,23 which can rapidly exclude many diverse molecules, 
including some antibiotics, from the bacterial cell. In addition, P. aeruginosa has a 
chromosomally-encoded AmpC β-lactamase.24 As a result of these mechanisms, the 
species is naturally resistant to many antibiotics and therapeutic options are 
generally limited to certain aminoglycosides, fluoroquinolones and β-lactams (table 
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1.1, figure 1.1). A combination of mutational and acquired resistance mechanisms 
can lead to resistance to almost all antimicrobial agents22 and as a last resort, 
against multi-resistant strains, polymyxin antibiotics are sometimes used. This 
section will cover the major agents used to treat P. aeruginosa infections and the 
prevalent resistance mechanisms of the species to these antibiotics; these are 
summarised in table 1.1. 
 Table 1.1: Resistance mechanisms of P. aeruginosa against major antibiotic classes used to treat infections with the species 
Class Examples                                          Resistance mechanisms 
  Chromosomal Acquired enzymes 
Aminoglycosides amikacin, gentamicin, 
tobramycin 
• Increased efflux (particularly MexXY-OprM 
pump) 
• Reduced cytoplasmic membrane transport 
• Aminoglycoside-modifying enzymes (AMEs)  
• 16S rRNA methylases (very rare) 
Fluoroquinolones ciprofloxacin, 
levofloxacin 
 
• Mutations in quinolone resistance determining 
region (QRDR) of gyrA, gyrB, parC, parE genes 
• Increased efflux (MexAB-OprM, MexCD-OprJ, 
MexEF-OprN and MexXY-OprM pumps) 
• Aminoglycoside acetyltransferase variant  
aac(6’)-Ib-cr (reduces susceptibility to ciprofloxacin) 
β-Lactams 
 
 • Increased efflux; particularly MexAB-OprM 
pump (resistance to all β-lactams except 
imipenem) 
 
• Overexpression of AmpC β-lactamase (resistance 
to all β-lactams except the carbapenems and 
carbenicillin)  
 
• Lower outer membrane permeability due to 
OprD porin loss (resistance only to imipenem 
and reduced susceptibility to meropenem) 
 
• Acquired penicillinases e.g. TEM-1/2, PSE-1/4 
(resistance only to penicillins) 
 
• Extended spectrum β-lactamases e.g. PER-1, VEB-1 
(resistance to all β-lactams except carbapenems) 
 
• Carbapenemases (resistance to most β-lactams 
including carbapenems; see also Section 1.5.3): 
– Class A (e.g. KPC, GES-5)  
– Class B /MBLs (e.g. VIM, IMP, NDM; these 
enzymes do not confer resistance to aztreonam) 
– Class D (e.g. OXA-48-like; these enzymes do not 
confer resistance to the cephalosporins) 
Carboxypenicillins 
 
carbenicillin, ticarcillin 
Ureidopenicillins piperacillin 
3
rd
 generation 
Cephalosporins 
 
ceftazidime 
4
th
 generation 
Cephalosporins 
 
cefepime, cefpirome 
Monobactams 
 
aztreonam 
Carbapenems imipenem, meropenem, 
doripenem 
Polymyxins colistin, polymyxin B 
 
• Mutations affecting LPS biosynthesis  
2
4 
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Figure 1.1: Chemical structures of main antibiotic classes used to treat P. 
aeruginosa infections 
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 Aminoglycosides 1.4.2
Aminoglycosides are bactericidal antibiotics that disrupt protein synthesis by 
binding to the 30S subunit of the bacterial ribosome, causing misreading.25 
Members of this class that are most commonly used – often in combination with β-
lactams – to treat P. aeruginosa infections include amikacin (figure 1.1), gentamicin 
and tobramycin. Increased efflux, particularly associated with the MexXY-OprM 
efflux pump, is a major mechanism of resistance to aminoglycosides in P. 
aeruginosa.26 Reduced cytoplasmic membrane transport, thought to be related to 
PhoP and PhoQ activity also contributes to resistance to aminoglycosides, possibly 
as a result of modifications of the LPS component of the outer membrane. 27  
Acquired mechanisms are less commonly seen, but include aminoglycoside-
modifying enzymes (AMEs) belonging to three main classes; acetyltransferases 
(AACs), nucleotidyltransferases (ANTs) and phosphotransferases (APHs)25 with 
members of all three AME classes described in P. aeruginosa.27 Although none of 
the AMEs confers resistance to all antibiotics in the class, multiple enzymes can be 
present in the same strain and, in combination, can do so. Acquired genes encoding 
16S rRNA methylases such as RmtA and RmtD, are reported, albeit rarely, in the 
species, in Japan and Brazil respectively, and confer pan-aminoglycoside 
resistance.28,29  
 Fluoroquinolones 1.4.3
Fluoroquinolones are inhibitors of DNA synthesis by their interactions with the 
bacterial DNA gyrase and topoisomerase IV enzymes. Members of this class used to 
treat P. aeruginosa infections include ciprofloxacin (figure 1.1) and levofloxacin. 
27 
 
Major mechanisms of resistance are mutations in the quinolone resistance 
determining region (QRDR) of genes encoding the DNA gyrase (gyrA or gyrB) or 
topoisomerase IV (parC or parE) enzymes.26 Mutations causing overexpression of 
efflux pumps, including the MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-
OprM pumps can also reduce susceptibility.26 The only acquired fluoroquinolone 
resistance determinant seen in P. aeruginosa is aac(6’)-Ib-cr30 encoding the AAC(6’)-
Ib-cr enzyme; this has two amino acid substitutions compared with AAC(6’)-Ib, 
which allow it to acetylate some fluoroquinolones (including ciprofloxacin but not 
levofloxacin), in addition to aminoglycosides.25,31 Other plasmid-mediated 
quinolone resistance genes, such as qnr-type, oqxAB and qepA that are seen in 
Enterobacteriaceae are not reported in P. aeruginosa. 
 β-Lactams  1.4.4
β-Lactams are a large class of antibiotics that target the bacterial D-alanyl-D-alanine 
transpeptidase enzymes (also known as penicillin-binding proteins), thus inhibiting 
cross-linking of the peptidoglycan bacterial cell wall. P. aeruginosa is intrinsically 
resistant to many β-lactams due to its low membrane permeability relative to other 
bacterial species, constitutive expression of efflux pumps, and a chromosomally-
encoded AmpC-type β-lactamase.  
Members of this antibiotic class that do usually remain active against P. aeruginosa 
are limited to carboxypenicillins (e.g. carbenicillin), ureidopenicillins (e.g. 
piperacillin), some third- (e.g. ceftazidime) and all fourth-generation (e.g. cefepime) 
cephalosporins, monobactams (e.g. aztreonam) and carbapenems (e.g. imipenem, 
meropenem and doripenem but not ertapenem).26 Structures of these antibiotics 
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are shown in figure 1.2. Carbapenems are particularly important as they have the 
broadest spectrum of activity against Gram-negative bacteria; they are discussed 
further in Section 1.5.   
Mutations affecting the species’ intrinsic resistance mechanisms are a major cause 
of resistance to ‘antipseudomonal’ β-lactams. Mutants that overexpress the 
chromosomal AmpC-type β-lactamase are generally resistant to all β-lactams, 
except for the carbapenems and, to a large extent, carbenicillin.9 Mutations leading 
to increased expression of efflux pumps, particularly the MexAB-OprM system, can 
also cause resistance to most β-lactams including the carbapenems meropenem 
and doripenem, but not imipenem. Reduced membrane permeability via loss of the 
OprD porin, confers resistance to imipenem and reduces meropenem 
susceptibility.9   
Acquired β-lactamases can also confer resistance although they are uncommon in 
the species compared with Enterobacteriaceae. They include (i) acquired 
penicillinases (e.g. TEM-1/2 PSE-1/4) conferring resistance to the penicillin 
antibiotics, (ii) extended-spectrum β-lactamases (ESBLs) (e.g. PER-1, VEB-1, LCR-1), 
which compromise all β-lactam antibiotics except carbapenems, and (iii) 
carbapenemases (e.g. VIM, IMP, NDM, KPC, OXA-48-like), which hydrolyse most or 
all β-lactams including carbapenems (although OXA-48-like enzymes do not confer 
resistance to cephalosporins, and aztreonam is stable against VIM, IMP and NDM 
types). Carbapenemases, though still rare, are increasingly being seen in P. 
aeruginosa
32 and will be covered in more detail in the following sections. 
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Figure 1.2: Structures of β-lactam antibiotics used to treat P. aeruginosa infections 
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 Polymyxins 1.4.5
Colistin (polymyxin E) and polymyxin B (figure 1.1) disrupt the bacterial outer 
membrane by binding to LPS. They were first used in the 1940s but, due to their 
neurotoxic and nephrotoxic side-effects, their intravenous use for treatment of P. 
aeruginosa infections was largely abandoned in the 1960s, once aminoglycosides 
and carbenicillin became available. Colistin is used as a nebulised drug for CF 
patients and is then considered relatively safe as there is little absorption across the 
lungs to other tissues. The intravenous formulations have also been readopted in 
recent years due to the increase of multi-drug resistant infections.33 Although 
susceptibility rates to these agents in P. aeruginosa remain high, resistance has 
been reported, generally due to mutations affecting LPS integrity and modification 
of its lipid A moiety.34,35 
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1.5  Resistance mechanisms to carbapenems in P. aeruginosa 
 Carbapenem antibiotics  1.5.1
The general structure of the carbapenem antibiotics is shown in figure 1.3. They 
differ from other β-lactams by the lack of a sulphur atom in the thiazolidinic ring, 
and in having a 6’ hydroxyethyl side chain rather than an amino-acyl substituent. 
These modifications increase stability to most β-lactamases.36  
 
Figure 1.3: General structure of the penicillin and carbapenem antibiotics 
 
Carbapenems are broad-spectrum agents, often considered as ‘antibiotics of last 
resort’ and used to treat serious infections. The first drug to be approved for use 
was imipenem, in the 1980s, followed by meropenem, ertapenem and more 
recently doripenem. Ertapenem is not active against P. aeruginosa, possibly owing 
to increased efflux and/or decreased uptake, due to its large side chain.37 However, 
imipenem, meropenem and doripenem are important agents against this species.36 
Carbapenem resistance in P. aeruginosa is increasingly seen worldwide. Data from 
the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 
bloodstream isolates from 2013 (figure 1.4) show a clear resistance gradient across 
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Europe, with resistance rates ranging from 2.9% in Denmark, to 60.5% in Romania; 
the rate in the UK was 5.2%. 
Carbapenem resistance and Pseudomonas spp. is one of the key drug-bug 
combinations recommended for monitoring of resistance in the UK Five Year 
Antimicrobial Resistance Strategy 2013 to 2018.38 Resistance rates are higher in 
chronic P. aeruginosa infections, such as in the lungs of cystic fibrosis patients, 
which progressively become resistant to multiple antibiotics including 
carbapenems.39,40 
 
Figure 1.4: Proportion of carbapenem resistant P. aeruginosa isolates in 
participating countries of the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) in 2013. Map obtained from the EARS-Net Antimicrobial 
Resistance Interactive Database (ecdc.europa.eu/en/healthtopics/antimicrobial_ 
resistance/database/Pages/database.aspx; last accessed on 3rd November 2015). 
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 Resistance mechanisms to carbapenems 1.5.2
Imipenem resistance in P. aeruginosa is most commonly due to reduced 
permeability, as a result of mutations causing loss of the OprD porin, while 
meropenem- and doripenem-resistant strains generally have a combination of porin 
loss and upregulated efflux, possibly coupled with constitutive AmpC expression.26 
Acquired carbapenemases are, however, increasingly being seen in the species 
worldwide.22 These enzymes, which also confer resistance to most other β-lactam 
antibiotics, pose a growing and major problem in P. aeruginosa as they frequently 
occur in isolates already resistant to multiple other drug classes, leaving few 
treatment options. 
 Carbapenemases  1.5.3
Acquired carbapenemases are seen in three of the four Ambler β-lactamase classes 
(A, B and D) and are discussed below. Carbapenemases of all these three classes 
have been found in P. aeruginosa isolates with those belonging to class B being the 
most common.  
1.5.3.1 Class A carbapenemases 
Class A enzymes are serine carbapenemases; they include KPC enzymes and those 
GES variants that have carbapenemase activity. Genes encoding KPC enzymes are 
found on transposable elements and transferable plasmids and are mostly seen in 
Enterobacteriaceae, particularly Klebsiella pneumoniae where they were 
discovered.41 However P. aeruginosa producing KPC-2 carbapenemases are 
reported to be widespread in Latin America,42–44  the Caribbean45,46 and China47  
although they have not been reported in this species in the UK or the rest of Europe 
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nor in mainland North America. GES variants with carbapenemase activity include 
GES-5, which has been recently detected in P. aeruginosa from an outbreak in 
Spain48, and in sporadic isolates from India,49 Turkey50,  South Africa51, Brazil 52 and 
China.53 A few P. aeruginosa producing GES-5 carbapenemases have also been 
submitted to Public Health England’s (PHE) Antimicrobial Resistance and Healthcare 
Associated Infections (AMRHAI) Reference Unit, from UK labs, over recent years 
(unpublished data). Other GES variants with carbapenemase activity are seen in P. 
aeruginosa and include GES-18 in Belgium54, GES-6 in Portugal,55 and GES-20, which 
was found to be widespread in the species in a recent multi-centre study in 
Mexico56.  
1.5.3.2 Class D carbapenemases 
Some class D (OXA) enzymes, also serine carbapenemases, are active against 
carbapenems. Several, including OXA-23, -40 and -58 are commonly seen in 
Acinetobacter baumannii, with OXA-40 and OXA-198 occasionally seen in P. 
aeruginosa.57,58 The OXA-48 carbapenemase, which is increasingly seen in 
Enterobacteriaceae has not been reported in P. aeruginosa, but the closely related 
enzyme, OXA-181, was recently seen in P. aeruginosa isolates submitted to 
AMRHAI, from a patient who was hospitalised in India (unpublished data).  
1.5.3.3 Class B carbapenemases 
Class B carbapenemases, also known as metallo-β-lactamases (MBLs), are 
widespread worldwide in P. aeruginosa, and are the most commonly reported 
carbapenemases in the species. These enzymes have a Zn2+ ion at their active site 
and can be distinguished from serine carbapenemases due to strong inhibition of 
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their activity by metal chelators, such as EDTA. MBLs are widely scattered in Gram-
negative species worldwide and can hydrolyse almost all β-lactam antibiotics 
including carbapenems, the exception being aztreonam to which P. aeruginosa is 
generally non-susceptible (according to EUCAST guidelines) for other reasons. A 
wide variety of MBLs are reported in P. aeruginosa as outlined in the following 
section.  
1.6 Metallo- β-lactamases 
Comprehensive epidemiological data for the worldwide occurrence and spread of 
MBLs in P. aeruginosa are not available and knowledge instead relies upon reports 
and surveys from particular countries or hospitals. The enzymes most widely seen 
globally in the species belong to the VIM and IMP families32, while other enzymes 
including the NDM, SPM, AIM, GIM and FIM MBLs are generally restricted to smaller 
geographical areas. MBL families and their epidemiology are outlined below. 
 IMP-type metallo-β-lactamases 1.6.1
IMP-1 was the first MBL to be reported in P. aeruginosa from Japan in 199159 Since 
then, a total of 53 different IMP alleles have been officially described in different 
species (www.lahey.org/Studies/other.asp; last accessed 19th November 2015). A 
phylogenetic tree showing the relationship between these enzymes is presented in 
figure 1.5. These enzymes vary in sequence, but with little effect on their spectrum 
of resistance.  Most variants are reported only in small geographical areas,32  but a 
few were seen across wider geographical ranges in P. aeruginosa, as well as other 
Gram-negative species. These include IMP-1 which, in addition to Japan, has been 
described in P. aeruginosa isolates from Singapore, Thailand, Brazil and Iran,52,60–62 
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and IMP-7, which has been reported in the species in Canada, Singapore, and 
central Europe.63–66 The enzymes are predominantly reported in Asian countries, 
and although several IMP variants were seen amongst P. aeruginosa in Europe, they 
are largely infrequent and geographically scattered and may represent imports from 
areas where the enzymes are more common.67 There are several reports of IMP-7-
producing P. aeruginosa in Poland, the Czech Republic and Slovakia65,68,69 suggesting 
that organisms encoding these enzymes may be circulating in central Europe. 
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Figure 1.5: Maximum-likelihood tree showing members of the IMP family of MBLs 
for which sequence data are available. Amino acid sequences were taken from 
GenBank using accession numbers detailed on the Lahey website 
(www.lahey.org/Studies/other.asp; last accessed 19th November 2015). The VIM-1 
sequence is included in the tree as an outgroup. The IMP alleles most commonly 
seen in P. aeruginosa are indicated by a star. Sequences were not available for IMP-
17, IMP-23, IMP-36, IMP-39, IMP-46, IMP-50 or IMP-53.  
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 VIM-type metallo-β-lactamases 1.6.2
The VIM-1 enzyme was first reported in 1999 in a P. aeruginosa isolate from Italy70 
and since then a total of 46 VIM-MBL variants have been assigned 
(www.lahey.org/Studies/other.asp; last accessed 19th November 2015) from P. 
aeruginosa and other Gram-negative species. The relationship between these 
enzymes is shown in figure 1.6. As with IMP-type MBLs, some variants, notably VIM-
2, are more widely reported than others. Three major subgroups are described, as 
shown in figure 1.6.71 Subgroup 1 includes the VIM-1 and VIM-4 variants that are 
commonly seen among P. aeruginosa in Europe, with VIM-1 having been reported 
in Italy, France and Greece72,73 while VIM-4 has been described in five European 
countries (Belgium, Greece, Hungary, Poland and Sweden)74–79 and also in Iran.62 
The most commonly seen enzyme in subgroup 2 is VIM-2, which is widespread 
worldwide, particularly in P. aeruginosa, and was the most commonly detected 
enzyme in a recent study of carbapenem-non-susceptible P. aeruginosa isolates 
from 14 European countries.80 VIM-2 enzymes have also been reported in P. 
aeruginosa from Canada,81 Colombia,82 Japan,83 Korea,84 Thailand,61 Saudi Arabia,85 
Singapore,64 South Africa86 and the USA.87 VIM-7 is the sole member of subgroup 3 
and has currently only been described in P. aeruginosa isolates in the USA.88,89     
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Figure 1.6: Maximum-likelihood tree showing members of the VIM family of MBLs 
for which sequence data are available. Amino acid sequences were taken from 
GenBank using accession numbers detailed on the Lahey website 
(www.lahey.org/Studies/other.asp; last accessed 19th November 2015). The IMP-1 
sequence is included as an outgroup. VIM alleles commonly seen in P. aeruginosa 
are indicated by a star. Sequences were not available for VIM-20, VIM-21, VIM-22, 
VIM-40, VIM-41 or VIM-46.  
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 Other metallo-β-lactamases 1.6.3
The NDM-1 MBL is believed to have emerged in India or Pakistan, and has become 
widely scattered in Enterobacteriaceae elsewhere.90 There are currently 16 
different alleles described (www.lahey.org/Studies/other.asp; last accessed 19th 
November 2015) of which NDM-1 remains the most widely reported.  There are 
several reports of P. aeruginosa isolates producing NDM MBLs in the Indian 
subcontinent,91,92 and it is suspected to be endemic in the Balkans region,93 with 
reports of the enzyme in other countries being associated with travel to these 
regions.94,95 Other MBLs reported in P. aeruginosa isolates remain largely restricted 
to the countries where they were originally found. They include SPM-1, which has 
become widespread in Brazil96,97 with only isolated cases seen elsewhere, from 
patients previously hospitalised in Brazil;  these include an isolate from a Swiss 
patient98 and an isolate received by AMRHAI in 2013 (unpublished data). Reports of 
P. aeruginosa with the AIM, GIM and FIM MBLs are restricted to Australia, Germany 
and Italy respectively.99–101  
1.7 Typing of P. aeruginosa 
As discussed above, P. aeruginosa infections are common in hospital settings, with 
outbreaks often seen. Discrimination between P. aeruginosa strains is therefore 
necessary to inform epidemiological studies. Typing can help to establish whether a 
temporal increase in P. aeruginosa cases is due to the spread of a specific strain or 
the accumulation of sporadic cases, informing appropriate infection control 
interventions. Typing is also used for longer term surveillance and can help to 
identify types that may cause difficult-to-treat infections. Finally, typing can be used 
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to describe the population genetics of bacteria when applied to large numbers of 
isolates from diverse sources.  
A variety of techniques are utilised for the typing of P. aeruginosa isolates with the 
most widely used including serotyping, pulsed-field gel electrophoresis (PFGE), 
variable number tandem-repeat (VNTR) analysis and multi-locus sequence typing 
(MLST). More recently, whole-genome sequencing (WGS) has been adopted for the 
molecular typing of several organisms including P. aeruginosa and offers a high level 
of discrimination. These typing methods, and their respective advantages and 
disadvantages will be discussed below.  
 Serotyping 1.7.1
Serotyping involves the detection of diverse O-antigens of the LPS, based on their 
reaction with particular anti-sera, and was previously the main reference method 
used for typing of many bacteria including P. aeruginosa.102 However, the method 
only offers crude discrimination compared with molecular methods, and some 
strains are not typable due to nonagglutination or polyagglutination.103 For these 
reasons its use has fallen into decline in recent years.  
 Pulsed-field gel electrophoresis (PFGE) 1.7.2
This method has been widely used and involves the digestion of DNA using specific 
rare-cutting restriction enzymes, most commonly SpeI for P. aeruginosa,104–106 and 
separation of the resulting fragments by PFGE. The DNA fingerprints thereby 
obtained can be compared for different isolates to determine their similarity. It is 
highly discriminatory, and useful for the investigation of single-hospital outbreaks. 
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However, it is labour intensive, has a long turnaround time and results are difficult 
to compare between laboratories due to differences in methodologies.  
 Variable number tandem-repeat analysis (VNTR) 1.7.3
VNTR analysis involves PCR amplification of multiple repetitive regions within the 
genome, known as tandem repeats. Due to a high mutation rate in these regions, 
resulting from strand slippage, deletion or insertion of repeat units often occurs. 
The variation in the length of these repeat regions can be detected by PCR using 
primers spanning the repeats and thereby sizing the resulting amplicons.  Several 
VNTR schemes are described for P. aeruginosa, each using a different selection of 
tandem-repeat loci. They include a 15-locus scheme,107 two nine-locus 
schemes,104,108 and a recently described 16-locus scheme, which incorporates loci 
from the two nine-locus schemes.109 VNTR offers shorter turnaround times than 
PFGE. It has a similarly high level of discrimination, and is useful for outbreak 
investigation.104 Due to the numerical nature of the resulting profiles it is easier to 
compare results between laboratories than for PFGE, although there is still the 
potential for interpretative differences, and as different laboratories may use 
different VNTR schemes, published data are not always readily comparable. 
 Multi-locus sequence typing (MLST) 1.7.4
MLST is increasingly used, with schemes being developed for many bacterial species 
in recent years. An MLST scheme for P. aeruginosa was proposed in 2004 by Curran 
et al.110 This technique involves sequencing seven housekeeping genes, with alleles 
of each gene being assigned a unique allele number, and each unique combination 
of alleles being used to define a sequence type (ST). STs sharing five or more of the 
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seven alleles are categorised as clonal complexes. The P. aeruginosa MLST scheme 
has a relatively low level of discrimination, with several VNTR or PFGE types often 
represented within a single ST.106,111 The method is more expensive than VNTR but 
it is readily transferable between laboratories and allows easy comparison of 
isolates in multiple hospitals, nationally or internationally. 
 Whole-genome sequencing (WGS) 1.7.5
The most definitive method for comparing isolates to each other is WGS. Unlike 
VNTR and MLST, which focus on specific areas of the genome, this method offers an 
overview of the whole genome, by the use of analyses such as single nucleotide 
polymorphism (SNP) analysis or whole genome MLST.112 A major advantage is that 
other aspects of the organism’s biology can be investigated in parallel, for example 
by seeking the presence of resistance or virulence determinants. The main barriers 
to the use of WGS methods in a clinical setting are high cost and the specialist 
knowledge needed for bioinformatic analyses of the resulting data. However, with 
improved technology and automated analysis pipelines, the method is fast 
becoming cheaper and accessible for a wide range of applications including for 
typing and outbreak investigation.  
1.8 P. aeruginosa ‘high-risk clones’ 
 Population structure of P. aeruginosa 1.8.1
In 1993, Smith et al. described bacterial population structures ranging from 
panmictic (i.e. with a random association between loci, due to a high level of 
recombination) to clonal, with an intermediate epidemic structure.113 MLST analysis 
of P. aeruginosa isolates has indicated that the species has a non-clonal epidemic 
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population structure i.e. it is predominantly panmictic but with occasional 
successful epidemic clones.110,114 This is consistent with several reports that have 
shown that, in general, clinical P. aeruginosa isolates are indistinguishable from 
environmental isolates in terms of typing data. For example, a recent study of 
isolates submitted to AMRHAI from UK hospitals showed considerable overlap 
between representatives from patient and environmental sources in the UK with 
the prevalent types found in diverse sources and locations.115 Pirnay and colleagues 
also investigated the population structure of P. aeruginosa using representatives 
collected from diverse environments in 30 countries over a 125 year time period. 
They confirmed the non-clonal epidemic structure, finding there was no specific 
disease habitat or geographical selection and that most isolates were diverse, but 
with occasional successful clones.103  
This population structure is illustrated in figure 1.7, showing an eBURST116  
population snapshot based on all types seen in the  P. aeruginosa MLST database 
(http://pubmlst.org/paeruginosa/; last accessed 20th November 2015), where most 
STs identified are singletons but with some clonal complexes consisting of closely 
related strains. Frequently-seen clones include clone C (ST17) and PA14 (ST253) as 
well as the Liverpool epidemic strain (ST146) commonly isolated from the lungs of 
cystic fibrosis patients.117 Additionally some successful lineages are termed ‘high-
risk clones’ and are thought to play a major role in the spread of resistance in P. 
aeruginosa, as described in the following section.118  
 
 
 
Figure 1.7: Population snapshot of the 2226 sequence types (ST) on the P. aeruginosa PubMLST database (http://pubmlst.org/paeruginosa/; 
last accessed 20th November 2015). The eBURST diagram was generated using the eBURST software v3 (available at 
http://eburst.mlst.net/default.asp).116 The algorithm identifies groups (termed clonal complexes) of related STs in a population and predicts 
the founding ST of each group. Each dot represents a different ST while lines connect single locus variants; blue dots show predicted primary 
founders, yellow dots show subgroup founders and black dots indicate all other STs. Founders of prevalent clonal complexes are labelled. 
4
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  Metallo-β-lactamases and ‘high-risk clones’ 1.8.2
‘High-risk clones’ are frequently associated with the carriage of diverse resistance 
genes including MBLs. A good early example is a multi-drug resistant clone of 
serotype O12 that was first reported in the 1980s, and is represented exclusively in 
clinical isolates. It has been associated with the expression of a variety of different 
resistance genes in European countries including the penicillinase PSE-1.119,120 The 
introduction of MLST has allowed the comparison of STs of multi-drug-resistant P. 
aeruginosa across the world and, although acquired MBLs are recorded in diverse 
STs, a large proportion of MBL-producing isolates belong to a few ‘high-risk 
clones’.118 The most common host STs worldwide include ST111, ST235 and ST175 
and isolates belonging to these clones often, but not exclusively, carry diverse 
resistance genes including MBLs. The worldwide distribution of these major lineages 
will be discussed in this section and is illustrated in figure 1.8. 
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Figure 1.8: Worldwide reports of P. aeruginosa ‘high-risk clones’ of sequence types 
(STs) 111, 235 and 175 carrying varied acquired resistance genes including blaMBL. 
Figure taken from Oliver et al.117 
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 ST111 ‘high-risk clone’ 1.8.3
ST111 is frequently described amongst MBL-producing P. aeruginosa, with isolates 
of this ST commonly reported to be of serotype O12, which has been recognised as 
a common host of multi-resistance in Europe since the 1980s (see above).120,121  
ST111 has been particularly associated with blaVIM-2 genes in Europe, and was the 
most common type in a nationwide study of MBL-producing P. aeruginosa in The 
Netherlands in 2010-11,121 as well as being responsible for outbreaks affecting 
hospitals in central Greece122 and Italy.123 ST111 isolates carrying blaVIM-2 genes have 
also been seen in smaller numbers in other European countries including 
Sweden,124 Croatia,125 Spain,126 Germany,127 Belgium80 and Portugal.80 Outside of 
Europe, ST111 was one of the most common types identified in a study of MBL-
producing P. aeruginosa in Colombia, again associated with blaVIM-2.
128 Isolates of 
ST111 have also been reported to carry a variety of other MBL genes including 
blaVIM-4 in Hungary,
74 blaVIM-1 in Greece
129 and blaIMP-13 in France,
130 while an 
outbreak of ST111 isolates carrying blaGIM-1 was recently reported in Germany.
131 An 
ST111 isolate from Colombia reportedly harboured a KPC-2 carbapenemase along 
with blaVIM-2.
132 Aside from carbapenemases, other resistance determinants 
reported among ST111 isolates include blaVEB-1 ESBL and blaPSE-1 penicillinase 
genes.30,133   
 ST235 ‘high-risk clone’ 1.8.4
ST235 has been widely reported around the world associated with a variety of 
MBLs. P. aeruginosa of ST235 are reported to belong to serotype O11, which was 
previously associated, though not exclusively, with multi-drug resistant  
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isolates.103,124,134,135 This ST was the most commonly identified among MBL-
producing P. aeruginosa in a study of five Mediterranean countries106 and an ST235 
clone with blaVIM-2 was found to be widespread across Russia, Belarus and 
Kazakhstan in a study conducted between 2002-2010.136 The ST was also associated 
with blaVIM-2 genes in Spain,
126 Croatia,125 Germany,127 Greece,129 Malaysia and Sri 
Lanka.137 Other blaVIM alleles associated with ST235 isolates including blaVIM-4 in 
Hungary,74 Norway,124 and Belgium,75 and blaVIM-13 in Spain.
138 blaIMP alleles are 
more commonly seen in the ST in Asia with blaIMP-6-carrying ST235 organisms 
causing outbreaks in Japan139 and South Korea.140 There are single reports of ST235 
isolates carrying blaNDM-1 and blaSPM-1 MBL genes in France,
94 and Brazil,97 
respectively. ST235 P. aeruginosa are also reported amongst KPC-2 and GES-5 
carbapenemase producers in Colombia128 and Spain, respectively, as well those 
carrying blaPSE-1 ESBL and blaPER-1 penicillinase genes.
48,75 
 ST175 ‘high-risk clone’ 1.8.5
ST175 has been described as a ‘high-risk clone’117 and is particularly widespread in 
Spain where it is often multi-drug resistant, with one Spanish hospital reporting a 
large outbreak of a VIM-2-MBL-producing ST175 clone.141,142 An outbreak involving 
a VIM-2-positive ST175 clone was also described in Germany.143 In addition to MBL-
producing strains, members of the ST also include strains not producing MBLs, 
including those isolated from France, 144 the Czech Republic145 and Spain,146 which 
are frequently multi-drug resistant due to mutations causing OprD inactivation, 
AmpC overproduction or increased efflux.117    
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 Other prevalent clones among MBL producers 1.8.6
While ST111, ST235 and to a lesser extent ST175 are the most widely reported 
clones among MBL-producers, others have been repeatedly associated with these  
acquired enzymes and are also considered as ‘high-risk clones’.117 Notable lineages 
include ST277 carrying blaSPM-1, widespread in Brazil,
97 although not often detected 
elsewhere and ST233, associated with blaVIM-2-positive isolates in several European 
and African countries and the USA30,124,147–150 as well as a blaIMP-1 variant in a 
Singaporean isolate.64 Other examples include ST654 reported in a blaVIM-2-carrying 
Swedish isolate (thought to be imported from Tunisia)124 and with blaIMP-1 and 
blaIMP-26 in Singapore;
64 ST357 associated with blaVIM-2 or blaIMP-7 genes in a hospital 
in the Czech Republic,68 and blaIMP-7 in Poland;
65 and ST773 reported among blaVIM-2-
carrying Indian isolates.137  
1.9 Genetic environment of MBL genes 
In order to devise effective control measures it is important to understand how MBL 
genes are mobilised and spread through bacterial populations. blaVIM and blaIMP 
genes are commonly located in class 1 integrons that often also contain genes 
conferring resistance to other antibiotic classes, such as aminoglycosides.151 This 
section will discuss the structure and origins of integrons along with mechanisms by 
which they may be mobilised.  
 Integron structure and function 1.9.1
Integrons are gene-capture systems that were first described in the late 1980s, and 
have since been observed in many Gram-negative bacterial species.152 They share 
three main features: (1) an integrase gene, intI, (2) an adjacent recombination site 
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(attI) recognised by the integrase and (3) a promoter upstream of this integration 
site (figure 1.9). Together, these features are able to capture and express gene 
cassettes, which are small circular elements that consist of a recombination site 
(attC) along with an open reading frame. Insertion of new gene cassettes is 
catalysed by the integrase, which recognises the attI and attC sites, in the integron 
and gene cassettes, respectively, and promotes recombination between them. 
Metagenomics studies show that these gene cassettes are abundant in a variety of 
environments and, based on the sequence of their encoding proteins, they are 
thought to have originated from diverse bacterial species.153 Hundreds of integron 
families have been identified, based on phylogeny of their intI genes, and they are 
estimated to be present in more than 15% of sequenced bacterial genomes where 
they are thought to have played a role in bacterial adaptation and evolution.153 Only 
integron classes 1-5 are associated with the carriage of resistance genes in clinical 
isolates, with class 1 integrons being the most commonly seen in Gram-negative 
pathogens and opportunists including P. aeruginosa.153 
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Figure 1.9: Integron structure. Integrons consist of an integrase gene (intI), an 
adjacent recombination site (attI) and a promoter, which can drive expression of 
integrated genes (Pc). Gene cassettes, consisting of a promoterless gene and a 
recombination site (attC), are ‘captured’ and inserted into the integron array by the 
integrase between the existing attI and attC sites. 
 
 Class 1 integrons 1.9.2
Class 1 integrons often carry one or more antibiotic resistance genes, and diverse 
gene cassette arrays have been characterised, often with genes encoding resistance 
to multiple antibiotic classes, such as β-lactams and aminoglycosides, and including 
the MBL genes blaVIM and blaIMP. Clinically-relevant class 1 integrons are thought to 
have emerged in recent years, driven by the selective pressure of antibiotics, as 
discussed further in Section 4.1. 
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 Mobilisation of class 1 integrons 1.9.3
Integrons cannot mobilise themselves, but are often located within transposon 
structures which, in turn, may be located on plasmids, or on mobilisable genomic 
islands within the chromosome. In the Enterobacteriaceae, class 1 integrons are 
often found on plasmids that can be easily transferred between strains by 
conjugation, but few studies have determined the genomic location of MBL-
encoding integrons in P. aeruginosa.151 Recent studies indicate that, although they 
can be present on plasmids in the species,154 they are more often located in the 
chromosome, often carried in large genomic islands that may also contain other 
resistance or virulence associated genes.30,147 More work is needed to better 
understand the structures that contain these integrons, their genomic location and 
whether they are mobilised between strains and this will be discussed further in 
Section 4.1.  
1.10 Reports of MBL-producing P. aeruginosa in the UK 
MBL-producers account for a small proportion of carbapenem resistant P. 
aeruginosa in the UK, with mutational mechanisms being more common. In a 
nationwide survey of bacteraemia isolates in the UK in 2012 by the British Society 
for Antimicrobial Chemotherapy (BSAC) 23/218 (11%) P. aeruginosa isolates were 
non-susceptible to imipenem but only one carried an MBL.155 Nevertheless, both 
the number of MBL-producing P. aeruginosa isolates submitted to AMRHAI (two in 
2003 vs. 52 in 2012) as well as the number of hospital laboratories referring MBL-
producing isolates (two in 2003 vs. 35 in 2012) have steadily increased over recent 
years. In addition, there are a few reports of MBL-producing P. aeruginosa causing 
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outbreaks in the UK. These include an outbreak of a VIM-producing strain belonging 
to serotype O15, also carrying a VEB-1a ESBL, which was reported at a hospital in 
the North-West of England with fifteen isolates collected between 2003 and 
2007.156 VIM-2-producing strains were also reported in a prolonged hospital-wide 
outbreak at a London site in 2005 to 2011 affecting 85 patients, with a smaller 
outbreak affecting four patients at the haematology unit at a hospital in the south 
of England between 2009 and 2010.157  
In contrast to data available for other countries, at the start of this PhD project 
there was little information on the molecular epidemiology of MBL-producing P. 
aeruginosa in the UK. In particular, there were no MLST data to allow producer 
strains to be compared with those seen internationally. Additionally, although the 
MBLs blaVIM and blaIMP were known to exist as part of class 1 integrons in the 
species, little was known about their wider genetic context and the extent to which 
they might move between strains.  
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1.11 Aims and Objectives 
The main aims of this thesis were therefore to investigate the molecular 
epidemiology of MBL-producing P. aeruginosa in UK hospitals and to determine the 
genetic context of the MBL genes they encode, to better understand how they 
might be horizontally transferred between strains. This was achieved by 
characterising a collection of MBL-producing P. aeruginosa isolates submitted to the 
UK national reference laboratory (AMRHAI) between 2003 and 2012. 
The specific objectives were: 
• To investigate the importance of international ‘high-risk clones’, sporadic 
isolates and local outbreak strains in the dissemination of MBL-producing P. 
aeruginosa in the UK by typing members of our collection (Chapter 3). 
• To determine the genetic context of the MBL genes, by studying the 
integron structures encoding them and their plasmid and/or chromosomal 
location (Chapter 4). 
• To explore the value of whole-genome sequencing methods in providing 
further discrimination between closely related isolates, including 
investigation of the acquired resistance genes that they carry (Chapter 5). 
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2 General materials and methods 
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This chapter will outline the bacterial isolates used in this study, along with the 
general methods used to study them. Methods relating to specific chapters are 
discussed therein. 
2.1 Bacterial isolates  
 MBL-producing P. aeruginosa study population 2.1.1
Three-hundred and thirty-four MBL-positive isolates were identified, as below, 
amongst P. aeruginosa isolates referred from UK hospital laboratories to AMRHAI 
between 2003 and 2012 for susceptibility testing, investigation of resistance 
mechanisms, and/or strain typing. 
The process used to select isolates is shown in figure 2.1. Isolates were identified as 
MBL-producers by PCR, as described in Section 2.2.4; this PCR was undertaken by 
AMRHAI staff at the time of referral for 307 isolates whilst the remaining 27 MBL-
producers were identified by retrospective screening (this study) of 121 isolates 
originally submitted only for typing between 2009 and 2012 that had similar VNTR 
types to those previously found to carry MBLs (accepting variants at up to three 
VNTR loci). 
Of these 334 MBL-positive isolates, 130 were previously typed by nine-locus VNTR 
as part of the reference service, as described in Section 3.2.1. In this study an 
additional 161 MBL-producing P. aeruginosa isolates were subjected to nine-locus 
VNTR analysis, whilst the remaining 43 isolates were no longer viable in AMRHAI’s 
archives.  
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The total of 334 MBL-positive isolates were from 267 patients, and VNTR profiles 
remained consistent when multiple isolates were received from the same patient. 
Accordingly, to reduce bias, one isolate per patient was retained for further study, 
leaving 267 non-duplicate-patient isolates; these were from 89 UK laboratories.  
The 89 referring laboratories mapped into 11 main regions, which were further sub-
divided into 18 sub-regions in the UK (figure 2.2). In this thesis, individual referring 
laboratories were assigned codes consisting of their respective region and a unique 
number within this region, in the format “region_number” (e.g. North West_1).  
 
 
Figure 2.1: Selection of MBL-producing P. aeruginosa isolates for further study 
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Figure 2.2: Regions and sub-regions of the UK referred to in this study
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 BSAC Bacteraemia Surveillance Programme P. aeruginosa 2.1.2
isolates 
As a comparator group, all 209 P. aeruginosa isolates collected in 2011 as part of 
the BSAC Bacteraemia Surveillance Programme (http://www.bsacsurv.org/) were 
studied. Thirty-nine hospitals in the UK or Irish Republic submitted up to seven non-
duplicate P. aeruginosa isolates from blood samples of bacteraemia patients 
between the 1st January and 31st December 2011. These isolates, along with patient 
demographic and minimum inhibitory concentration (MIC) data were provided by 
the BSAC. 
 MBL-producing Pseudomonas spp. other than P. aeruginosa 2.1.3
Twenty-three isolates of MBL-producing Pseudomonas spp. other than P. 
aeruginosa were submitted to AMRHAI between 2003 and 2012, the same time 
period as the MBL-producing P. aeruginosa. The 23 isolates were referred from 12 
different UK hospital laboratories; 21 were isolated from patient specimens, while 
the remaining three isolates were from the hospital environment. 
2.2 General methods 
 Culture 2.2.1
Isolates were cultured on nutrient agar and incubated at 37oC overnight (16-20 
hours). Where required, liquid cultures were prepared in nutrient broth and 
incubated at 37oC overnight (16-20 hours), with shaking. 
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 Minimum inhibitory concentration (MIC) determination 2.2.2
MICs were previously determined by the BSAC agar dilution method158 and are 
interpreted using EUCAST breakpoints (www.eucast.org/clinical_breakpoints/). 
MICs were determined by AMRHAI staff, as part of the reference service or the 
BSAC Bacteraemia Surveillance Programme. 
 PCR and Sanger Sequencing 2.2.3
2.2.3.1 Preparation of DNA templates for PCR 
Crude DNA extracts were prepared by suspending 3-5 colonies from overnight 
culture plates in 100 μl PCR-grade water and vortexing for 10 seconds. The 
suspension was heated at 95 oC for 5 minutes and centrifuged for 2 minutes at 
15500 rcf (g).  
2.2.3.2 PCR setup 
Primers were obtained from Sigma-Aldrich (Poole, UK). Primer stocks were made up 
at 100μM and stored at -20oC and 10 μM working stocks were made up as 
necessary. In general, PCR was set up using the Taq DNA Polymerase Kit (Qiagen, 
Sussex, UK). In some cases, as indicated, PCR reactions were set up using the 
QIAgility robot (Qiagen), in which case the Taq DNA Polymerase Kit (Qiagen) was 
used as above except that Qiagen Taq Polymerase was replaced with the Platinum 
Taq DNA Polymerase (Invitrogen, Paisley, UK).  Final concentrations of reagents 
used were 1 x PCR Buffer, 1.5 mM MgCl2, 200 µM of each dNTP, 0.4 µM of each 
primer and 1 U Taq Polymerase per 25 µl reaction. Q solution (which helps in the 
amplification of GC rich DNA templates and those with high levels of secondary 
structure) from the Taq DNA Polymerase Kit (Qiagen) was used at 1 x concentration 
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for some PCRs, as indicated in the relevant methods sections. Long-range PCRs 
were carried out with the LongRange PCR Kit (Qiagen). Final concentrations of 
reagents were as above, except that 2.5 mM MgCl2 and 500 µM of each dNTP were 
used. Primers used are shown in table 2.1 and cycling conditions, which varied for 
each PCR, are described in the respective methods sections. 
 
 
Table 2.1: Primers used in this study  
Primer Primer sequences (5’-3’) Target Reference 
IMP mp fwd GGAATAGAGTGGCTTAATTCTC blaIMP  
159
 
IMP mp rev II CCAAACCACTACGTTATCT blaIMP 
159
 
VIM mp fwd GATGGTGTTTGGTCGCATA blaVIM 
159
 
VIM mp rev II CGAATGCGCAGCACCAG blaVIM 
159
 
SPM mp fwd AAAATCTGGGTACGCAAACG blaSPM  
159
 
SPM mp rev II ACATTATCCGCTGGAACAGG blaSPM  
159
 
GIM mp fwd TCGACACACCTTGGTCTGAA blaGIM  
159
 
GIM mp rev II AACTTCCAACTTTGCCATGC blaGIM 
159
 
SIM-1-F TACAAGGGATTCGGCATCG blaSIM 
159
 
SIM-1-R TAATGGCCTGTTCCCATGTG blaSIM  
159
 
NDM-F GGGCAGTCGCTTCCAACGGT blaNDM 
160
 
NDM-R  GTAGTGCTCAGTGTCGGCAT blaNDM 
160
 
ms172L  GGATTCTCTCGCACGAGGT ms172 (VNTR) 104  
ms172R TACGTGACCTGACGTTGGTG ms172 (VNTR) 104 
ms211L  ACAAGCGCCAGCCGAACCTGT ms211 (VNTR) 104 
ms211R  CTTCGAACAGGTGCTGACCGC ms211 (VNTR) 104 
ms213L CTGGGCAAGTGTTGGTGGATC ms213 (VNTR) 104 
ms213R TGGCGTACTCCGAGCTGATG ms213 (VNTR) 104 
ms214L  AAACGCTGTTCGCCAACCTCTA ms214 (VNTR) 104 
ms214R  CCATCATCCTCCTACTGGGTT ms214 (VNTR) 104 
ms217L  TTCTGGCTGTCGCGACTGAT ms217 (VNTR) 104 
ms217R  GAACAGCGTCTTTTCCTCGC ms217 (VNTR) 104 
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Primer Primer sequences (5’-3’) Target Reference 
ms222L  AGAGGTGCTTAACGACGGAT ms222 (VNTR) 104 
ms222R TGCAGTTCTGCGAGGAAGGCG ms222 (VNTR) 104 
ms207L * ACGGCGAACAGCACCAGCA ms207 (VNTR) 104 
ms207R  CTCTTGAGCCTCGGTCACT ms207 (VNTR) 104 
ms209L* CAGCCAGGAACTGCGGAGT ms209 (VNTR) 104 
ms209R  CTTCTCGCAACTGAGCTGGT ms209 (VNTR) 104 
ms61L* CTTGCCGTGCTACCGATCC ms61 (VNTR) 104 
ms61R CCCCCATGCCAGTTGC ms61 (VNTR) 104 
acsA-F  ACCTGGTGTACGCCTCGCTGAC acsA (MLST amplification) 110 
acsA-R GACATAGATGCCCTGCCCCTTGAT acsA (MLST amplification) 110 
aroE-F TGGGGCTATGACTGGAAACC aroE (MLST amplification) 110 
aroE-R TAACCCGGTTTTGTGATTCCTACA aroE (MLST amplification) 110 
guaA-F CGGCCTCGACGTGTGGATGA guaA (MLST amplification) 110 
guaA-R  AACGCCTGGCTGGTCTTGTGGTA guaA (MLST amplification) 110 
mutL-F CCAGATCGCCGCCGGTGAGGTG mutL (MLST amplification) 110 
mutL-R CAGGGTGCCATAGAGGAAGTC mutL (MLST amplification) 110 
nuoD-F ACCGCCACCCGTACTG nuoD (MLST amplification) 110 
nuoD-R TCTCGCCCATCTTGACCA nuoD (MLST amplification) 110 
ppsA-F  GGTCGCTCGGTCAAGGTAGTGG ppsA (MLST amplification) 110 
ppsA-R GGGTTCTCTTCTTCCGGCTCGTAG ppsA (MLST amplification) 110 
trpE-F GCGGCCCAGGGTCGTGAG trpE (MLST amplification) 110 
trpE-R CCCGGCGCTTGTTGATGGTT trpE (MLST amplification) 110 
acsA-SF GCCACACCTACATCGTCTAT acsA (MLST sequencing) 110 
acsA-SR AGGTTGCCGAGGTTGTCCAC acsA (MLST sequencing)  110 
Table 2.1 continued  
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Primer Primer sequences (5’-3’) Target Reference 
aroE-SF ATGTCACCGTGCCGTTCAAG aroE (MLST sequencing)  110 
aroE-SR TGAAGGCAGTCGGTTCCTTG aroE (MLST sequencing) 110 
guaA-SF AGGTCGGTTCCTCCAAGGTC guaA (MLST sequencing) 110 
guaA-SR GACGTTGTGGTGCGACTTGA guaA (MLST sequencing) 110 
mutL-SF AGAAGACCGAGTTCGACCAT mutL (MLST sequencing) 110 
mutL-SR GGTGCCATAGAGGAAGTCAT mutL (MLST sequencing) 110 
nuoD-SF  ACGGCGAGAACGAGGACTAC nuoD (MLST sequencing) 110 
nuoD-SR  TGGCGGTCGGTGAAGGTGAA nuoD (MLST sequencing) 110 
ppsA-SF GGTGACGACGGCAAGCTGTA ppsA (MLST sequencing) 110 
ppsA-SR GTATCGCCTTCGGCACAGGA ppsA (MLST sequencing) 110 
trpE-SF TTCAACTTCGGCGACTTCCA trpE (MLST sequencing) 110 
trpE-SR GGTGTCCATGTTGCCGTTCC  trpE (MLST sequencing) 110 
5’CS GGCATCCAAGCAGCAAG 5’cs of class 1 integrons (intl1 gene) 161 
3’CS_1 AAGCAGACTTGACCTGA 3’cs of class 1 integrons 161 
3’CS_2 CGGATGTTGCGATTACTTCG 3’cs of class 1 integrons 162 
Tni-CF CGATCTCTGCGAAGAACTCG tniC gene of Tn402-like 3’ region  162 
VIM2004A GTTTGGTCGCATATCGCAAC blaVIM gene 
163 
VIM2004B AATGCGCAGCACCAGGATAG blaVIM gene 
163 
VIM-2A ATGTTCAAACTTTTGAGTAA blaVIM gene (sequencing) 
164 
VIM-2B CTACTCAACGACTGAGCG blaVIM gene (sequencing) 
164 
IMP Fwd GAAGGYGTTTATGTTCATAC blaIMP gene 
163 
IMP Rev GTAMGTTTCAAGAGTGATGC blaIMP gene 
163 
dhfr2_F CCACCTTTGGCTTCGGAGAT dhfr2 gene This study 
dhfr2_R TGTGCAATACCAACCGACGA dhfr2 gene This study 
Table 2.1 continued  
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Primer Primer sequences (5’-3’) Target Reference 
Sul-R CCGACTTCAGCTTTTGAAGG sul1 gene of class 1 integron 165 
aacA29AB1 GAAAGAACAAGACGCTGCCG aacA29a or b genes 166 
aacA29AB2 ACTTGCGGTGCGTGATGACC aacA29a or b genes 166 
aacA4-F GACCTTGCGATGCTCTATG aacA4 gene 167 
aacA4-R CAGCAACTCAACCAGAGC aacA4 gene 167 
OXA10like-F GGTGTCATAAAGAATGAGCAT oxa-10 like gene 167 
OXA10like-R TCCATGTTAAAGGCGAAAAAGT oxa-10 like gene 167 
AACA7-F AGCATTGGGCTCGTGGTCG aacA7 gene 84 
AACA7-R GACACCTCCGTGAATCCAG aacA7 gene 84 
aacA7-F2 GCTTCCGGAAACCGTTGTGA aacA7 gene This study 
strAstrB-F TATCTGCGATTGGACCCTCTG strAstrB genes 124 
strAstrB-R CATTGCTCATCATTTGATCGGCT   strAstrB genes 124 
NDM-orfF ATGGAATTGCCCAATATTATG blaNDM This study 
NDM-orfR TCAGCGCAGCTTGTCGGCCA blaNDM This study 
CM7 AACCAGTTCCGCGTTGGCCTGG rpoB  168 
CM31B CCTGAACAACACGCTCCGGA rpoB 168 
PA5101_F AATCCGGTAATGCTCCTCGC PA5101 gene  This study 
PA5101_R ATGCAGTGACCTTCGGCTAC PA5101 gene  This study 
VIMGI-LH_R GGGAAATCAGGGATCGGAGC Left hand portion of genomic island A This study 
VIMGI-RH_F TGCCACGATCAAGGGATTCG Right hand portion of genomic island A This study 
PA2229_F CCTGGATGCCCTTCTCACC PA2229 gene This study 
PA2229_R CTGGTGCTGAAGTTCTCGCC PA2229 gene This study 
ST111-GI-J1_R GATCAGTACCTCCTGCGACG Left hand junction of genomic island B This study 
ST111-G1-J2_F TTCTGAGACGACCCCAAGTT Right hand junction of genomic island B This study 
Table 2.1 continued  
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Primer Primer sequences (5’-3’) Target Reference 
endA_F GCTACTCGGGAAATCGTGTCG endA  This study 
endA_R TATTGCTGGGGTTTCTGCGG endA  This study 
PACS171b-J1_R TTTCGCTAAGCCCGCAACTA phage integrase gene of PACS171b-like 
genomic island 
This study 
PACS171b-J2_F TGAGATGGGCCTGGTGGTAT transposase gene of PACS171b-like 
genomic  island 
This study 
glykin_F GAACCCCCTACTCTGGCAAC glycerate kinase gene This study 
glykin_R GCGAAGGGAGGTTGGATGAA glycerate kinase gene This study 
urf2_R CGGAATACGTCGAGCACTTCT urf2Δ of Tn6249 This study 
TnpATn6249_F TCGATTGGTTGCAAAGCGTC TnpA of Tn6249 This study 
cse3_For ATGTACCTGACCAGACTGACCCTTGATCCTCGCAGCG cse3 gene (Type I-E CRISPR-Cas) 169 
cse3_Rev GGCTCAGCAGGCCACAGCCGAAAGCCTTG  cse3 gene (Type I-E CRISPR-Cas) 169 
csy1_FOR ATGACCTCTCCCCTCCCAACGCCTACG csy1 gene (Type I-F CRISPR-Cas) 169 
csy1_REV TCAGTCACGCTCATCTTCGAGTATCTCC csy1 gene (Type I-F CRISPR-Cas) 169 
* indicates primers that were fluorescently labelled at their 5’end with either 6-FAM (ms207L), NED (ms209L) or VIC (ms61L) 
Table 2.1 continued  
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2.2.3.3 Analysis of PCR amplicons 
Amplicons were analysed on 1.5% agarose gels, except for PCRs targeting integrons, 
which were sized on 1% agarose gels. DNA ladders Hyperladder 50 bp or 
Hyperladder 1 kb (both Bioline, London, UK) were used depending on the expected 
product size. 
2.2.3.4 Sanger Sequencing 
Amplicons were treated with ExoSAP-IT (Affymetrix, Santa Clara, USA). Two μl of 
ExoSAP-IT was added per 5 μl of amplicon and the mixture was incubated at 37oC 
for 15 minutes followed by inactivation at 80oC for 15 minutes. Following Exo-SAP-
IT treatment, 1.5 μl amounts of the PCR products were combined with 0.5 μl of the 
relevant primer (10μM) and 4 μl PCR-grade water, and submitted to the Genomic 
Services and Development Unit at PHE Colindale for Sanger sequencing. Resulting 
sequences were analysed using Bionumerics software v6.1 (Applied Maths, Sint-
Martens-Latem, Belgium). Primers used for sequencing are shown in table 2.1 and 
referred to in the relevant methods sections.  
 Detection of MBL genes 2.2.4
Genes encoding VIM-, IMP-, SPM-, GIM-, and SIM-type MBLs were sought by 
multiplex PCR, as detailed by Ellington et al.159 using primer pairs IMP mp Fwd with 
IMP mp rev II, VIM mp fwd with VIM mp rev II, SPM mp fwd with SPM mp rev II, 
GIM mp fwd with GIM mp rev II, and SIM-1-F with SIM-1-R, respectively (see table 
2.1). Genes for NDM-type MBLs were sought using a single PCR using primers NDM-
F and NDM-R, as previously described.160 For both PCRs cycling conditions were 
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95oC for 5 minutes, followed by 30 cycles of 94oC for 30 seconds, 56oC for 40 
seconds and 72oC for 40 seconds and a final extension step of 72oC for 5 minutes.  
 Whole genome sequencing 2.2.5
2.2.5.1 DNA extraction 
Genomic DNA was extracted using the GeneJet Genomic DNA Purification Kit 
(Thermo Scientific, Loughborough, UK) according to manufacturer instructions. DNA 
concentration was estimated using the Qubit dsDNA BR Assay Kit on the Qubit 
Fluorometer (Life Technologies, Paisley, UK). DNA quality was estimated using the 
Nanodrop ND-1000 Spectrophotometer (Thermo Scientific) with 260 nm/ 280 nm 
absorbance readings between 1.8 and 2.0 deemed acceptable.  
2.2.5.2 Illumina Sequencing 
DNA was diluted to between 10-30 ng/μl before submission to the Genomic 
Services and Development Unit, PHE Colindale for Illumina sequencing, where the 
following steps were carried out. Library preparation was performed using the 
Nextera XT DNA Sample Preparation Kit (Illumina, Cambridge, UK). Quality checks 
were performed on the libraries thereby generated using the LabChip GX 
instrument (Perkin Elmer, Beaconsfield, UK) to determine the average  fragment 
size and the KAPA Universal Library Quantification Kit (KAPA Biosystems, London, 
UK) to determine the concentration of clusterable material for loading onto the 
Illumina HiSeq. The library was clustered onto a HiSeq Flow Cell using The TruSeq 
Rapid Duo Sample Loading Kit on a cBot instrument before analysis was carried out 
on a HiSeq instrument, on ‘Rapid Run’ mode using TruSeq Rapid PE Cluster v2 Kit 
and TruSeq Rapid 144 SBS v2 Kit (200 cycles) (all Illumina). The resulting fastq reads 
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were trimmed using Trimmomatic 0.32,170 and the trimmed fastq files were used in 
the analyses described in the following chapters. 
2.2.5.3 MinION sequencing 
MinION sequencing was carried out as part of the MinION access programme 
(Oxford Nanopore Technologies, Oxford, UK) at the University of East Anglia (UEA), 
Norwich (run 1) or PHE, Colindale (run 2), using the latest protocols and reagents 
available at the time the work was undertaken. The reagents used were from the 
Nanopore Sequencing Kit SQK-MAP004 (run 1) or SQK-MAP005 (run 2), both Oxford 
Nanopore Technologies, except where otherwise specified. Run 1 was carried out 
by Justin O’Grady, Solomon Mwaigwisya and Katarzyna Schmidt at UEA, Norwich 
while run 2 was carried out by the author, with the help of Jane Turton, at PHE, 
Colindale. 
Shearing was performed on extracted DNA in a g-TUBE (Covaris, Massachusetts, 
USA) using 1.5 μg DNA in a total volume of 81 µl at 6000 rpm (run 1) or 4200 rpm 
(run 2), to yield fragments of around 8 kb or 20 kb respectively, in an Eppendorf 
5424 centrifuge (this centrifuge was recommended by Oxford Nanopore 
Technologies, as different centrifuges have varying ramp speeds, which can affect 
shearing). For run 1 PreCR treatment was carried out using the PreCR Repair 
Treatment Kit (New England BioLabs, Hertfordshire, UK). Eighty μl of fragmented 
DNA, 6 μl nuclease-free water, 10 μl 10 x Thermopol Buffer, 1 μl 10x NAD+, 1 μl 10 
mM dNTPs and 2 μl PreCR Repair Mix were combined, mixed gently and incubated 
at 37oC for 30 minutes. The DNA was cleaned up using Agencourt AMPure XP Beads 
(Beckmann-Coulter, High Wycombe, UK): these were first resuspended by 
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vortexing, then 100 μl were added to the reaction, and incubated at room 
temperature for 5 minutes to bind to DNA. The suspension was spun down briefly 
at 13000 rcf and pelleted on a magnetic rack, with the supernatant aspirated once 
it became clear and colourless. The beads were then washed twice with 200 μl of 
freshly prepared 70% ethanol. The tube was briefly spun down as before and 
replaced on the magnet before residual ethanol was aspirated. The pellet was 
resuspended in 81 μl 10 mM Tris-HCl pH 8.5 and incubated for 2 minutes at room 
temperature. The beads were then re-pelleted on the magnet and the eluate 
removed once clear and colourless. This eluate (run 1), or the fragmented DNA 
without PreCR treatment (run 2) were quantified using the Qubit Fluorometer as 
before and 1 μg DNA in a total volume of 80 μl was taken forward for the end-
repair step. Here, the 80 μl of DNA solution was combined with 10 μl End-Repair 
Buffer, 5 μl End-Repair Enzyme Mix, both from the NEBNext End Repair Module Kit 
(New England BioLabs), and 5 μl DNA CS (ligation control DNA) provided in the 
Nanopore Sequencing Kits. The reagents were mixed and incubated at room 
temperature for 20 minutes. The reaction was cleaned up with the Agencourt 
AMPure XP Beads as before except that the DNA was eluted into a final volume of 
26 μl of 10 mM Tris-HCl pH 8.5 (run 1) or nuclease-free water (run 2). The dA-tailing 
reaction was set up using the NEBNext dA Tailing Module (New England BioLabs). 
Twenty-five μl of the end-repaired DNA was combined with 3 μl 10x dA-Tailing 
Buffer and 2 μl dA-Tailing Enzyme (Klenow Fragment). The reaction was cleaned up 
with the Agencourt AMPure XP Beads as before except that the DNA was eluted 
into a final volume of 31 μl of 10 mM Tris-HCl pH 8.5 (run 1) or nuclease-free water 
(run 2).  
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Thirty μl of the dA-tailed DNA were mixed with 10 μl Adapter Mix, 10 μl HP Adapter 
and 50 μl Blunt/TA Ligase Mastermix, in a 1.5 ml Protein LoBind Tube (Eppendorf, 
Hamburg, Germany). The mixture was briefly spun down in a centrifuge at 13000 
rcf and incubated for 10 minutes at room temperature. His-Tag Dynabeads (Life 
Technologies) were prepared by pelleting 10 μl on the magnet, aspirating the 
supernatant and washing twice with 200 μl 1 x Bead Binding Buffer, before 
resuspending the washed and pelleted beads in 2x Bead Binding Buffer. These 
washed beads were added to the 100 μl adapter ligated DNA in a Protein LoBind 
Tube, mixed carefully by pipetting and incubated at room temperature for five 
minutes. The beads were pelleted on the magnetic rack and the supernatant 
aspirated; subsequently the pelleted beads were washed twice with 200 μl of 1 x 
Bead Binding Buffer. The tube was spun down briefly and placed back on the 
magnetic rack for 1-2 minutes before the remaining Bead Binding Buffer was 
aspirated. The library was eluted from the beads by resuspending in 25 μl Elution 
Buffer, incubating at room temperature for 10 minutes, pelleting the beads on the 
magnet and transferring the eluate to a new tube. One μl of this pre-sequencing 
mix was quantified on the Qubit fluorimeter to ensure that at least 100 ng DNA was 
still present. 
A new MinION Flow Cell was inserted into the MinION (both Oxford Nanopore 
Technologies), which was connected to a laptop with the MinKNOW software 
(Oxford Nanopore Technologies) then started. Before loading the library onto the 
MinION Flow Cell 150 μl 1x Running Buffer was prepared (75 μl 2 x Running Buffer, 
3 μl Fuel Mix, both from the Nanopore sequencing kit, and 72 μl nuclease-free 
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water) and loaded onto the MinION Flow Cell, this was repeated after 10 minutes. 
The library was prepared for loading by combining 75 μl 2 x Running Buffer, 60 μl 
nuclease-free water, 3 μl Fuel Mix, and 12 μl of the library to a final volume of 150 
μl. This prepared library was loaded onto the MinION Flow Cell. Additional library 
was loaded onto the MinION Flow Cell, as before, after approximately 16 and 24 
hours (run 2 only). 
Reads were analysed using the Metrichor program using Workflow 2D Basecalling v 
1.14 (Oxford Nanopore Technologies). This software generates fast5 files, which 
include both the raw data and the resulting base-calls in fastq format. Sequence 
data from these fast5 files of multiple reads were extracted to a multi-fasta file 
using a simple script (carried out by Justin O’Grady or Jack Turton). The resulting 
fasta file was used for the analyses described in later chapters. 
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3 Molecular epidemiology 
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3.1 Introduction 
As described in Chapter 1, P. aeruginosa ‘high-risk clones’, including STs 235, 111 
and 175 have been identified worldwide and are frequently associated with the 
carriage of diverse resistance genes, including MBL genes. However, before this 
study began there were few data available on the molecular epidemiology of MBL-
producing P. aeruginosa in the UK despite increasing numbers being referred to 
AMRHAI over recent years.  
 Selection of typing methods 3.1.1
When this study commenced VNTR analysis was the main method used for the 
typing of P. aeruginosa at AMRHAI, having replaced PFGE in 2009. As discussed in 
Section 1.7, VNTR is a highly discriminatory typing method well suited to outbreak 
investigation and so was chosen as the primary typing method here. MLST was 
chosen as a secondary typing method since although it is less discriminatory than 
VNTR, it is more helpful for comparison of isolates from diverse locations including 
lineages reported internationally. 
 Aims 3.1.2
The overall aim of this part of the study was to investigate the molecular 
epidemiology of MBL-producing P. aeruginosa in the UK. Specific aims were: (1) to 
investigate the population structure of MBL-producing P. aeruginosa in the UK, 
using VNTR and MLST, including assessing the prevalence of internationally 
reported ‘high-risk clones’ in the UK and (2) to investigate whether any prevalent 
MBL-producing types represent clonal expansion of strains that had acquired MBLs, 
or the repeated acquisition of MBL genes by P. aeruginosa lineages that are 
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common anyway in serious infections; this was achieved by VNTR typing of a 
comparator population of isolates from the BSAC Bacteraemia Surveillance 
Programme. 
This chapter first describes the study population in terms of the patient 
characteristics and submitting hospitals. It then describes the typing results by 
VNTR and MLST, and compares these data to typing data for the comparator 
population of isolates from the BSAC Bacteraemia Surveillance Programme. 
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3.2 Methods 
 Variable number tandem repeat (VNTR) analysis 3.2.1
Nine-locus VNTR analysis was performed as previously described by Turton et al.104  
Primer pairs (table 3.1, table 2.1), targeted nine VNTR loci (ms172, ms211, ms213, 
ms214, ms217, ms222 ms207, ms209 and ms61). For loci ms207, ms209 and ms61, 
fluorescently-labelled forward primers were used. PCR was set up as described in 
Section 2.2.3 on the QIAgility robot (Qiagen). Cycling conditions were 94oC for 3 
minutes, followed by 35 cycles of 94oC for 30 seconds, 60oC for 30 seconds and 
72oC for 45 seconds and a final extension step of 72oC for 10 minutes. PCR products 
for six loci with 54- to 115-bp repeats (ms172, ms211, ms213, ms214, ms217 and 
ms222) were sized on 1.5% agarose gels run at 150 V for 2 hours. Fluorescently-
labelled PCR products corresponding to the remaining three loci (ms207, ms209 
and ms61) with 6-bp repeats, were combined with molecular grade water at a 
dilution of 1:40 in a total volume of 200 μl and 1 μl of each combined dilution was 
added to 10 μl Hi-Di formamide, and 0.5 μl Genescan LIZ-600 Size Standard (both 
Applied Biosystems, Foster City, USA). The amplicons were sized by fragment 
analysis on an ABI sequencing instrument by the GSDU, PHE Colindale and traces 
analysed using Peak Scanner v2 (Applied Biosystems). Repeat numbers for each 
locus were determined by comparing amplicon sizes with a table of expected sizes 
(PHE data). Data were analysed and minimum spanning trees produced using 
Bionumerics Software v6.1 (Applied Maths).  
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Table 3.1: Primers and repeat lengths for the nine VNTR loci 
VNTR loci Primer 1
a
 Primer 2
a
 VNTR repeat 
length (bp) 
ms172 ms172L  ms172R 54 
ms211 ms211L  ms211R 101 
ms213 ms213L ms213R 103 
ms214 ms214L  ms214R 115 
ms217 ms217L  ms217R 109 
ms222 ms222L  ms222R 101 
ms207 ms207L  ms207R 6 
ms209 ms209L ms209R 6 
ms61 ms61L ms61R 6 
arefer to table 2.1 for primer sequences 
 
 
 Multi-Locus Sequence Typing (MLST) 3.2.2
MLST was undertaken as described by Curran et al.110 PCR and sequencing of the 
seven housekeeping genes acsA, aroE, guaA, mutL, nuoD, ppsA and trpE was carried 
out using the primers described in table 3.2; sequences of the primers are shown in 
table 2.1. Cycling conditions were 95oC for 5 minutes, followed by 35 cycles of 95oC 
for 1 minute, 55oC for 1 minute and 72oC for 1 minute, and a final extension step of 
72oC for 10 minutes. Sequencing of the PCR products was carried out as described 
in Section 2.2.3.4. Sequences were analysed using Bionumerics Software v6.1 
(Applied Maths) and sequence types (STs) assigned using the P. aeruginosa MLST 
database (http://pubmlst.org/paeruginosa/).  
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Table 3.2: Primers used for MLST 
MLST 
loci 
Amplification Sequencing 
Primer 1
a
 Primer 2
a
 Primer 1
a
 Primer 2
a
 
acsA acsA-F  acsA-R acsA-SF acsA-SR 
aroE aroE-F aroE-R aroE-SF aroE-SR 
guaA guaA-F guaA-R guaA-SF guaA-SR 
mutL mutL-F mutL-R mutL-SF mutL-SF  
nuoD nuoD-F nuoD-R nuoD-SF  nuoD-SF 
ppsA ppsA-F  ppsA-R ppsA-SF ppsA-SF 
trpE trpE-F trpE-R trpE-SF trpE-SF 
arefer to table 2.1 for primer sequences 
 
 Sequencing of MBL genes 3.2.3
Sequencing was carried out as described in Section 2.2.3.4. For sequencing of blaVIM 
and blaIMP MBL genes, primers specific to blaVIM (VIM2004A, VIM2004B) or blaIMP 
(IMP_Fwd, IMP_Rev) were used together with those specific to class 1 integrons 
(5’CS, 3’CS_1, TniCF). Sequencing of blaNDM genes was performed with primers 
NDM-orfF and NDM-orfR. Primer sequences are shown in table 2.1. 
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3.3 Results 
 Patient and isolate characteristics 3.3.1
As described in Chapter 2, 267 P. aeruginosa non-duplicate-patient isolates were 
selected for study. The number of MBL-producing P. aeruginosa isolates submitted 
to AMRHAI increased steadily over the ten-year period from two in 2003 to 52 in 
2012, as did the number of hospital laboratories referring isolates to us, with two in 
2003 and 35 in 2012 (figure 3.1). Of the total 89 referring laboratories, 83 
submitted isolates from fewer than ten patients, with 71 submitting only one to 
two isolates each. The remaining six laboratories submitted between 13 and 31 
isolates each, collectively accounting for 43% (116/267) of all source patients, with 
isolates from each hospital being submitted over long periods of six to nine years.  
Patient demographic and isolation site data were extracted from the PHE 
laboratory information management system, and were based on information 
provided by referring laboratories. Data for the 267 non-duplicate-patient isolates 
are presented in table 3.3. Ages of the patients ranged from 0-94, mean 54 yrs. 
Sixty percent were male, 35% female; for 5% gender was not stated. Predominant 
isolation sites were urine (24%), respiratory tract (18%), wounds (17%), blood 
(13%), and indwelling devices (7%), whereas few were from skin (3%) and faecal 
(3%) specimens.  
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blaVIM genes alone were detected in 243 isolates (91%), blaIMP in 22 (8.2%), and 
blaNDM in one (0.4%); one further isolate had both blaVIM and blaNDM. The specific 
blaMBL alleles seen are described in Section 3.3.2.5. 
MIC data were available for 224/267 isolates tested as part of the AMRHAI’s 
reference service; the distributions of MICs among the isolates are shown in table 
3.4. The majority of MBL-producing P. aeruginosa isolates were resistant to almost 
all tested antibiotics. The main exceptions were aztreonam to which 69% of tested 
isolates remained intermediate, or for one isolate susceptible, and colistin, to which 
all isolates remained susceptible.  
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Figure 3.1: (a) Numbers of isolates and referring laboratories and (b) proportions of 
different MBL classes among the 267 non-duplicate-patient MBL-producing P. 
aeruginosa referred to the UK reference laboratory for each year from 2003 to 
2012. 
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Table 3.3: Demographic and isolation site data for MBL-producing P. aeruginosa 
isolates (n=267) 
 
 
 Number of 
patients (%) 
Age (years)  
0-4 12 (4) 
5-19 6 (2) 
20-39 36 (13) 
40-49 29 (11) 
50-59 39 (15) 
60-69 58 (22) 
70-79 48 (18) 
80+ 11 (4) 
Not available 28 (10) 
  
Gender  
Female 94 (35) 
Male 160 (60) 
Not available 13 (5) 
  
Isolation site  
Urine 65 (24) 
Respiratory 47 (18) 
Wound 45 (17) 
Blood 35 (13) 
Indwelling device 19 (7) 
Skin 9 (3) 
Faeces 8 (3) 
Others 20 (8) 
Not available 19 (7) 
  
 
 
Table 3.4: MIC distributions for MBL-producing P. aeruginosa isolates (n=267) 
Antibiotic Number of isolates with MIC (mg/L) ND %S %I %R 
  ≤0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128         
Amikacin 1 3 7 10 25 28 61 86 46 9.5 11.3 79.1 
Gentamicin 1 1 7 9 7 11 32 153* 46 8.2 - 91.8 
Tobramycin 1 1 1 1 1 1 11 26 177* 47 2.3 - 97.7 
Piperacillin-tazobactam 1 18 44 60 96 48 8.7 - 91.3 
Ceftazidime 2 3 44 49 37 86 46 2.3 - 97.7 
Imipenem 1 4 7 18 68a 126 43 0.4 1.8 97.7 
Meropenem 1 6 12 13 24 168* 43 0.4 2.7 96.9 
Aztreonam 1 1 14 54 80 20 9 38 50 0.4 68.7 30.9 
Ciprofloxacin 2 5 6   1 5 3 199* 46 5.9 0 94.1 
Colistin     7 181 32             47 100 - 0 
S, susceptible; I, intermediate; R, resistant; ND: not determined. Cells shaded dark grey represent resistant isolates, light grey represents 
intermediate, and white susceptible 
*Isolates with MIC ≥ indicated value 
aincludes 22 isolates for which the MICs were reported as >32 mg/L 
 
 
 
 
 
 
 
8
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 Typing of MBL-producing isolates 3.3.2
3.3.2.1 VNTR typing 
Among the 267 non-duplicate-patient isolates, 232 had VNTR data already available 
or generated in this study (figure 3.2). A minimum spanning tree for these 232 
isolates is shown in figure 3.3. The remaining 35 isolates were not available in the 
archive for retrospective VNTR typing, but 19 had previously-determined PFGE 
profiles (not shown) identical to those of isolates with known VNTR types and 
collected over the same time period at the same hospital. These isolates were 
therefore assumed to belong to the corresponding VNTR complex and are included, 
along with the 232 VNTR-typed isolates in table 3.6, as shown in figure 3.2. The 
remaining 16/35 unavailable isolates had no typing data, or belonged to PFGE types 
unique to their respective hospital; these latter isolates, from 12 laboratories, are 
excluded from table 3.6; all carried blaVIM.  
Six VNTR complexes (designated A-F) accounted for 86% of the 251 isolates with 
VNTR data available or inferred from PFGE data (table 3.5, figure 3.3). Owing to 
their predominance, isolates belonging to these complexes became the focus of 
further study. Isolates belonging to each of the six VNTR complexes were referred 
from nine to 25 laboratories each. Single VNTR types persisted at a few sites for 
prolonged periods ranging from seven months to nine years (table 3.6), as detailed 
in the following sections.  
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Figure 3.2: Isolates typed by VNTR from the study population of 267 non-duplicate-
patient MBL-producing P. aeruginosa isolates. 
 
 
 
 
  
 
Figure 3.3: Minimum spanning tree, based on clustering at the first eight VNTR loci for MBL-positive P. aeruginosa, with one isolate included 
per patient (n=232). The six main complexes A-F are labelled. Coloured segments of the circles indicate laboratories that submitted three or 
more isolates, white segments represent laboratories submitting one or two isolates. The diameters of the circle are relative to the number of 
isolates with the VNTR profile. Shading indicates complexes. Thick solid lines represent single-locus variants; thin solid lines and dotted lines 
represent multi-locus variants.  
8
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Table 3.5: VNTR complexes identified among the MBL-producing P. aeruginosa isolates (n=251) 
VNTR 
Complex 
VNTR type 
a 
No. of 
different VNTR 
profiles 
MLST type(s) (no. of 
isolates tested) 
No. of 
isolates
b 
No. of 
submitting 
laboratories 
MBLs detected 
(no. of isolates) 
A 11,3,4,3,2,2,x,4,x  6 ST111 (11) 75 25 VIM (70) 
IMP (5) 
B 13,3,6,4,5,1,x,2,x 16 ST235 (18) 52 25 VIM (46) 
IMP (6) 
C 12,3,4,5,3,1,x,2,x 11 ST233 (10) 26 16 VIM (26) 
D 11,3,2,15,3,1,x,3,x 6 ST654 (10), ST964 (1) 19 11 VIM (17) 
IMP (1) 
NDM (1) 
E 13,2,1,5,2,3,6,x,x 7 ST357 (9) 30 9 VIM (30) 
F 12,4,6,5,3,1,10,x,x 3 ST773 (5) 13 11 VIM (13) 
Others Diverse 26 Not done 36 25 VIM (25) 
IMP (10) 
VIM and NDM (1) 
ax represents loci where the repeat number varies among isolates within a complex 
bone isolate per patient was included; these numbers include four isolates (complex B), 14 isolates (complex E) and one isolate (complex F) where the MBL-
positive organisms were no longer available in the archive for VNTR analysis, but which were previously found to share a PFGE profile, and are from the 
same hospital outbreak as other isolates in the respective complex. Isolates with a PFGE profile corresponding to complex A were also received from an 
additional 39 patients at London_17; these are not included here as they had not been screened for MBL genes and were no longer available in AMRHAI’s 
archives. 
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Table 3.6: Geographical and temporal distribution of MBL-producing P. aeruginosa belonging to the six major complexes (215 isolates) among 
referring laboratories 
VNTR 
Complex  
Major Contributors (≥ 5 referred isolates) Minor Contributors 
 Referring 
laboratorya 
Number of 
isolatesb 
Time period 
over which 
isolates referred 
MBL genes 
detected 
A (n=75) London_17 c 29 (39%) 80 months all with blaVIM 2 laboratories with 4 representatives each 
Wales_1 13 (17%) 18 months all with blaVIM 2  laboratories with 3 representatives each 
    19 laboratories with 1 representative each 
B (n=52) London_7 8 (15%) 87 months all with blaVIM 1 laboratory with 3 representatives 
London_13 8 (15%) 7 months all with blaVIM 6  laboratories with 2 representatives each 
Scotland_2 6 (12%) 27 months all with blaVIM 15  laboratories with 1 representative each 
C (n=26) London_7 5 (19%) 27 months all with blaVIM 3  laboratories with 2 representatives each 
London_13 4 (15%) 18 months all with blaVIM 11  laboratories with 1 representative each 
D (n=19) South East_6 7 (37%) 36 months all with blaVIM 2  laboratories with 2 representatives each 
    8  laboratories with 1 representative each 
E (n=30) North West_15 22 (73%) 103 months all with blaVIM 8  laboratories with 1 representative each 
F (n=13) No major contributors 2  laboratories with 2 representatives each 
 9  laboratories with 1 representative each 
areferring laboratories are coded in the format ‘UK region_number’. 
bone isolate per patient is included; these numbers include four isolates (complex B), 14 isolates (complex E) and one isolate (complex F) that were not 
available in the archive for VNTR analysis, but which shared a PFGE profile and are from the same hospital outbreak as other isolates in the complex.  
c Isolates were also received from an additional 39 patients at London_17 with a PFGE type corresponding to complex A. These are not included here as they 
had not been screened for MBL production and were no longer available in AMRHAI’s archives.
8
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3.3.2.2 MLST analysis 
Sixty-four organisms, representing the variation in VNTR profile within each of the 
six main complexes, were selected for MLST analysis. Isolates belonging to 
complexes A, B, C, D, E and F were found to belong to ST111, ST235, ST233, 
ST654/ST964, ST357 and ST773, respectively (table 3.5). Ten of 11 MLST-typed 
complex D isolates belonged to ST654, but one belonged to ST964; this is a single 
locus variant (SLV) differing only in the acsA allele, where ST964 has allele 145 with 
a single C to T substitution compared with allele 17 in ST654.   
3.3.2.3 Distribution of isolates from each complex among referring 
laboratories 
Table 3.6 shows the distribution of each of the major complexes among referring 
laboratories. The largest group of isolates was complex A (corresponding to ST111; 
VNTR type 11,3,4,3,2,2,x,4,x, where x is variable), with 75 representatives. It 
included isolates from 25 laboratories spread across the UK, with few 
epidemiological links between them. More than half of the isolates came from long 
term ‘outbreaks’ at London_17 and Wales_1, referring 29 and 13 isolates scattered 
over seven-year (2006-2012) and 18-month (2010-2011) periods, respectively, all 
with blaVIM. Most other complex A isolates (28/33) also had blaVIM, but five, from 
two laboratories, had blaIMP. VNTR profiles were highly conserved amongst all 
complex A isolates, with most only differing by repeat numbers between six and 
eight at locus 61. For nine isolates the referring laboratory had provided recent 
patient travel history; only two of these patients had recently travelled, both to 
Greece. 
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Complex B (ST235; 13,3,6,4,5,1,x,2,x) was the second largest group, comprising 52 
isolates referred from 25 different laboratories. Major contributors included 
London_13, referring eight blaVIM-positive isolates over a seven-month period in 
2004. Scotland_2 referred six blaVIM-carrying isolates; five of these six were received 
over a five month period in 2008-2009 while the remaining isolate was collected 27 
months after the initial representative, in 2010. Another laboratory (London_7) also 
submitted complex B isolates carrying blaVIM from eight patients scattered over an 
eight-year period, albeit with three of these isolates received over a four-month 
period in 2010. The remaining 30 complex B isolates were from 22 laboratories, 
each submitting one to three representatives; 24 of these diverse-source 
representatives had blaVIM, and six had blaIMP. Six of 16 patients with corresponding 
travel data had travelled recently to Italy (three patients), the United Arab Emirates, 
Thailand or India.  
Twenty-six isolates belonged to complex C (ST233; 12,3,4,5,3,1,x,x,x). These all 
carried blaVIM and were from 16 laboratories, which submitted one to five 
representatives each. They included persistent ST233 lineages at London_7 and 
London_13, referring five or four isolates scattered over 27- and 18-month periods, 
respectively. Of ten isolates with patient travel data, three patients had recently 
travelled, to South Africa, Saudi Arabia or Kuwait. 
Nineteen isolates from 11 laboratories belonged to complex D (ST654/964; 
11,3,2,15,3,1,x,3,x). Seven blaVIM-positive representatives were submitted from 
South East_6 over a three year period (2009-2012), although four of the seven were 
submitted over a two-week period in 2010. One or two isolates were referred from 
92 
 
each of the remaining ten laboratories; ten isolates had blaVIM, one had blaIMP, and 
one blaNDM. Corresponding patient travel data were available for five isolates; two 
VIM-producing isolates were associated with travel to Russia or the Indian 
subcontinent, while the isolate producing an NDM enzyme was associated with 
patient travel to India. 
Most of the 30 complex E isolates (ST357; 13,2,1,5,2,3,6,5,x), all with blaVIM, were 
from an outbreak at North West_15, with 22 isolates referred over a nine-year 
period, though 12/22 were submitted in 2007. Each of the remaining eight complex 
E isolates was referred from a different laboratory. Patient travel data were 
provided for seven of the isolates; three patients had recently travelled to Egypt, 
India, or both Dubai and India. 
Finally, 13 isolates, all with blaVIM, belonged to complex F (ST773; 
12,4,6,5,3,1,10,x,x) and were received from 11 laboratories in diverse areas of the 
UK.  Patient travel history was provided for five isolates, with patients having 
travelled to India (three patients), or an unknown location (one patient), while the 
one remaining patient had not recently travelled. 
The 14% of isolates (n=36) that did not belong to any of these six major complexes 
were diverse, representing 26 different VNTR profiles. They were referred from 24 
laboratories across the UK, each submitting one to three isolates each; 26 had 
blaVIM, 10 had blaIMP and one had both blaVIM and blaNDM genes.  
Among the six laboratories that submitted more than ten isolates, three were 
dominated by representatives of a single VNTR complex while the remaining three 
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submitted diverse types; timelines showing examples of each situation are shown in 
figure 3.4. The three laboratories submitting isolates belonging to predominantly 
one type included London_17 (figure 3.4) where 29/31 isolates referred over a 
seven-year period belonged to complex A (ST111). The other two such laboratories 
were North West_15, with all 22 isolates referred over nine years belonging to 
complex E (ST357) and Wales_1 where 14/15 isolates referred over six years 
belonged to complex A (ST111).  
The three laboratories contributing more than ten isolates with diverse types 
represented included London_7 (figure 3.4) and London_12, referring 19 and 15 
isolates, respectively, over seven- and eight-year periods. Isolates belonging to 
complexes A, B and C (STs 111, 235, 233) were seen at both laboratories and 
London_7 also referred an isolate belonging to ST654. The remaining laboratory, 
London_13, had temporally-separate outbreaks (lasting seven to 18 months) of 
MBL-positive isolates belonging to complexes B and C (STs 235 and 233), with eight 
and four representatives, respectively, separated by a six-year gap; an ST111 isolate 
was also received from the laboratory.  
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Figure 3.4: Time plots showing the prevalence of different VNTR complexes at 
London_17 and London_7. Laboratories referred isolates of a single predominant 
VNTR type (London_17) or of diverse types (London_7). Pre-2010 isolates were also 
received from an additional 39 patients at London_17 with a PFGE type, 
corresponding to complex A. These are not included here as they had not been 
screened for MBL production and were no longer available in AMRHAI’s archives, 
but are likely to be representatives of the same strain.
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3.3.2.4 Regional distribution of MBL-positive isolates  
The distribution of the 267 non-duplicate patient isolates among sub-regions of the 
UK is shown in figure 3.5. London accounted for 47% of these organisms, with MBL-
positive isolates referred from 28 London-region laboratories; all six major 
complexes (A-F) were represented in the capital, and nine other VNTR types were 
seen. Four of these 28 London laboratories were among the six sites that submitted 
more than 10 isolates, as described above. Twelve per cent (31/267) of isolates 
were referred from six different laboratories in the Greater Manchester sub-region. 
Isolates belonging to complex E (ST357) predominated there, mostly from the nine-
year persistence at North West_15, although isolates belonging to complexes A, B 
and D (STs 111, 235 and 654) were also seen at the five remaining laboratories. In 
the Sussex, Surrey and Kent sub-region half of the 18 representatives, received 
from five sites, belonged to complex D (ST654) with seven of these nine received 
from South_East_6; the remaining 9/18 isolates belonged to complexes B and C 
(STs 235 and 233) or had other VNTR profiles. Wales accounted for 6% (15/267) of 
isolates, mostly (13/15) from the outbreak of ST111 at Wales_1, although one 
ST111 isolate was from another laboratory and one ST773 isolate was referred from 
the region. Finally, the 12 (4%) isolates submitted from five laboratories in Scotland 
variously belonged to complexes A, B, C and F (STs 111, 235, 233 and 773). Fewer 
than ten isolates were referred from each of the remaining UK sub-regions.  
 
 
 
  
 
 
Figure 3.5: Geographical sources of isolates in the UK, and distribution of the six main complexes (A-F) in each of the five sub-regions referring 
more than ten isolates. The sub-regions represented in this map are described in figure 2.2. 
9
6 
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3.3.2.5 Sequencing of MBL genes 
Isolates belonging to complexes C, E and F (STs 233, 357 and 773) consistently 
carried blaVIM, while complex A, B and D isolates (STs 111, 235 and 654/964) 
variously carried blaVIM, blaIMP, or blaNDM genes.  
In order to assess the diversity of MBL gene alleles within the six main complexes, 
representatives were selected to cover the VNTR variation. In complexes A, C, D, E 
and F (STs 111, 233, 654, 357 and 773) all blaVIM-positive representatives had  
blaVIM-2 alleles, whereas eight isolates selected from complex B (ST235) variously 
had blaVIM-1 (two isolates), blaVIM-2 (four isolates), blaVIM-4 (one isolate) or blaVIM-6 
(one isolate). Amongst eight representatives of the 22 blaIMP-positive isolates, 
blaIMP-1 (three isolates), blaIMP-7 (two isolates), blaIMP-10 (one isolate) and blaIMP-13 
(two isolates) alleles were seen. Both blaNDM-positive isolates had the blaNDM-1 
allele. 
 Typing of comparator P. aeruginosa bacteraemia isolates 3.3.3
As described in Section 2.1.2, the comparator set comprised 209 P. aeruginosa 
isolates collected in the UK and Ireland as part of the BSAC Bacteraemia Resistance 
Surveillance Programme in 2011.  Patient demographic and MIC data, provided by 
the BSAC, are presented in tables 3.7 and 3.8. Sixty percent of patients were male 
and 40% female, while the most prevalent age groups were 60-69 (23%), 70-79 
(27%) and 80+ (18%). Most isolates remained susceptible to all tested antibiotics. 
Only 4.8% were resistant to the carbapenems imipenem and meropenem, while 
6.7% were resistant to doripenem. None of these isolates carried MBLs, indicating 
98 
 
that their carbapenem resistance was likely mediated by mutations leading to OprD 
inactivation, AmpC hyperproduction or increased efflux.  
All 209 isolates were typed by VNTR and showed far greater diversity than the MBL 
producers, with 136 different VNTR profiles represented (figure 3.6). Two isolates 
had a VNTR profile consistent with complex B (ST235) and one had a profile 
indicative of complex C (ST233); the remaining 206 isolates did not share VNTR 
profiles with any of the major complexes identified amongst the MBL-producing 
isolates.  
 
Table 3.7: Patient demographic data for BSAC bacteraemia isolates from 2011 
(n=209) 
Demographic Number of patients (%) 
Age (years)  
0-4  10 (5) 
5-19  5 (2) 
20-39  12 (6) 
40-49  13 (6) 
50-59  26 (12) 
60-69  48 (23) 
70-79  56 (27) 
80+  37 (18) 
Not available 2 (1) 
  
Gender  
Female 83 (40) 
Male 126 (60) 
  
 
Table 3.8: MIC distributions for 209 P. aeruginosa isolates from the BSAC Bacteraemia Resistance Surveillance Programme in 2011 
 
 
 
 
 
 
 
S, susceptible; I, intermediate; R, resistant. Cells shaded in dark grey represent resistant isolates, light grey represent intermediate, and white 
susceptible.  
*Isolates have an MIC of ≥ the indicated value 
Antibiotic Number of isolates with MIC (mg/L) %S %I %R 
  ≤0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128       
Gentamicin 3 2 35 122 36 5 2 1 3 97.1 - 2.9 
Ceftazidime 6 71 98 20 10 1 3* 98.1 - 1.9 
Imipenem 3 13 26 110 35 4 8 10* 91.4 3.8 4.8 
Meropenem 42 70 47 20 12 8 3 6 1* 91.4 3.8 4.8 
Doripenem 98 49 36 9 3 11 1 1 1* 91.9 1.4 6.7 
Piperacillin-tazobactam 2 31 125 29 12 6 1 3 95.2 - 4.8 
Ciprofloxacin 73 83 17 19 3 3 3 5 1 1 1 82.8 9.1 8.1 
Colistin   2 6 199 2             100 - 0 99 
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Figure 3.6: Minimum spanning tree based on clustering at the first eight VNTR loci 
for P. aeruginosa isolates from the BSAC Bacteraemia Resistance Surveillance 
Programme (n=209). The diameter of the circle is relative to the number of isolates 
with that VNTR profile. Shading indicates complexes. Thick solid lines represent 
single locus variants while thin solid lines and dotted lines represent multi-locus 
variants. Isolates corresponding to VNTR complexes B and C (STs 235 and 233, 
respectively) are shown in black circles. Isolates corresponding to previously 
reported clones as described by Martin et al.115 are indicated and had the following 
VNTR profiles; Clusters A (8,3,4,5,2,3,5,2,x), D (10,3,5,5,4,1,3,x,x,), E 
(11,4,5,2,2,1,x,2,x) and H (12,5,1,5,2,2,x,x,x), Clone C (11,6,2,2,1,3,7/8,2/3,x), and 
PA14 (12,2,1,5,5,2,x,5,x). Two novel clusters are indicated with VNTR profiles 
12,5,5,5,4,3,7,6,x and 12,8,2,2,4,3,5,1,x, respectively. 
 
  
PA14 (ST253)
Cluster H
Clone C 
(ST17)
Complex B 
(ST235)
Complex C 
(ST233)
Cluster A 
(ST27) Cluster D 
(ST395)
Cluster E
Novel cluster 1
Novel cluster 2
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3.4 Discussion 
Most (86%) of the MBL-producing P. aeruginosa  isolates referred to the UK 
reference laboratory between 2003 and 2012 belonged to six VNTR complexes, 
corresponding to internationally recognised ‘high-risk clones’, STs 111, 235, 233, 
357, 654 and 773, and the majority had VIM-type MBLs. These findings are in 
striking contrast to the general population structure of P. aeruginosa, as described 
in Chapter 1, where a recent UK study115 shows considerable diversity, with overlap 
between environmental isolates and those causing clinical infection, although with 
a few prevalent clusters in diverse locations. This general diversity was confirmed 
by typing isolates from the BSAC Bacteraemia Surveillance Programme. 
The six major complexes seen here among MBL-producers were not prevalent 
amongst MBL-negative isolates in this previous UK study, 115 nor were they 
prevalent in our comparator collection of (largely susceptible) P. aeruginosa isolates 
from the BSAC Bacteraemia Resistance Surveillance Programme, where they 
accounted for just 1.4% (3/209) of isolates. Rather, these ‘high-risk clones’ seem to 
represent a distinct subset of P. aeruginosa lineages, which may be successful 
precisely due to a particularly strong ability to acquire and/or maintain resistance 
genes compared with the general P. aeruginosa population.  Notably, the reference 
laboratory has also received representatives corresponding to these six major 
complexes that carry non-metallo-carbapenemases, including a few ST235 isolates 
carrying blaGES-5 and two isolates from a single patient with a VNTR profile 
corresponding to ST773 and both carrying blaOXA-181 (unpublished AMRHAI data). 
Moreover, in three of these six complexes, we encountered isolates that variously 
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had either blaVIM or blaIMP genes, and in one complex (B; ST235), several different 
blaVIM alleles, indicating that organisms belonging to the same complex had 
independently acquired different genes.  
As described in detail in Section 1.8, ‘high-risk clones’ with STs 111 and 235 are 
among the most commonly reported lineages amongst MBL-producing P. 
aeruginosa worldwide. These lineages, corresponding to complex A (ST111) and 
complex B (ST235), were also the most prevalent amongst our UK MBL-producing P. 
aeruginosa, accounting for 30% and 21% of isolates, respectively.  
Complex A (ST111) was the largest group in the MBL-producing collection, and most 
isolates were blaVIM-positive, with all sequenced representatives carrying blaVIM-2, as 
most commonly reported for ST111 in other European countries,80,121–127 although 
we did also receive five representatives with blaIMP-1 or blaIMP-13. Although 25 
laboratories referred isolates belonging to the complex, it was dominated by 
representatives from long-term ‘outbreaks’ at London_17 and Wales_1, lasting 7 
years and 18 months, respectively. VNTR profiles within this complex were highly 
similar even when referred from different hospitals, with most differing only at 
locus 61, the most variable of the nine VNTR loci.104  
Isolates belonging to complex B (ST235) had more diverse VNTR profiles than those 
in complex A. Representatives came from 25 referring laboratories, with no more 
than eight from any single site, and no known epidemiological links between most 
isolates. Although most carried blaVIM, diverse alleles were identified (blaVIM-1, -2, -4 
and -6); this variation is in contrast to the situation in Russia, Belarus and 
Kazakhstan, where an ST235 clone consistently carried blaVIM-2 as part of the same 
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integron structure.136  Together with the VNTR diversity, this carbapenemase 
diversity, including enzymes belonging to different VIM subgroups, suggests 
multiple imports and/or acquisitions of blaVIM and blaIMP alleles by ST235 P. 
aeruginosa have occurred in UK hospitals.  
The other four major complexes (C-F) also correspond to ‘high-risk clones,’ 
previously reported as hosts for MBLs. We consistently saw blaVIM-2 in complex C 
(ST233) isolates. ST233 representatives with blaVIM-2 have likewise been found in 
Norway (imported from Ghana),124 Japan,171 South Africa,86 the USA,147 and 
Romania,172 though a ST233 organism was reported to carry a blaIMP-1 variant in 
Singapore.64  ST654 (complex D) has been reported in Sweden (imported from 
Tunisia) carrying blaVIM-2 genes,
124 in Singapore carrying blaIMP-1 and blaIMP-26,
64 and 
in Argentina carrying a KPC carbapenemase.42 Here we predominantly saw blaVIM-2, 
in ST654 but one isolate had blaNDM-1; a gene strongly associated with India, to 
which the patient had travelled. The sole ST964 isolate (also complex D/ST654-
related) had blaIMP-1, as also reported in this ST in Singapore.
64 We saw only blaVIM-2 
in representatives of complex E (ST357), referred from nine different laboratories 
over a nine-year period, but this ST has previously been reported with blaVIM-2 or 
blaIMP-7 genes in a hospital in the Czech Republic,
68 whilst a few ST357 isolates with 
blaIMP-7 were reported in Poland.
65 Finally, ST773 (complex F) has been recently 
reported among Indian isolates carrying blaVIM-2.
137 Interestingly, the geographically 
scattered complex F isolates tested here also all had blaVIM-2 and four were from 
patients who had recently travelled to India; travel history for the other nine 
patients was not available.  
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The remaining VNTR profiles, accounting for 14% of MBL producers, were diverse, 
and probably represent multiple separate acquisitions of blaVIM and blaIMP genes 
either de novo from an undefined source species or as a result of horizontal 
exchange of genetic elements between P. aeruginosa strains.  
Although comprehensive epidemiological data are lacking, VIM-type MBLs clearly 
are the predominant carbapenemases seen in P. aeruginosa in Europe, with only 
sporadic isolation, and/or local spread of strains producing IMP- or NDM- types (see 
Section 1.6), although some regional spread of the latter has been reported in the 
Balkan region.93  
The 22 isolates harbouring blaIMP genes belonged to diverse VNTR types and had 
varied blaIMP alleles (blaIMP-1, -7, -10 or -13) with no identifiable epidemiological links 
among most isolates. Just two blaNDM-1-positive isolates were found, both with 
different VNTR types. These IMP- and NDM-MBL-producing isolates may have been 
imported from outside the UK, or acquired locally, with limited spread of IMP-
producers at a few sites. Unfortunately, data on patient travel were not available 
for most isolates, but single isolates carrying blaNDM and blaIMP were from patients 
who had travelled to India and Pakistan, respectively.  
MBL-positive P. aeruginosa were referred from around half the hospital 
laboratories in the UK, with all six major complexes found in multiple UK regions. 
Referral of suspect isolates to the AMRHAI reference unit is not mandatory, and 
some likely MBL producers were no longer viable in AMRHAI’s archives, so the 
numbers reported here under-estimate the true incidence of infection and 
colonisation by MBL-producing P. aeruginosa in the UK.  
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MBL-producers were rare at most referring sites, but a few sites did have persistent 
problems with single clones. These included the previously reported outbreak of 
ST357 P. aeruginosa at North West_15156 where the strain, which also produced a 
VEB-1a extended-spectrum-β-lactamase, was thought to have been imported via a 
patient transferred from an Indian hospital, but to have acquired the VIM-MBL 
locally in the UK. In addition, the persistence of ST111 and ST654 at London_17 and 
South East_6, respectively, were previously reported157. The ST111 strain was seen 
in more than 89 patient isolates at London_17 between 2005 and 2012,157 of which 
29 were included here. The patients were dispersed across different hospital wards 
and scattered over the seven-year period, suggesting a widespread environmental 
source of the organism was more likely than patient-to-patient transfer. Possible 
environmental sources were investigated as part of this previous study157 and while 
all samples of the water supply remained negative, some samples from waste 
outlets, as well as the hospital sewer, were positive. On this basis, the wastewater 
system was suggested as the source of these infections, with blockages and 
subsequent backflow of waste potentially contaminating clinical areas. 
Alternatively, the wastewater system could have simply been contaminated from 
infected patients, and it remains possible that there was another unidentified 
reservoir of the organism in the hospital that caused this long-term problem.  
In contrast to this persistence of a single strain at a site over a long period, two 
laboratories (London_7 and London_12) referred MBL-positive isolates of diverse 
types over seven and eight year periods, respectively, implying that MBL-producing 
P. aeruginosa were introduced repeatedly. Since these ‘high-risk clones’ are 
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reported amongst MBL-producing P. aeruginosa worldwide, it is important not to 
assume that isolates with the same VNTR or ST profile are directly related unless 
this view is supported by epidemiological links between affected patients; it is just 
as likely that cases could represent repeated imports of the same clone from 
different sources. 
In summary, internationally reported ‘high-risk clones’ with STs 111, 235, 233, 654, 
773 and 357 were important in the increase in MBL-producing P. aeruginosa in the 
UK. These clones represent a distinct subset of isolates, as they were not prevalent 
in our comparator collection of mostly carbapenem susceptible isolates from the 
BSAC Bacteraemia Surveillance Programme, and appear to have a strong ability to 
acquire and/or maintain resistance genes or the mobile elements containing them. 
Possible reasons for this could include that these lineages have either stable genetic 
structures by which they can acquire new genes, or biological features that mean 
that they are more likely to acquire or maintain diverse horizontally-transferred 
genetic elements. To explore this more fully I went on to characterise the class 1 
integron structures that usually contain these blaMBL genes and the wider genetic 
environment of these elements including their chromosomal or plasmid location. 
This work is described in the following chapter. 
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4 Genetic environment of MBL genes 
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4.1 Introduction 
Chapter 3 explored the molecular epidemiology of MBL-producing P. aeruginosa 
isolates in the UK and showed that most of these organisms belonged to 
international ‘high-risk clones’. As described in Section 1.9 the literature indicates 
that MBL genes blaVIM and blaIMP are usually located in class 1 integrons, which 
often also contain genes conferring resistance to other antibiotic classes, such as 
aminoglycosides. Class 1 integrons may in turn be located on mobilisable genetic 
elements, such as transposons, plasmids or genomic islands. It is important to 
determine the genetic environment of the MBL genes, including the integrons and 
mobile genetic elements containing them, to understand how they are able to 
spread among bacterial strains.  
 Origin of clinically relevant class 1 integrons  4.1.1
The class 1 integrons that are commonly seen among clinical isolates usually share 
two structures, the 5’ and 3’ conserved sequences (5’CS and 3’CS), often with 
diverse arrays of resistance gene ‘cassettes’ between them (figure 4.1). The 5’CS 
consists of the class 1 integrase gene (intI1), the attI1 recombination site, and the 
promoter (Pc) while the 3’CS consists of fused qacEΔ1 and sul1 genes, conferring 
resistance to quaternary ammonium compounds and sulphonamides respectively, 
followed by an open reading frame, orf5, of unknown function. Class 1 integrons, 
containing the 5’ and 3’CS, are commonly found as part of Tn21-like structures173 
(figure 4.1); they are thought to have emerged as a result of a series of random 
events, with selection pressures during the antibiotic era, favouring their 
proliferation.174 
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Figure 4.1: Tn21 transposon structure. Figure taken from Liebert et al.173 
 
Metagenomics studies of DNA from various environmental sources have discovered 
diverse class 1 integrase genes, some sharing as little as 92% nucleotide identity.175 
However the integrase genes of clinically-relevant class 1 integrons are almost 
always identical to one another, suggesting that they may be descended from a 
single ancestor.153,175,176 Structures with similar intl1 genes to clinical class 1 
integrons are found on the chromosome of many members of the 
Betaproteobacteria, where they are generally species-specific.153 On this basis, the 
ancestor of the clinically-relevant class 1 integrons is thought to have been 
captured from the chromosome of a member of the Betaproteobacteria by a 
Tn5090-like transposon (also known as a Tn402-like transposon).153 Tn5090 is a 
member of the Tn5053 transposon family and readily inserts at the resolution (res) 
sites often found in plasmids.177 So, once the Tn5090-like transposon had acquired 
the integron it was likely to be incorporated into a variety of plasmids, which then 
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allowed it to be mobilised between different bacteria. This Tn5090-like structure is 
thus thought to have been incorporated into a plasmid-encoded transposon, similar 
to Tn21. Such a structure, with the integron additionally having acquired a qacE 
gene, may have been selected by the use of quaternary ammonium compounds as 
hospital disinfectants in the early 1930s. Subsequently, insertion of a sul1 gene, 
truncating qacEΔ1, could have been selected for by the introduction of the 
sulphonamides, an early synthetic antibacterial class, in the late 1930s. Around the 
same time a deletion event is thought to have resulted in the loss of the Tn5090 
transposition function (including loss of the tniC and part of the tniB genes), leading 
to the Tn21-like structures that are now commonly seen in association with diverse 
resistance gene cassettes.173 
While this classical class 1 integron structure containing both the 5’ and 3’CS, is the 
most common in Gram-negative bacterial species from clinical sources, including P. 
aeruginosa,
153 other  variants lacking the 3’CS, are described in the literature, as 
shown in figure 4.2. Some have functional Tn5090-like transposon genes, including 
tniC, in their 3’ region, as first reported amongst P. aeruginosa isolates in the USA87  
and subsequently in India,162 Russia,136 Norway,178 and Tanzania.179 These are 
thought to be descended from the same Tn5090-like ancestor, as the classical class 
1 integron.162 Another atypical class 1 integron structure contains a sul1 gene and 
partial 5’CS in its 3’ region, but lacks the qacEΔ1 gene, and was associated with 
downstream Tn5501 and Tn5393 genes, as found in a P. aeruginosa isolate from 
Sweden.124  
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Figure 4.2: Examples of class 1 integrons with different 3’ structures that have been 
seen in clinical isolates of P. aeruginosa. Not to scale. 
 
 Genetic context of class 1 integrons 4.1.2
Similar class 1 integron structures are found in different bacterial strains and 
species so mobilisation is thought to play an important part in the spread of the 
resistance genes they contain. However the mechanisms responsible for this lateral 
transfer are not well understood. As discussed in Section 1.9, the MBL-encoding 
class 1 integrons seen in P. aeruginosa have sometimes been localised on plasmids. 
For example, Li and colleagues described a 24-kb plasmid including a blaVIM-7-
containing class 1 integron from a P. aeruginosa isolate in the USA,89 whilst a ~45-
kb blaVIM-2-containing plasmid was found in a clinical P. aeruginosa isolate from 
France,164,180 and the blaIMP-9 gene was located on a large ~450-kb plasmid in P. 
aeruginosa isolates from China.181  
However, in many cases MBL-encoding plasmids cannot be found in MBL-producing 
P. aeruginosa, therefore it is thought that these and other acquired resistance 
genes may be more commonly located on the chromosome in this species.151  With 
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the increased availability of whole-genome sequencing (WGS) technology, several 
recent studies have shown that these resistance genes can be carried within 
genomic islands - large structures present in chromosomal regions that show 
evidence of being acquired by horizontal gene transfer.  
In P. aeruginosa, these structures include a blaVIM-2-containing genomic island 
inserted in the chromosomal PA5101 gene of an ST233 P. aeruginosa from an 
outbreak in the USA (figure 4.3).147 This island contained two class 1 integrons 
carrying genes conferring resistance to multiple antibiotics along with a mercury 
resistance operon. Another example is a blaVIM-1-containing genomic island found in 
an ST235 P. aeruginosa strain isolated in Italy (figure 4.4), in which the blaVIM-1 gene 
was located within the transposon Tn6249, itself located within a disrupted 
glycerate kinase gene situated within a PA143/97 (PACS171b-like) genomic island; 
this in turn, was inserted within the chromosomal endA gene.182 The Tn6249 
transposon contains two class 1 integrons which, in addition to the blaVIM-1 gene, 
carried genes conferring resistance to aminoglycosides and chloramphenicol.  
  
Figure 4.3: blaVIM-2 containing genomic island (VIM GI) found in ST233 P. aeruginosa from the USA (GenBank accession number KJ463833), 
indicating the similarity of part the genomic island to an integron present in Salmonella genomic island 2 (SGI2).  Figure taken from Perez et al. 147  
1
1
3 
  
 
 
Figure 4.4: blaVIM-1-containing genomic island found an ST235 P. aeruginosa strain isolated in Italy (GenBank accession number: LK054503). The 
blaVIM-1 containing island is located within the disrupted glycerate kinase gene, which is in turn located within a PACS171b-like genomic island 
(PA143/97) inserted in the endA gene of the P. aeruginosa chromosome Figure taken from Di Pilato et al.182  
1
1
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Similar genomic islands, or segments of genomic islands, have been found in 
epidemiologically diverse bacteria, of the same or different species, suggesting that 
horizontal transfer of these structures can occur. For example, the blaVIM-2-
containing island shown in figure 4.3 contained an integron with similarity to part of 
Salmonella genomic island 2.147  The mechanisms by which these genomic islands 
may be mobilised between different strains and species are only beginning to be 
understood. It is apparent that they often contain transposons or similar mobile 
genetic elements, such as insertion sequence common regions (ISCR), which could 
mobilise the DNA to a mobile genetic element capable of lateral transfer, such as a 
conjugative plasmid. However, some genomic island structures can mobilise 
themselves, either alone or with the help of other elements, by conjugation or 
transduction.183 These include bacteriophage, integrative and conjugative elements 
(ICE), and integrative and mobilisable elements (IME), which share some similar 
features and are described below. 
Bacteriophages are viruses that infect and replicate in bacterial cells. Bacteriophage 
genomes can exist either as an extrachromosomal form or in some cases integrated 
into the bacterial chromosome as latent ‘prophage’.  During transduction 
bacteriophages may transfer sections of the host genome to another bacterial cell, 
and were shown to mediate the transfer of antibiotic resistance genes in several 
bacteria. For example, P22 phages were reported to mobilise multiple resistance 
genes in Salmonella184 and bacteriophage-mediated transfer of tetM and ant(2”)-I 
resistance genes was demonstrated in enterococci.185 
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ICE are a diverse, and growing class of elements that are able to self-excise and 
integrate into the genome, like bacteriophage, but which are also capable of 
conjugation, similarly to conjugative plasmids.186 In addition to genes necessary for 
these functions, ICE contain diverse accessory genes, including acquired antibiotic 
resistance determinants, and are found in the genomes of many bacteria. ICE that 
have been described in Pseudomonas spp. include the genomic island PAPI-1, which 
encodes genes involved in virulence and biofilm formation, and ICEclc, which is 
involved in chlorcatechol degradation.187 Several Tn4371-like ICEs have been found 
in P. aeruginosa, carrying a variety of accessory genes including those encoding RND 
efflux and arsenate resistance pumps;188 they include ICETn43716061 which was 
found on the chromosome of a Brazilian P. aeruginosa isolate carrying blaSPM, 
although this MBL gene was associated with an ISCR4 element, not a class 1 
integron.189 
Further genomic island structures, called IME have also been described. These share 
some features with ICE, such as the ability to integrate and excise themselves, but 
require a helper element, such as a conjugative plasmid, for cell-to-cell transfer.186 
As with ICE, IMEs encode diverse accessory functions, with several having been 
associated with antibiotic resistance genes.190 For example the Salmonella genomic 
island 1 includes a complex class 1 integron encoding multiple resistance genes and 
can excise itself from the genome into a circular form that can be mobilised in trans 
with the help of an IncC plasmid, after which the element can integrate into the 
genome.191  
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 Determining the genetic context of class 1 integrons 4.1.3
Many studies have characterised class 1 integron gene cassette arrays by PCR 
targeting conserved 5’ and 3’ regions.151 While this information can be useful to 
inform epidemiological studies, it does not give any information on the wider 
genetic environment of the elements. 
A few studies have attempted to determine the wider genetic context of these 
elements. Their localisation within plasmids can be determined by attempting 
plasmid transfer by transformation or conjugation. However, not all plasmids 
transfer well using these methods, due to factors such as their large size, low 
replicon number, or because they do not encode conjugation functions. S1 nuclease 
digestion and hybridisation studies have also been used to detect plasmids, 
particularly large ones.192 S1 nuclease cuts only single-stranded DNA, as is present 
transiently in supercoiled plasmids, due to torsional stress of the molecule, and thus 
converts plasmids to linear DNA. The enzyme does not so frequently cut 
chromosomal DNA. Consequently, after S1 nuclease treatment, linearised plasmid 
DNA can be separated from relatively intact chromosomal DNA by PFGE. The 
linearised plasmid can also be reliably sized with reference to a DNA ladder, in 
contrast to a supercoiled plasmid, where its secondary structure affects migration. 
Hybridisation of the separated products from the S1 nuclease digest with a blaMBL-
specific probe can then be used to determine whether the MBL gene is located on 
the plasmid.  
A similar approach can be used to locate genes on the chromosome. The technique, 
first described by Liu et al.,193 involves the use of the I-ceu I restriction enzyme, 
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which acts on ribosomal RNA genes and thus cuts bacterial chromosomal DNA at a 
few sites. For example I-ceu I digests P. aeruginosa DNA at four sites, resulting in 
four chromosomal fragments. As with S1 nuclease, separation of I-ceu I digestion 
products by PFGE, followed by hybridisation, can be used to localise an MBL gene to 
a chromosomal fragment.  
Whole genome sequencing methods are increasingly available and have also been 
used to determine the structure of antibiotic-resistance-encoding genomic islands 
and plasmids, including those in P. aeruginosa.147,182 Short-read technologies, such 
as Illumina sequencing are often used, but it can be problematic to assemble the 
repetitive regions often found in integron-containing structures, confounding 
attempts to determine their genetic context. Long-read technologies such as the 
MinION (Oxford Nanopore Technologies) or PacBio RS II (Pacific Biosciences, 
California, USA) are more expensive and, in the case of MinION, have lower 
accuracy than the short-read technologies, but can be used to scaffold the more 
accurate short reads. For example, Ashton and colleagues recently used a 
combination of Illumina and MinION reads to determine the structure and 
chromosomal location of a  24-kb antibiotic resistance island in Salmonella.194 
 Aims 4.1.4
The overall aim of the work described in this chapter was to investigate the genetic 
context of the MBL genes in our collection of MBL-producing P. aeruginosa isolates. 
Specific aims were (1) to characterise the blaVIM- and blaIMP-containing class 1 
integron structures found in the MBL-producing P. aeruginosa isolates, including 
the sequencing of prevalent integrons, and (2) to investigate the wider genetic 
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environment of these integrons including their chromosomal and/or plasmid 
locations.   
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4.2 Methods 
 Detection of class 1 integrons 4.2.1
The strategy for the amplification of MBL-encoding class 1 integrons is illustrated in 
figure 4.5. Integrons were sought by two PCRs, initially using primers specific to the 
5’ or 3’ CS (5’CS with 3’CS_1 3’CS_2), together with blaVIM- and blaIMP- specific 
primers (VIM-2004A, VIM2004B, IMP Fwd or IMP Rev). Where no amplicon was 
generated using reverse primers specific to the 3’CS together with an MBL-gene-
specific forward primer, atypical class 1 integron structures were investigated. 
Tn5090-like class 1 integrons (which lack the 3’CS), and structures containing the 
sul1 gene, but not qacEΔ1,124 were sought using a reverse primer specific to tniC 
(Tni-CF) or sul1 (Sul-R), respectively, together with an MBL-gene-specific forward 
primer (figure 4.5). Primer sequences are shown in table 2.1. Cycling conditions 
were 94oC for 3 minutes, followed by 35 cycles of 94oC for 1 minute, 55oC for 1 
minute and 72oC for 5 minutes, and a final extension step of 72oC for 15 minutes; 
the long elongation times were to allow for amplification of large integrons.  
Resulting PCR products were sized on 1% agarose gels. For isolates where the 
amplicon sizes were similar for both the 5’ and 3’ regions of the integron, the 
amplicons were digested using AccI or SmlI restriction enzymes (New England 
BioLabs) at 37oC or 55oC, respectively, and electrophoresed on 1.5% agarose gels; 
resulting fingerprints were compared visually. Variable regions of frequently-
detected integrons were sequenced using the primers described above for the 
amplification of class 1 integrons as well as additional primers targeting MBL or 
other genes contained within the integrons (VIM-2A, VIM-2B, dhfr2_F, dhfr2_R, 
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aacA29AB1, aacA29AB2, aacA4-F, aacA4-R, OXA10like-F, OXA10like-R, AACA7-F, 
AACA7-R, aacA7-F2, strAstrB-F and strAstrB-R). All primer sequences are shown in 
table 2.1. 
 
Figure 4.5: Strategy for the amplification of different class 1 integron 3’ regions 
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 rpoB gene sequencing 4.2.2
A region of the rpoB gene was amplified using primers CM7 and CM31B (see table 
2.1), as described by Mollet and colleagues.168 Cycling conditions were 94oC for 3 
minutes, followed by 35 cycles of 94oC for 30 seconds, 60oC for 30 seconds and 72oC 
for 45 seconds, and a final extension step of 72oC for 10 minutes. Amplicons were 
sequenced as described in Section 2.2.3.4, using the same primers. Resulting 
sequences were analysed in Bionumerics Software v6.1 (Applied Maths) and 
compared with sequences in our database, including those for type strains for most 
of the species found clinically, and strains detailed by Ait Tayeb and colleagues,195 to 
identify them to species level. 
 Plasmid transformations 4.2.3
Overnight cultures of MBL-producing P. aeruginosa strains were prepared in 
nutrient broth. Plasmid extractions were carried out using the QIAprep Spin 
Miniprep Kit (Qiagen), according to the manufacturer’s instructions. 
Transformations were attempted by electroporation into the DH5α E. coli strain 
(Thermo Scientific). Briefly, DH5α cells were thawed on ice and 20 μl cells were 
mixed with 2 μl of the plasmid extract in a 0.5 ml tube and kept on ice. The mixture 
was added to a 0.1 cm Electroporation Cuvette (Bio-Rad, Hemel Hempsted, UK) and 
pulsed at 1.8 kV on the Gene Pulser Xcell Electroporation System (Bio-Rad). After 
pulsing, 0.5 ml of Super-Optimal Broth with Catabolite Repression (SOC broth; 
Bioline) was immediately added to the cuvette and the contents transferred to a 15 
ml conical tube, which was incubated at 37˚C with shaking for approximately one 
hour. To select any transformants, 100 μl of the broth mixture was spread on to 
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Luria-Bertani (LB) agar plates containing 100 mg/L ampicillin and incubated at 37˚C 
overnight. Any resulting colonies were screened for the presence of the 
carbapenemase gene by PCR, as described in Section 2.2.4.  
 S1 nuclease and I-ceu I digests 4.2.4
S1 nuclease and I-ceu I digests and hybridisation were carried out as first described 
by Barton et al.192 and Liu et al.,193 respectively, as outlined below.  
4.2.4.1 Preparation of agarose plugs 
Overnight cultures were grown on nutrient agar. Bacterial suspensions were made 
in 1 ml of SE buffer (75 mM NaCl, 25 mM EDTA, pH 7.5) to a turbidity of 2.3-2.7 
MacFarland units. An equal volume of bacterial suspension was mixed with 2% 
Macrosieve Low Melt Agarose (Flowgen, Nottingham, UK) in SE buffer at 56oC and 
dispensed into the assembled mould, which was kept at 4oC until plugs were set. 
The agarose plugs were then removed to bijou bottles and incubated overnight at 
37oC with shaking in 3 ml of first lysis buffer (6 mM Tris, 100 mM EDTA, 1M NaCl, 
0.5% w/v Brij 58, 0.2% w/v sodium deoxycholate, 0.5% N-lauroyl sarcosine, 1 mM 
MgCl2) containing 500 µg/ml lysozyme. The lysis buffer was then replaced with 3 ml 
alkaline lysis buffer (1% (w/v) N-lauroyl sarcosine, 0.5 M EDTA, pH 9.5) containing 
60 µg/ml proteinase K and incubated overnight at 56oC with shaking. The plugs 
were then washed three times at 4oC  using 3 ml TE buffer (10 mM Tris, 10 mM 
EDTA, pH 7.5), for a minimum of 30 minutes per wash. After the third wash the 
buffer was removed and replaced with a further 2 ml TE buffer. The plugs were 
stored at 4oC until use. 
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4.2.4.2 Digestion of plugs 
Whole plugs were digested using S1 nuclease (Thermo Scientific) or I-ceu I (New 
England BioLabs). These plugs were first equilibrated in 1x S1 Buffer or 1x CutSmart 
Buffer for 20 minutes. The buffer was then removed and replaced with 1x S1 Buffer 
containing 0.08 U/μl S1 nuclease or 1x CutSmart Buffer containing 0.04 U/μl I-ceu I 
enzyme and incubated at 37oC for 45 minutes or 3 hours, respectively. At the end of 
the incubation period 10 μl of 0.5 M EDTA was added to stop the reaction. 
4.2.4.3 PFGE running conditions 
Digested DNA in the plugs was separated by PFGE on a 1.2% agarose gel on CHEF 
DRII apparatus (Bio-Rad). The Lambda Ladder PFG Marker (New England BioLabs) 
was used to size the fragments. Gels were run at 6 V for 24 hours at 12oC with 
switch times of 20-120 seconds.   
4.2.4.4 In-gel hybridisation  
In-gel hybridisation was carried out as described by Khan and Nawaz.196 The gel was 
washed twice in distilled water for 10 minutes, to remove salts, and then dried 
between two sheets of blotting paper in a hybridisation oven at 55oC overnight. The 
dried gel was then rehydrated in distilled water for 10 minutes resulting in a 
thinner, stronger gel able to withstand subsequent steps. The DNA was denatured 
by immersing the gel in 100 ml denaturation buffer (0.5 M NaOH, 1.5 M NaCl) for 30 
minutes, washing it twice in distilled water for 5 minutes and neutralising in 100 ml 
neutralisation buffer (0.5 M Tris-HCl, pH 7.5, 1.5 M NaCl). The DNA was cross-linked 
to the gel by placing on a UV transilluminator for 5 minutes. The gel was incubated 
at hybridisation temperature (42oC) with gentle shaking for 2 hours in 15 ml per 100 
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cm2 of pre-heated DIG EasyHyb (Roche, Sussex, UK), in a sealed plastic container in 
the water bath. An 801-bp DIG-labelled blaVIM probe was prepared using primers 
VIM-2A and VIM-2B (table 2.1) and the PCR DIG Probe Synthesis Kit (Roche), 
according to the manufacturer’s instructions. Cycling conditions were 95oC for 2 
minutes, followed by 30 cycles of 95oC for 10 seconds, 55oC for 30 seconds and 72oC 
for 2 minutes and a final extension step of 72oC for 7 minutes. The probe was 
denatured at 95oC for 5 minutes, followed by rapid cooling on ice immediately prior 
to use; then 2 μl of probe per ml was added to 50 ml pre-heated Hybridisation 
Solution (Roche). The gel was incubated with this mixture at 42oC overnight with 
gentle shaking. Stringency washes were carried out twice with ample 2x SSC, SDS 
0.1% for 5 minutes at room temperature, followed by twice with 0.2x SSC, SDS 0.1% 
for 15 minutes at 68oC, both with gentle shaking.  
The following steps were all carried out at room temperature with gentle shaking 
unless otherwise stated. First, the gel was washed with 100 ml of 1x Wash Buffer 
(Roche) for 5 minutes, followed by incubation in 100 ml of Blocking Solution (Roche) 
for 30 minutes. The Anti-DIG-AP Conjugate (Roche) was centrifuged at 15700 rcf for 
5 minutes and diluted 1:5000 in blocking solution; the gel was incubated together 
with this antibody mixture for 30 minutes. Following this, the gel was washed twice, 
for 15 minutes each, in 100 ml Washing Solution (Roche) and equilibrated in 100 ml 
Detection Buffer (Roche) for 5-10 minutes. After transferring to a clean container 
approximately 40 ml of freshly prepared NBT/BCIP (Roche) was poured on to the 
gel, which was incubated in the dark without shaking until the colour had developed 
sufficiently (2 hours – overnight). This colour reaction was stopped by washing the 
gel in distilled water for 15 minutes. 
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 Whole genome sequencing (WGS) data analysis for detection 4.2.5
of genomic islands 
Genomes were sequenced using Illumina and MinION technology, as described in 
Section 2.2.5. Genome assemblies were carried out using tools available on the PHE 
instance of the Galaxy server (https://galaxyproject.org/). Assemblies of Illumina 
fastq reads only were produced using SPAdes version 2.5.0 
(http://bioinf.spbau.ru/spades) with the following settings:  
Single cell: No,  
Careful correction: Yes,  
Use rectangle correction for repeat resolution: No,  
Number of threads: 16,  
Number of iterations for read error correction: 1,  
K-mers to use; 21, 33, 55, 77  
For hybrid assemblies, the multi-fasta files containing MinION reads were used in 
combination with fastq files produced by Illumina sequencing using SPAdes version 
3.1.1 (http://bioinf.spbau.ru/spades); settings were as above, except that the 
‘supply long reads’ option was enabled to allow the inclusion of the multi-fasta file 
containing the MinION reads in the analysis. 
MinION reads were mapped to the Illumina-only or SPAdes assemblies using the 
Map with LAST tool version 1.0 (http://last.cbrc.jp/), also on the PHE galaxy server; 
default settings were used as follows:  
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Use custom match/mismatch score matrix: False,  
Type of alignment: local,  
Match score: 1,  
Mismatch cost: 1, 
Gap existence cost: 1,  
Gap extension cost: 1,  
Insertion existence cost: 1,  
Insertion extension cost: 1,  
Minimum score for gapped alignments: 40  
The LAST output in the resulting text files was converted to BLAST format using the 
maf-convert.py script and parsed as previously described194 (this was carried out by 
Philip Ashton, Gastrointestinal Bacteria Reference Unit, PHE). Each resulting .xml file 
detailed each of the MinION reads and corresponding contigs of the assembly to 
which the read mapped as well as the position of MinION read in relation to the 
contig. The contig containing the blaVIM gene for each assembly was located by a 
BLAST search. The parsed map with LAST data were used to manually scaffold other 
contigs shown to be linked to the blaVIM-encoding contig by MinION reads, to obtain 
information on the genomic location of the blaVIM gene in the bacterial 
chromosome.  
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 PCR detection of genomic islands 4.2.6
Four different multiplex PCRs were designed to amplify the left- and right-hand 
chromosomal junctions of three different blaVIM-encoding genomic islands (referred 
to as genomic islands A, B and C; see below), which were previously described147,182 
(figures 4.3 and 4.4) or were identified as part of this work. Figure 4.6 shows the 
strategy for investigation of each of the three blaVIM containing genomic islands; 
primers used in the four PCRs are described below and their sequences are shown 
in table 2.1. For all PCRs, the cycling conditions were 94oC for 3 minutes, followed 
by 30 cycles of 94oC for 30 seconds, 60oC for 30 seconds and 72oC for 1 minute, with 
a final extension step of 72oC for 5 minutes. Q solution was included in the reaction 
mix for these PCRs, as described in Section 2.2.3. 
To detect genomic island A, isolates were screened for the junctions of a previously-
described147 blaVIM-2 containing genomic island insertion within the chromosomal 
PA5101 gene (figure 4.3; GenBank accession number KJ463833). The multiplex PCR, 
designated PCR 1, used primers targeting the PA5101 gene (PA5101_F and 
PA5101_R) and the left-hand (VIMGI-LH_R) and right-hand (VIMGI-RH_F) regions of 
the genomic island.  
Isolates were screened for a second blaVIM-2 containing genomic island (genomic 
island B), identified during this study (as described in Section 4.3.5.2) using 
multiplex PCR 2. Primers targeted the PA2229 chromosomal gene (PA2229_F and 
PA2229_R) and the left-hand (ST111-GI-J1_R) and right-hand (ST111-GI-J2_F) 
regions of the genomic island. 
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Selected isolates were screened for the insertion sites of a previously described182  
blaVIM-1-containing structure described in a ST235 P. aeruginosa isolate (genomic 
island C; figure 4.4; GenBank accession number LK054503) using two different 
multiplex PCRs (PCRs 3 and 4) designed as part of this work. PCR 3 targeted the 
insertion of a PACS171b-like genomic island (primers PACS171b_J1_R and 
PACS171b_J2_F) in the chromosomal endA gene (primers endA_F and endA_R); PCR 
4 targeted the junctions of the Tn6249-like transposon (primers urf2_R and 
TnpATn6249_F) within the glycerate kinase gene (primers glykin_F and glykin_R) of 
this PACS171b-like genomic island.  
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Figure 4.6: Strategy for PCR-based investigation of (a) genomic island A, (b) genomic 
island B and (c) genomic island C. Primer sequences are shown in table 2.1. 
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 Long-range PCR 4.2.7
Long-range PCR was carried out as described in Section 2.2.3.2 to check the linkage 
of genomic-island-associated blaVIM genes identified in this study with chromosomal 
genes. Primers PA5101_F, PA2229_R or glykin_F, targeting the chromosomal genes 
in which the genomic islands were inserted were used together with VIM2004B, 
which was specific to the blaVIM gene (see table 2.1 for primer sequences). Cycling 
conditions were 93oC for 3 minutes, followed by 30 cycles of 95oC for 30 seconds, 
60oC for 30 seconds and 68oC for 10 minutes, no final extension step was required. 
Q solution was included in the reaction mix for all long-range PCRs, as described in 
Section 2.2.3.2. 
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4.3 Results 
 Integrons found amongst P. aeruginosa isolates 4.3.1
Amplicons were obtained using a primer specific for the 5’CS together with another 
specific for the appropriate blaMBL gene from all of the 218/266 non-duplicate 
blaVIM- or blaIMP-carrying isolates of P. aeruginosa that could be recovered from 
AMRHAI’s archives. One hundred and nineteen of these 218 isolates had an MBL-
encoding integron with the 3’CS, 65 had Tn5090-like 3’ regions and 17 had the sul1 
gene but lacked qacEΔ1; the 3’ region could not be amplified using any primer 
combinations for the remaining 17 isolates. 
A total of 42 different blaVIM-containing integrons were seen amongst the 196 
blaVIM-positive isolates, detected in one to 58 isolates each; these isolates were 
referred from 74 hospital laboratories over the ten-year period, with individual sites 
referring one to 21 isolates each. Eight integron profiles were detected amongst the 
22 IMP-producers, referred from 15 different laboratories over the ten-year period, 
each referring one to five isolates each. Five blaIMP integrons had the 3’CS, two had 
Tn5090-like 3' regions and for one the 3’ region could not be amplified.  
4.3.1.1 Prevalent integron structures 
Six integron profiles (designated I-VI), all containing blaVIM, were each seen in more 
than five isolates. Each of these gave consistent restriction patterns on digestion 
with AccI or SmlI enzymes and these six integrons became the focus of further 
study. Representatives were selected for sequencing of the integron variable 
region: five of those studied contained blaVIM-2 cassettes, whilst one contained a 
blaVIM-6 cassette. Sequences of the variable regions of these integrons were 
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deposited in GenBank (accession numbers KR337988-KR337993), and their 
structures are shown in figure 4.7.  
A minimum spanning tree and a table showing the distribution of these six major 
integron types among isolates belonging to the main VNTR complexes (A-F), 
described in Chapter 3, are presented in figure 4.8 and table 4.1, respectively. Table 
4.2 shows the distribution of the integrons I-VI among different referring 
laboratories and maps showing this geographical distribution are presented in 
figure 4.9; these data are discussed further in the following sections. Most integrons 
were carried by representatives from multiple laboratories across the UK, the 
exception being integron VI, only seen at a single site, as detailed below. 
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Figure 4.7: Schematic diagrams of MBL-encoding class 1 integron variable regions 
identified in more than five isolates each (not to scale). Only partial integron 
structures could be obtained for integrons III and V with regions not confirmed with 
sequence data indicated by dotted lines. 
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Figure 4.8: Minimum spanning tree, based on clustering at the first eight VNTR loci 
for the 218 MBL-producing isolates still viable in the archives for study of their 
integron content. The six main complexes A-F and their corresponding STs are 
labelled. The size of the circle is relative to the number of isolates with that VNTR 
profile. Coloured segments of the circles represent the six main blaVIM-containing 
integron structures (I-VI), and white circles represent isolates that did not have one 
of the main integron types. Grey shading indicates complexes. Thick solid lines 
represent single locus variants; thin solid lines and dotted lines represent multi-
locus variants. 
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Table 4.1: Integrons detected amongst isolates belonging to each of the VNTR 
complexes (n=218) 
VNTR complex 
(corresponding 
ST)
 
Total 
isolates 
Number of 
submitting 
laboratories 
MBLs 
detected 
Major 
integron 
profiles 
seen
a 
Other integron 
profiles detected 
A (ST111) 65 25 VIM (60) 
IMP (5) 
I (58; 89%) Four integron 
profiles (two blaVIM- 
and two blaIMP-
containing) amongst 
remaining seven 
isolates  
B (ST235) 47 25 VIM (41) 
IMP (6) 
II (14; 30%) 
VI (4; 9%) 
15 integron profiles 
(13 blaVIM- and two 
blaIMP-containing) 
amongst remaining 
29 isolates   
C (ST233) 25 15 VIM (25) II (25; 
100%) 
None 
D (ST654/ 
ST964) 
18 11 VIM (17) 
IMP (1) 
IV (15; 83%) Three integron 
profiles (two blaVIM- 
and one blaIMP-
containing) amongst 
remaining three 
isolates   
E (ST357) 16 9 VIM (16) V (6; 38%) Eight integron 
profiles (all blaVIM-
containing) amongst 
remaining 10 
isolates  
F (ST773) 12 11 VIM (12) III (12, 
100%) 
none 
Other types 35 25 VIM (25) 
IMP (10) 
II (3; 9%) 
VI (7; 20%) 
19 integron profiles 
(15 blaVIM-, four 
blaIMP) amongst 
remaining 25 
isolates  
apercentages in brackets represent the proportion of the total number of isolates in each 
complex that carried each of the main integrons. 
 
 
 
 
  
  
 
Table 4.2: Geographical data for the major VNTR complex/ integron combinations 
Integron Complex 
(ST) 
No. of 
isolates 
No. of 
laboratories 
Overall time 
frame 
Major contributors (≥3 isolates) Minor contributors (1-2 isolates) 
I A (ST111) 58 20 7 years 
(2006-2012) 
London_17; 21 representatives over 80-month period 
Wales_1; 13 representatives over 18-month period 
London_26; 4 representatives over 45-month period 
London_12; 3 representatives over 23-month period 
One laboratory  referring two isolates 
Fifteen laboratories referring one isolate 
II B (ST235) 14 6 9 years  
(2004 - 2012) 
London_13; 5 representatives over 3-week perioda 
Scotland_4; 5 representatives over 114-month period 
Four laboratories referring one isolate 
 C (ST233) 25 15 5 years  
(2008-2012) 
London_7; 5 representatives over 27-month period 
London_13; 4 representatives over 18-month perioda 
Three laboratories referring two isolates 
Ten laboratories referring one isolate 
 Others 3 3 6 years 
(2006-2011) 
None Three laboratories referring one isolate 
III F (ST773) 12 11 7 years  
(2006-2012) 
No major contributors 
 
One laboratory referring two isolates  
Ten laboratories referring one isolate 
IV D (ST654/ 
ST964) 
15 7 9 years  
(2004 – 2012) 
South East_6; 7 representatives over 36-month period Two laboratories referring two isolates 
Four laboratories referring one isolate 
V E (ST357) 6 1 8 years  
(2003 – 2010) 
North West_15; 6 representatives over 103-month 
period 
none 
VI B (ST235) 4 3 7 years 
(2006-2012) 
None One laboratory referring two isolatesb 
Two laboratories referring one isolate 
 Others 7 4 2 years 
(2010-2012) 
South East_7; 3 representatives over 20-month period One laboratory referring two isolates 
Two laboratories referring one isolate 
a isolates of ST235 and ST233 carrying integron II were received from London_13 in 2004, and 2010-2012 respectively 
b these two isolates also came from South East_7
1
3
7 
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Figure 4.9: Distribution of isolates carrying each of the six main integrons across the 
main sub-regions of the UK. Coloured circles denote the ST/VNTR complexes (see 
Chapter 3) with numbers of isolates of the respective ST from each sub-region 
indicated. The sub-regions represented in these maps are explained in figure 2.2. 
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Integron I was an In59-like structure, differing from In59 (GenBank: AF263519)197 by 
substitutions in non-coding regions, and contained a blaVIM-2 gene flanked by two 
highly similar aminoglycoside resistance genes, aacA29a and aacA29b, followed by 
the 3’CS. This integron was only seen in ST111 (complex A) isolates where it was 
present in 58/65 (89%) representatives. The integron was sequenced for nine of 
these isolates and all had the same In59 variant. The 58 isolates carrying the In59-
like integron were collected at 20 laboratories over seven years, and included all of 
the ST111 outbreak representatives at London_17 and Wales_1, referred over 
seven-year and 18-month periods.  
Sequencing showed integron II to be identical to In559 (GenBank: DQ522233). 
Besides blaVIM-2 this element also contained aacA7, dfrB5 and aacCA5 gene 
cassettes and had a Tn5090-like 3’ region. All 25 isolates belonging to ST233 
(complex C), referred from 15 laboratories, carried integron II as did 14/47 (28%) 
isolates belonging to ST235 (complex B) and three isolates that did not belong to 
any of the main VNTR complexes. Affected sites included London_7 with five ST233 
representatives referred over a 27-month period and Scotland_4 submitting five 
ST235 isolates over a two-year period. London_13 referred four ST233 and five 
ST235 isolates over 18-month and three-week periods respectively, with these 
‘outbreaks’ separated by six years. 
‘Integron’ III was an integron-like element containing blaOXA-10, aacA4, arr2 and 
dhfr2 gene cassettes along with blaVIM-2, but with a 3’ region that could not be 
amplified with any primer combination. This element was seen in all 12 isolates 
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belonging to ST773 (complex F), referred from 11 different laboratories over a 
seven-year period, each submitting only one or two isolates.  
Integron IV had an unusual 3’ region consisting of a partial 5’CS followed by a sul1 
gene. Fifteen of the 18 isolates belonging to complex D (ST654 and its close relative 
ST964) carried integron IV. These were referred from seven laboratories over a 
nine-year period. Referring sites included South East_6, from which seven 
representatives were received over a three-year period; the remaining six 
laboratories referred only one or two isolates.  
Integron V, which contained blaVIM-2, aacA7 and aadB gene cassettes, yielded 
amplicons using primers targeting both the 5’ and 3’CS together with those 
targeting the blaVIM-2 gene, but the 3’ region could not be confirmed due to mixed 
sequencing reads using primers targeting this region. All six isolates carrying 
integron V belonged to ST357 (complex E) and were referred from the same 
laboratory (North West_ 15) over a seven-year period, with three submitted in 
2010.  
Sequencing of integron VI showed that it was identical to the previously-reported 
In496 (GenBank FM994936).198 This integron was seen in four ST235 (complex B) 
isolates from three laboratories and seven additional isolates of four different VNTR 
types, not belonging to any of the major complexes. These seven included four 
isolates referred from South East_7 belonging to ST235 (complex B) or two different 
VNTR types for which the ST was not determined. Two of the four isolates, each 
having a different VNTR type, were from patients on the same hospital ward in 
2010 and separated by a 10-week period.   
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4.3.1.2 Distribution of integrons amongst the major VNTR complexes 
One to 17 different integron profiles were seen within each of the six major 
ST/VNTR complexes. Complexes C and F (corresponding to STs 233 and 773) had a 
single integron type present in all representatives. In ST111 (complex A, n=65), 
integron I was found in 89% of isolates, with two different blaVIM- and two different 
blaIMP-encoding integrons seen among the remaining 11% (n=7); all three of the 
identified 3’ regions were represented among the integrons of these latter seven 
isolates. Among ST654/964 (complex D, n=18) representatives, 83% harboured 
integron IV; one further ST654 isolate carried an otherwise identical integron with 
an additional aadB cassette present following the blaVIM-2 gene, while one carried a 
unique blaVIM-containing integron with a 3’CS; the other, an ST964 organism had a 
blaIMP-containing integron with the 3’CS. 
Isolates belonging to the remaining two complexes, B and E (ST235, n=47 and 
ST357, n=16), harboured diverse integrons, with 17 and nine different types seen in 
these complexes, respectively. In ST235 (complex B), 13 different blaVIM- and two 
different blaIMP-encoding integrons were seen among the 29 representatives (62%) 
not carrying the main integron types (II and VI); none of these diverse integrons was 
seen in more than four isolates belonging to this complex. The majority of these 
diverse integrons had the 3’CS, but one blaVIM-containing integron had a Tn5090-
like region and none of the major 3’ regions was detected for one blaIMP-containing 
integron. Eight blaVIM-containing integrons were seen among the 10 (62%) ST357 
(complex E) isolates not harbouring integron V; these were received from nine 
different laboratories; four had the 3’CS and four had Tn5090-like 3’ regions.  
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Integrons II and VI, respectively, also were seen in 9% and 21% of isolates not 
belonging to the main VNTR complexes but, otherwise, the integrons in these 
isolates were diverse.  Among the remaining 70% (n=25) of these isolates, 15 from 
12 laboratories carried different blaVIM-containing integrons while four blaIMP-
containing integrons were seen in the remaining 10 isolates, each associated with a 
different VNTR type; eight integrons had the 3’CS, nine had Tn5090-like 3’ regions 
and no 3’ region could be amplified for integrons of the remaining two isolates.  
 Integrons seen in Pseudomonas spp. besides P. aeruginosa. 4.3.2
Twenty-three isolates belonging to Pseudomonas spp. other than P. aeruginosa 
were submitted to AMRHAI between 2003 and 2012 (as detailed in Section 2.1.3); 
17 carried blaVIM genes while six carried blaIMP. Sixteen of these 23 isolates were 
viable in the archives and were studied, as described in later chapters, to 
investigate their potential as an environmental reservoir for MBL-containing 
integrons. These 16 isolates were referred from ten different UK hospital 
laboratories; 15 were isolated from patient specimens, while the remaining isolate 
was from a hospital sink. Isolates were identified to species level by sequencing of 
their rpoB gene, as described in Section 4.2.2 (figure 4.10). Several species belonged 
to the P. putida group, i.e. P. mosselii (seven isolates), P. monteilli (one isolate), and 
other members of the P. putida group not closely related to any of the reference 
strains (six isolates). A further two isolates belonged to the P. aeruginosa group; 
one was P. oleovorans, while the other was P. alcaligenes. 
143 
 
 
Figure 4.10: Neighbour-joining tree showing the relationship of rpoB gene 
sequences between MBL-producing isolates of non-aeruginosa Pseudomonas spp. 
described in this study (indicated by a star) and reference strains.  
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Nine different blaVIM-containing and four different blaIMP-containing integron 
structures were seen among these 16 non-aeruginosa isolates; none of these 
corresponded to the major integron structures (I-VI). Five isolates nevertheless had 
one of the less common integron profiles (identical in amplicon size and restriction 
pattern) seen among the MBL-producing P. aeruginosa.  
Only one of these latter five Pseudomonas spp. isolates shared an integron profile 
with an MBL-producing P. aeruginosa isolate from the same hospital. This was a P. 
mosselii isolate cultured from a hospital sink at London_12 in 2004, which shared a 
blaVIM-encoding integron profile with four MBL-producing P. aeruginosa isolates 
from different patients, two of them from London_12, also in 2004; one collected 
one week, and the other nine months before the P. mosselii isolate. The other two 
P. aeruginosa isolates with this integron profile were submitted from other London 
hospitals in 2009 and 2010.  
The remaining four Pseudomonas spp. isolates that shared integron profiles with P. 
aeruginosa representatives were not linked in time and place to these P. 
aeruginosa isolates. A blaVIM-positive P. monteilli isolate shared an integron profile 
with a P. aeruginosa strain isolated from a different hospital; both were isolated in 
2012. A P. putida group isolate carrying blaVIM and submitted in 2010 shared the 
same integron profile as five P. aeruginosa isolates submitted between 2008 and 
2012; none of these was from the same hospital as the P. putida group strain. A 
blaVIM-positive P. putida group isolate submitted in 2011 shared an integron profile 
with a P. aeruginosa isolate from a neighbouring London hospital received one year 
previously. Lastly, a P. putida group isolate carrying blaIMP had a similar integron 
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profile to five P. aeruginosa isolates submitted from four different laboratories 
between 2005 and 2011.  
 
 Plasmid transformations 4.3.3
Attempts to transform plasmids from single representative isolates of each of the 
main integron/ST combinations (integron I/ST111, integron II/ST235, integron 
II/ST233, integron III/ST773, integron IV/ST654, integron V/ST357, and integron 
VI/ST235) into the E. coli DH5α strain were consistently and repeatedly 
unsuccessful. A plasmid carrying blaVIM-2 from a P. aeruginosa strain previously 
isolated at AMRHAI (Paer_pl1), tested as a control, was successfully transferred. 
 S1 nuclease and I-ceu I hybridisation 4.3.4
Representatives of each of the main integron/ST combinations, as above, were 
subjected to S1 nuclease and I-ceu I digest followed by in-gel hybridisation with a 
VIM-specific probe, as described in Section 4.2.4. The control strain (Paer_pl1) was 
also included. The resulting gels are shown in figure 4.11.  
For the control strain (Paer_pl1), as expected, the VIM probe hybridised to a 
plasmid band, of approximately 300 kb, in the S1 nuclease digest. Similarly, for a 
representative of ST235 with integron VI (Paer_LW_50), the VIM-probe hybridised 
with a c.450-kb plasmid band from the S1 nuclease digest. In contrast, for 
representatives of ST773 with integron III (Paer_LW_167), ST654 with integron IV 
(Paer_LW_121) and ST357 with integron V (Paer_LW_197), the VIM-probe 
hybridised with chromosomal bands of the I-ceu I digest, indicating that the blaVIM 
gene was located on the chromosome.  
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The VIM-probe did not hybridise to any plasmid or chromosomal bands for the 
representatives of ST111 with integron I (Paer_LW_238) or either ST235 
(Paer_LW_13) or ST233 (Paer_LW_109) with integron II; these isolates were 
investigated further using other methods. 
 
 
  
 
 
Figure 4.11: S1 and I-Ceu I digests; (a) digestion products separated by gel electrophoresis. (b) after in-gel hybridisation with a VIM-specific 
probe. Arrows indicate hybridisation. Representative isolates used are as follows; ST111/Integron I (lane 1), ST233/Integron II (lane 2), 
ST773/Integron III (lane 3), ST654/Integron IV (lane 4), ST357/Integron V (lane 5), ST235/Integron VI (lane 6), ST235/Integron II (lane 7), 
Control strain with VIM plasmid (lane 8). The Lambda Ladder PFG Marker was used to size the fragments.  
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 Identification of genomic islands 4.3.5
4.3.5.1 Genomic island structure carrying integron II in ST233 isolates 
Integron II (In559) was previously identified in a genomic island (genomic island A) 
inserted in the PA5101 gene on the chromosome of an ST233 P. aeruginosa isolate 
from the USA (figure 4.3).147 Long-range PCR (as described in Section 4.2.7) using 
primers PA5101_F and VIM2004B on a representative of ST233 (Paer_LW_109) 
from our collection resulted in an amplicon of the expected size (6266 bp) based on 
the genomic island identified in the US isolate,147 confirming that the blaVIM-2 gene 
was linked to the chromosomal PA5101 gene in this isolate (figure 4.12a). 
A multiplex PCR (PCR 1) was carried out, as described in Section 4.2.6 and figure 
4.6a, on all 42 isolates with integron II from this study to seek any evidence of a 
similar insertion of genomic island A into the PA5101 gene (figure 4.12b). Amplicons 
were not obtained using primers targeting the intact chromosomal PA5101 gene 
(PA5101_F and PA5101_R) for any of the 25 ST233 (complex C) isolates. However, 
amplicons were obtained for these 25 isolates using primers targeting PA5101 
together with the left-hand (VIMGI-LH_R) and right-hand (VIMGI-RH_F) junctions of 
the genomic island, indicating a similar insertion in the PA5101 gene as for this 
previous US study;147 24/25 produced amplicons of the expected size (349 and 478 
bp) while the remaining isolate gave a smaller product for the right-hand junction 
due to a 164-bp deletion in the PA5101 gene. None of the remaining 17 isolates 
with integron II (belonging to ST235 or to other VNTR types) yielded products to 
indicate an insertion within PA5101. However, the 14 ST235 (complex B) isolates 
with integron II yielded a single 239-bp amplicon corresponding to an intact 
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PA5101, as did the two isolates not belonging to any of the main VNTR complexes 
(figure 4.12b). The final isolate, which also did not belong to any of the major VNTR 
complexes, yielded no amplicon with any primer combination.   
 
 
 
Figure 4.12: (a) Long PCR, confirming the linkage the blaVIM gene with the 
chromosomal PA5101 gene using primers PA5101_F and VIM2004B; shown are 
integron II (In559) carrying ST233 (lane 1), and ST235 (lane 2) representatives and 
no template control (lane 3) (b) Example of amplicons obtained for PCR 1 (detection 
of genomic island A). Representatives carrying integron II (In559), belonging either 
to ST233 (lanes 1-4, 6 and 8) or ST235 (lanes 5 and 7), are shown. Amplicons for 
representatives carrying the other main integron structure (I or III-VI) are also 
indicated as follows: ST111/integron I, lane 9; ST773/integron III, lane 10; 
ST654/integron IV, lane 11; ST357/integron V, lane 12; ST235/integron VI, lane 13. 
The no template control is in lane 14. 
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4.3.5.2 Genomic island structure carrying integron I in ST111 isolates 
A representative of ST111 carrying integron I (Paer_LW_238) was selected for 
further investigation of the genetic location of the integron within the genome by 
WGS. Sequencing reads were obtained from two separate Illumina runs, and were 
combined, giving an average genome coverage of approximately 44x. De novo 
assembly of these Illumina reads, using SPAdes as described in Section 4.2.5, 
resulted in 166 contigs and an N50 (the contig length for which 50% of the entire 
assembly is contained within contigs of equal or greater value) of 100 kb, as shown 
in table 4.3. The blaVIM-2 gene was found on a 1044-bp contig, but the analysis gave 
no information about its wider environment or its chromosomal or plasmid 
location.  
Table 4.3: Assembly statistics for SPAdes assemblies of the ST111 representative 
Assembly No. of 
contigs 
Total 
length of 
contigs 
N50 (bp) Minimum 
contig size 
(bp) 
Maximum 
contig size 
(bp) 
SPAdes 
(Illumina 
only) 
166 7135311 100452 
 
88 
 
464511 
 
SPAdes  
(hybrid) 
92 7180261 162575 210 499444 
 
To overcome this failure, long reads were obtained using MinION technology, as 
described in Section 2.2.5.3. These reads were used together with the short 
Illumina reads, to produce a hybrid assembly using SPAdes, as described in Section 
4.2.5. This hybrid assembly had 92 contigs (table 4.3), of which two (called node 33; 
71384 bp and node 66; 9204 bp) mapped to part of the integron I (In59-like) 
structure. The MinION reads were mapped to these contigs using Map with LAST, 
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and parsed as described in Section 4.2.5. Mapping results were checked manually 
and a total of 58 and 12 overlapping MinION reads were identified which, together, 
mapped to the full length of nodes 33 and 66, respectively, confirming that the 
contigs were correctly assembled. These included two MinION reads that each 
mapped to both the contigs (nodes 33 and 66), confirming that these were adjacent 
and approximately 460 bp apart. The MinION reads that spanned the two contigs 
also mapped to the full length of the integron I (In59) sequence obtained by PCR 
and Sanger sequencing of the same isolate; the 460-bp section of DNA 
corresponding to the aacA29a cassette. Thus these two contigs were assembled 
together with the integron I Sanger sequence, giving the c. 81-kb chromosomal 
fragment illustrated in figure 4.13.  
Annotation of this 81-kb fragment revealed that integron I was part of a 28.5-kb 
genomic island inserted within a homologue of the PA2229 gene of P. aeruginosa 
PA01. Integron I was contained within a truncated Tn21-like transposon including 
Tn5090-like tniA and tniBΔ transposon genes and a partial mer operon encoding 
mercury resistance. Downstream of this region the sequence had 99% nucleotide 
identity to Tn4661 (NG_036554),199 a Tn4651-like replicative transposon. 
Replicative transposons, such as this, can insert into their target site and replicate, 
forming an intermediate structure known as a cointegrate.199 Homologous 
recombination at the resolution (rst) site separates the original and target 
sequences resulting in a single copy being present in both the original and target 
locations. The Tn4661-like structure seen here included the genes necessary for 
cointegrate formation (tnpA and tnpC) and resolution (tnpS and tnpT), as well as the 
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intact rst sequence (figure 4.13). Inverted repeats (iR) of Tn4661 were present at 
either side of the Tn4661-like sequence, as reported previously,199 with an identical 
sequence also at the junction of the chromosome with the Tn21-like portion of the 
genomic island. An 11-bp portion of the PA2229 gene (CGGNGGTACCT) was also 
present on either side of the genomic island, indicative of the target-site duplication 
produced by a transposition event. 
  
 
 
Figure 4.13: Structure of the integron I (In59)-containing genomic island (genomic island B) found in an ST111 isolate (Paer_LW_238). The 
relative positions of the Illumina hybrid contigs (designated nodes 33 and 66) and integron I sequence (obtained by PCR and Sanger 
sequencing) that were together used to assemble the sequence of the genomic island are indicated. The positions of the inverted repeat (iR) 
(GGGGTCATGCCGAGATAAGGGGAAAATTCATTCATTTGGAATGTAAG) and the resolution (rst; CAAAAACGGCTGCTTCGCGGTCGTTTCCCAGTACAC) 
sequences of Tn4661 are also shown. 
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Long-range PCR on the same representative of ST111 using primers PA2229_R and 
VIM2004B, as described in Section 4.2.7, resulted in an amplicon of the expected 
size (7154 bp), confirming that the blaVIM gene was linked to the chromosomal 
PA2229 gene (figure 4.14a). 
A multiplex PCR (PCR 2) was designed, as described in Section 4.2.6 and figure 4.6b, 
to amplify the chromosomal junctions of genomic island B, using primers targeting 
the chromosomal PA2229 gene (PA2229_F and PA2229_R) together with those 
targeting the island (ST111-GI-J1_R and ST111-GI-J2_F). PCR of 56/58 integron I 
(In59-like)-containing ST111 isolates yielded two amplicons of expected sizes (594 
and 371 bp), indicating that a similar genomic island to that in the fully 
characterised isolate Paer_LW_238, was inserted in the same location in their 
genomes (figure 4.14b). The remaining 2/58 ST111 isolates carrying integron I, and 
6/7 of the ST111 isolates carrying other blaVIM- or blaIMP-containing integrons 
yielded a single predicted 371-bp PCR product corresponding to the junction of the 
Tn4661-like region of the genomic island with the chromosomal PA2229 gene 
(primers PA2229_F and ST111GI-J2_R), but no product corresponding to the 
junction of the PA2229 gene with the Tn21-like part of the genomic island (primers 
PA2229_R and ST111GI-J1_F), indicating that Tn4661 insertions were also present in 
these isolates. The final ST111 isolate, with a unique blaVIM-containing integron, 
yielded a single predicted 267-bp amplicon corresponding to that expected for an 
intact PA2229 gene (primers PA2229_F and PA2229_R) as did single representatives 
of other ST/ integron combinations (ST235/ integron II, ST233/integron II, 
ST654/integron IV, ST773/integron II, ST357/integron V and ST235/integron VI) 
indicating that they lacked insertions in the PA2229 gene (figure 4.14b).   
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Figure 4.14: (a) Long-range PCR confirming the linkage of the blaVIM gene with the 
chromosomal PA2229 gene, using primers PA2229_R and VIM2004B, for the 
integron I (In59)- carrying ST111 representative (lane 1), and the no-template 
control (lane 2) (b) Example of amplicons obtained for PCR 2 (detection of genomic 
island B) for ST111 isolates carrying integron I (lanes 1-4), ST111 isolates carrying 
other MBL encoding integrons (lanes 5-7); these had either one or two amplicons 
corresponding to the junctions of the chromosome with the genomic island and 
indicating an insertion is present in the chromosomal PA2229 gene. Those obtained 
from isolates belonging to STs 235 (lane 8), 233 (lane 9), 654 (lane 10) and 773 (lane 
11) are also shown and indicate that no insertion was present in the PA2229 gene. 
The no template control is shown in lane 12. 
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4.3.5.3 Genomic island structure carrying integron II in ST235 isolates 
The genomic location of integron II (In559) in a representative of ST235 
(Paer_LW_13) was similarly investigated by WGS. Illumina reads were obtained 
from two separate runs and the data combined, giving an average genome coverage 
of 36x. De novo assembly using SPAdes, as described in Section 4.2.5, resulted in an 
assembly of 129 contigs with an N50 of 127 kb (table 4.4). blaVIM-2 was located on a 
4661-bp contig (designated node 84), which also contained dfrB5 and aacC-A5 
genes. This approach however gave no information about the wider environment of 
the MBL gene nor its chromosomal or plasmid location.  
Table 4.4: Assembly statistics for SPAdes assemblies of the ST235 representative 
Assembly No. of 
contigs 
Total 
length of 
contigs 
N50 (bp) Minimum 
contig size 
(bp) 
Maximum 
contig size 
(bp) 
SPAdes 
(Illumina 
only) 
129 6661853 126926 81 316935 
SPAdes  
(hybrid) 
82 6703780 214124 81 530386 
 
The strain was therefore sequenced on the MinION, as detailed in Section 2.2.5.3 
with a total of 6232 two-direction reads that passed Metrichor analysis obtained. 
Hybrid de novo assembly, using the MinION long reads together with the Illumina 
reads, was carried out with SPAdes, as described in Section 4.2.5, resulting in an 
assembly of 82 contigs with an N50 of 214 kb (table 4.4); this placed the blaVIM-2 
gene on the edge of a 125774-bp contig (designated node 21).  
The MinION reads were mapped to the contigs from the hybrid assembly using Map 
with LAST and parsed as described in Section 4.2.5. A total of 225 MinION reads 
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were identified that mapped to the blaVIM-2-containing contig (node 21) but, there 
was a ~10-kb region of node 21 (nucleotides 58985-68829) to which no MinION 
reads mapped, indicating that this contig was misassembled.  
Based on this experience, the MinION reads were re-mapped to the SPAdes 
assembly obtained from the Illumina data only, using Map with LAST, and parsed as 
before. Nineteen MinION reads mapped to the blaVIM-2-containing contig (node 84, 
4661 bp) linking it to the full length of nodes 53, 93 and parts of node 73, indicating 
that this latter contig was again misassembled. MinION reads additionally linked 
node 93 and parts of node 73 to node 20, and overlapped with reads that mapped 
to node 84, the blaVIM-2-containing contig. The relative orientation of these contigs, 
as inferred from the overlapping MinION reads, is shown in figure 4.15. 
 
 
 
  
 
 
Figure 4.15: Deduced structure of the~23-kb genomic island found in the ST235 representative (Paer_LW_13) carrying integron II (In559). The 
relative positions of the contigs from the SPAdes Illumina-only assembly (nodes 53, 93, 73, 84 and 20) as determined by scaffolding with the 
MinION reads are shown. Positions of the inverted repeats (IRs) (GGGGNNATAGAGAAAACGGAAAAAATCGTACGNTAAG) and the putative 
resolution (res) sites (TGACGCCTAGTTAGGGCATGCCTCAGTCTGACAGTGATGAGTCGCAGGCGTTCGGATCGGCATCGGTTTCGCTCCCGGTCTTGGCGC 
GCGCCTGGAAGCGCTGATAGCACTCCAGCCCGCAGAAGTGCTCGACGTAT), as seen in the previously reported Tn6249 structure (GenBank 
accession LK054503),182 are indicated. The tniB gene downstream of the In559 integron spanned the junction of node 84 and a fragment of 
node 73 and so it is unclear whether this gene is complete. 
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Annotation of these contigs indicated that the blaVIM-containing integron II (In559) 
was part of an approximately 23-kb genomic island itself inserted within the 
glycerate kinase gene of another PACS171b-like genomic island (GenBank accession 
number EU595750), which was in turn situated within the disrupted endA 
chromosomal gene. The genomic island contained two integrons in a tail-to-tail 
organisation: these were integron II (In559) as previously identified here, and 
another integron with 100% nucleotide identity to In51 (GenBank Accession 
AF140629). Integron II (In559) had the Tn5090-like tniC, tniQ, tniB and tniA genes in 
its 3’ region; the tniB gene spanned the junction of nodes 84 and part of node 73, so 
it is unclear whether this gene is complete. In51 contained the genes aadA6 and 
gcuD, with a classical 3’CS structure; it was also part of a Tn5090-like structure, 
which had a tniA and a disrupted tniB gene. The double integron structure was 
flanked by the transposase genes of IsPa7. Tn6249-like inverted repeat (IR) 
sequences were present at both junctions of the VIM-2-encoding genomic island, as 
in a previously reported blaVIM-1 containing genomic island sequence (figure 4.4, 
GenBank accession LK054503), but the tnpA gene of Tn6249 and the adjacent tnpR 
and res sequences of this previous sequence were not present.    
Long-range PCR with primers glykin_F and VIM2004B (as described in Section 4.2.7) 
confirmed that blaVIM was linked to the disrupted glycerate kinase, with an amplicon 
of approximately 4.6 kb obtained, (figure 4.16) as expected based on the inferred 
structure illustrated in figure 4.15.  
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Figure 4.16: Long-range PCR indicating that the blaVIM gene of the ST235 
representative (Paer_LW_13) was linked to the glycerate kinase gene of the 
PACS171b-like genomic island (genomic island C) using primers glykin_F and 
VIM2004B for isolates carrying integron II (In559) of ST235 (lane 1), and ST233 (lane 
2) and a no template control (lane 3). 
 
This double integron arrangement is similar to that seen in a previously published182 
genomic island containing blaVIM-1, shown in figure 4.4, which was also situated 
within the disrupted glycerate kinase gene of a PACS171b-like genomic island. On 
this basis, and in parallel to the WGS work, PCR investigations were carried out on 
ST235 isolates seeking evidence of this previously-described structure.  
Two multiplex PCRs were designed, as described in Section 4.2.6 and shown in 
figure 4.6c. 
 The first PCR targeted the insertion site of the PACS171b genomic island (genomic 
island C) in the endA gene of the P. aeruginosa chromosome (PCR 3), using primers 
targeting the chromosomal endA gene (endA_F and endA_R) together with primers 
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targeting the left and right hand junctions of the PACS171b-like genomic island 
(PACS171b_J1_R and PACS171b_J2_F).  
The second PCR targeted a Tn6249-like insertion in the glycerate kinase gene of the 
PACS171b genomic island (PCR 4), using primers targeting the glycerate kinase gene 
of the PACS171b-like genomic island (primers glykin_F and glykin_R) together with 
those targeting the left- and right-hand junctions of the Tn6249-like transposon 
(primers urf2_R and TnpATn6249_F).  
A panel of 54 isolates was subjected to PCR. This included 44/52 MBL-positive 
complex B (ST235) isolates that were still viable in the archives. These came from 25 
different laboratories, spanning ten years. Also included were two MBL-negative 
and largely antibiotic susceptible ST235 representatives, collected in 2012. Three 
integron II-carrying isolates not belonging to the main VNTR complexes and single 
representatives of each of the other main complexes A and C-F (STs 111, 233, 654, 
773 and 357) were also analysed. A summary of amplicons obtained from these 
isolates for the two PCRs is shown in tables 4.5 and 4.6, and figure 4.17a and b, 
respectively.  
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Table 4.5 Amplicons obtained by multiplex PCR (PCR 3) targeting the insertion of a 
PACS171b-like genomic island in the chromosomal endA gene for isolates of ST235 
and other types (n=54) 
Amplicons
a
 MBL- 
positive 
ST235 
(n=44) 
MBL-
negative 
ST235 
(n=2) 
Other 
types 
Implication 
377 bp and 
600 bp 
40 1 0 PACS171b-like insertion present in endA 
gene and both junctions present 
377 bp 
only 
2 0 0 PACS171b-like insertion present in endA 
gene but only single junction amplified 
283 bp 
only 
2 1 8 Intact endA gene, no insertion of a 
PACS171b island 
a expected amplicon sizes for the respective primer pairs included in the multiplex were  
283 bp (endA_F and endA_R), 377 bp (endA_F and PACS171b_J1_R), and 600 bp 
(PACS171b_J2_F and endA_R); also see figure 4.6c 
 
 
Table 4.6: Amplicons obtained by multiplex PCR (PCR 4) targeting the insertion of a 
Tn6249-like structure in the glycerate kinase gene of the PACS171b-like genomic 
island, for the ST235 isolates positive for the PACS171b-like island (n=43) 
Amplicons
a
 
 
MBL- 
positive 
(n=42) 
MBL-
negative 
(n=1) 
Implication 
591 bp  and 
373 bp 
19 1 A Tn6249-like insertion in glycerate kinase gene, 
with both junctions amplified 
373 bp only 16 0 Tn6249-like insertion present, but with only the left-
hand junction amplified suggesting differences in 
sequence at the right-hand junction of the Tn6249 
gene with the PACS171b-like genomic island 
591 bp only 6b 0 Tn6249-like insertion present, but only the right-
hand junction amplified suggesting differences in 
sequence at the left-hand junction of the Tn6249 
gene with the PACS171b-like genomic island 
No 
amplicons 
1 0 A different insertion was present in the glycerate 
kinase gene without sequence similarity to Tn6249 
or no insertion was present 
a expected amplicon sizes for the respective primer pairs included in the multiplex were 271 
bp (glykin_F and glykin_R), 373 bp (glykin_F and urf2_R), and 591 bp (TnpATn6249_R and 
glykin_R); also see figure 4.6c  
b three of these six isolates additionally had a 2kb amplicon  
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Figure 4.17: (a) Example of amplicons obtained using primers targeting the insertion 
site of the PACS171b-like island in the chromosomal endA gene (PCR 3) for MBL-
positive ST235 isolates (lanes 1-9), MBL-negative ST235 isolates (lanes 10 and 11), 
isolates belonging to STs 111, 233, 357, 654 and 773 (lanes 12-16) and the no 
template control (lane 17). These variously yielded either two amplicons (377 and 
600 bp) corresponding to the junctions of the chromosome with the PACS171b-like 
genomic island and indicating an insertion within the endA gene, or a single 
amplicon (283 bp) corresponding that expected for the intact endA gene. (b) 
Example of amplicons obtained using primers targeting the insertion of a Tn4661-
like structure in the glycerate kinase gene of the PACS171b-like genomic island (PCR 
4). MBL-positive ST235 (lanes 1-11) and the MBL-neg ST235 isolate (lane 12); all had 
products indicating an insertion in the glycerate kinase gene except for the 
representative in lane 11). The no template control is shown in lane 13.  
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The first of these multiplex PCRs (PCR 3; table 4.5 and figure 4.17a), targeting the 
insertion of a PACS171b-like genomic island in the chromosomal endA gene, 
suggested that such an insertion was present in 40/44 MBL-positive ST235 P. 
aeruginosa isolates and one of the two MBL-negative ST235 isolates. For each of 
these isolates two amplicons were obtained corresponding to the expected sizes 
(377 and 600 bp) for primer pairs targeting the two junctions of the PACS171b-like 
genomic island with the chromosome (endA_F with PACS171b_J1_R, and 
PACS171b_J2_F with endA_R, respectively). Two of the four remaining MBL-positive 
ST235 isolates yielded only a 377-bp PCR product, indicating that the left-hand 
junction of the PACS171b genomic island was present (primers endA_F and 
PACS171b_J1_R), but that the right-hand junction was modified. The remaining two 
MBL-positive and one MBL-negative ST235 isolates yielded a 283-bp product 
corresponding to that expected for an intact endA gene (primers endA_F and 
endA_R), as did the three isolates carrying integron II that did not belong to the 
main VNTR complexes, and the five representatives of other complexes. 
PCR 4 (table 4.6 and figure 4.17b) was carried out on the 42 MBL-positive 
representatives and one MBL-negative (and fully antibiotic susceptible) ST235 
isolate that produced an amplicon with PCR 3. Nineteen of the 42 MBL-positive 
isolates, and the MBL-negative isolate, yielded two PCR products with expected size 
(373 and 591 bp) using primers targeting the glycerate kinase gene of the 
PACS171b-like genomic island (primers glykin_F and glykin_R) together with those 
targeting the left- and right-hand junctions of the Tn6249-like transposon (primers 
urf2_R and TnpATn6249_F); this indicated that a similar structure was inserted 
within the PACS171b genomic island in these 19 isolates (table 4.6, figure 4.17b). 
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Twenty-two of the remaining 23 MBL-positive isolates yielded PCR products for one 
of the two junctions indicating that the glycerate kinase was also disrupted. Sixteen 
of these 22 isolates, including the 13 isolates carrying integron II, yielded a 373-bp 
amplicon of the expected size for primer pair glykin_F and urf2_R only. Six further 
isolates yielded 591-bp amplicons corresponding to the expected size for primers 
glykin_R and TnpATn6249_F, with three of these additionally yielding an 
approximately 2-kb PCR product. The final MBL-positive ST235 isolate gave no 
amplicons with any primer combination.  
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4.4 Discussion 
Diverse MBL-encoding class 1 integrons were seen amongst the 218 MBL-producing 
P. aeruginosa from UK hospital laboratories, with at least three different 3’ regions 
observed. The most common arrangements were the classical 3’CS (55%) and 
Tn5090-like regions (30%). In four of the six major sequence types (STs 111, 233, 
654/964 and 773), single integrons or integron-like elements (I, II, IV and III 
respectively) predominated, with the same or similar integrons also having 
previously been reported internationally, as outlined below, in isolates belonging to 
the same STs. In contrast, a high diversity of integron types was seen in ST235 
(complex B) and ST357 (complex E) isolates, with 17 and nine profiles seen, 
respectively. 
The majority of isolates belonging to ST111 (complex A) carried integron I, a variant 
of In59; this organisation has also been reported in several European countries, 
again usually associated with ST111. In59 itself was first reported in 2001 in 
France.197 Subsequently, an In59 variant identical to that seen here was reported in 
ST111 isolates from Norway and Sweden, including from a patient previously 
hospitalised in Greece,124 and in three hospitals in central Greece.122 ST111 isolates 
harbouring In59-like integrons have also been reported in Austria200 and, most 
recently, in Colombia.128  
Integron II, which corresponds to In559, was seen here in all MBL-producing ST233 
isolates, 30% of ST235 isolates and three isolates not belonging to the main VNTR 
complexes. This integron was first described in isolates of unknown ST from a 
hospital outbreak in the USA in 2005,87 and was subsequently reported in a single 
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ST233 isolate recovered from a patient in Norway (thought to be imported from 
Ghana),124 and in an outbreak of ST233 P. aeruginosa in a US hospital.147 The 
integron was also reported in isolates of ST1488,  which is closely related to ST233, 
from the Ivory Coast.201 An ST235 P. aeruginosa clone carrying In559 is widely 
disseminated across Russia, Belarus and Kazakhstan;136 In559 was also associated 
with sporadic isolates of STs 234 and 244 in these countries. Additionally, In559 was 
detected in ST235 isolates from Malaysia and Sri Lanka,137 ST244 and ST640 isolates 
in Tanzania,179 and isolates of unknown STs in Taiwan202 and India (GenBank: 
HQ005291).   
All isolates belonging to ST773 (complex F) carried integron III-like elements. The 
partial sequence obtained had an identical cassette array to an integron previously 
reported in ST773 isolates in India,137 although we were not able to amplify the 3’  
region reported in the Indian isolates. Of the 5/12 patients for whom travel history 
was available, four had travelled to India. These four were admitted to different UK 
hospitals; the remaining patient was treated on the same hospital ward as one of 
the patients who had travelled and may reflect local cross infection. 
Integron IV predominated amongst the isolates belonging to ST654/ST964 (complex 
D). A similar integron, with the same unusual 3’ region seen in our isolates, but with 
an additional aadB cassette, was previously reported in an ST654 isolate from 
Sweden and was thought to have been imported from Tunisia.124 This previously-
described integron was located upstream of Tn5501-like and Tn5393-like 
transposon genes, along with strA and strB cassettes, in this previous study.124 PCR 
analyses showed that these cassettes were also linked to the blaVIM-containing 
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integron in our isolates, suggesting a similar genetic environment to the Swedish 
isolate.  
Integron V was observed from six out of 16 isolates belonging to ST357 (complex E). 
This cassette arrangement has not been reported previously and sequencing of an 
amplicon obtained for the blaVIM-to-3’CS region consistently resulted in mixed 
reads, possibly due to two co-migrating amplicons, as a result of two copies of the 
blaVIM gene being present in different integrons. 
Isolates of diverse types harboured integron VI, including members of ST235 and 
five other VNTR types. This integron is identical to In496, and was previously 
reported in P. aeruginosa isolates from India and the Philippines.198   
Although some hospitals had persistent problems, including the ST111 outbreak 
that was possibly associated with the colonisation of the wastewater systems at 
London_17,157 many isolates with the prevalent VNTR complex/integron 
combinations did not cluster in terms of time or place, being referred from between 
six and 21 laboratories over seven- to nine-year periods, suggesting multiple 
introductions into different UK hospitals. A major exception was the case of ST357 
(complex E) isolates carrying integron V, where all six representatives were from the 
same laboratory (North West_15) and were part of the previously-reported 
outbreak.156  
In some cases, integron data provided further discrimination between isolates that 
otherwise were identical or very similar by VNTR typing. For example, isolates of 
ST235 from eight patients were received from hospital laboratory London_7 over a 
seven-year period; three isolates were received in a three-month period with the 
169 
 
remaining five being received between six and 33 months apart from each other. 
Although they comprised just two VNTR profiles the organisms variously carried six 
different integrons of diverse sizes, with both 3’CS and Tn5090-like 3’ regions 
represented. This observation, together with their temporal scatter, suggests that 
ST235 organisms were likely imported to the hospital on multiple occasions rather 
than persisting in the hospital. In contrast, the large (n=21) cluster of ST111 isolates 
referred from London_17 consistently carried integron I despite being collected 
over a nine-year period. This fits with the persistence of the strain in the 
environment, possibly the wastewater system,157 with repeated infection from this 
source.  
While four of the six main integron structures (I, III, IV and V) were only seen in 
single VNTR complexes (corresponding to STs 111, 773, 654/964 and 357, 
respectively) integrons II and VI were seen in more diverse STs. Identical integron II 
(In559) structures were found in isolates of different VNTR types, including ST235 
and ST233 (complexes B and C). Wider analysis of their genetic environments 
indicated that these integrons were located in lineage-specific chromosomally-
located genomic islands in these ST235 and ST233 isolates. Neither of these were 
detected in isolates of other VNTR types carrying integron II, indicating that 
horizontal transfer of an entire genomic island was not responsible for the integrons 
dissemination. In both the ST233 and ST235 genomic islands the integrons were 
part of a Tn5090-like transposon that included all the genes necessary for 
transposition, although the tniC gene of this transposon was disrupted by ISPa54 in 
the ST233 isolate, and it was not known whether tniB was intact in the ST235 strain, 
due to low sequence coverage of the region. Nevertheless, it is possible that an 
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ancestor of this Tn5090-like transposon containing integron II, with the intact 
transposition genes, was transferred independently to representatives of ST235, 
ST233 and other lineages, with the tniC gene subsequently becoming disrupted in 
an ancestor of the ST233 strains. Alternatively this gene cassette arrangement may 
have been assembled independently in the different lineages.  
Isolates of different types carrying integron VI were referred from six different 
laboratories spread over a seven-year period. These submissions included two 
isolates of different VNTR types referred over a ten-week period from two patients 
treated on the same hospital ward at South East_6. Analysis of a representative 
carrying integron VI from this study, and a previous report198 showed that the 
integron was located on a plasmid. This, together with the epidemiological 
information, suggests that plasmid-mediated spread of integron VI may have 
occurred between P. aeruginosa of different VNTR types.  
Various Pseudomonas spp. besides P. aeruginosa with blaIMP or blaVIM genes are 
sometimes isolated from patients or clinical environments,203–206 and it is suggested 
they may act as an environmental reservoir for MBL-containing integrons.205 Of the 
16 isolates of other Pseudomonas spp. studied here, four had integron profiles 
matching those of minor types seen amongst P. aeruginosa (none corresponded to 
major integrons I-VI) but only one of these isolates (a P. mosselii) was found at the 
same hospital as P. aeruginosa isolates carrying the same integron. As the P. 
mosselii was recovered from the hospital environment after known cases of P. 
aeruginosa patient infections, it is not clear whether the integron was transferred 
to or from a P. aeruginosa strain. 
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Integrons I, II and III were previously reported to be located on the P. aeruginosa 
chromosome in isolates from Scandinavia, USA, and India respectively,124,137,147 
whereas integron VI  (also associated with transmission among VNTR types here) 
was found on a 35-kb plasmid in Indian isolates.198 Attempts to transform any VIM-
carbapenemase-encoding elements from isolates by electroporation were 
consistently unsuccessful. S1 nuclease and I-ceu I digests confirmed that integrons 
III, IV and V were located on the chromosome in representatives of STs 773, 654 
and 357, respectively, while integron VI was located on a plasmid in an ST235 
isolate. Further analysis by PCR and WGS data confirmed that integron I, in a 
representative of ST111, and integron II, in representatives of STs 233 and 235 were 
also located chromosomally. 
In559, which is identical to integron II, was previously found to be located in a 35-kb 
genomic island inserted in the chromosomal PA5101 gene in ST233 P. aeruginosa 
isolates from a recent outbreak in the USA.147 We found evidence of a similar 
organisation, with PA5101 disrupted, in all the ST233 (complex C) isolates studied 
here, supporting the view that ST233 P. aeruginosa with this arrangement may have 
spread internationally. However, the PA5101 gene was not disrupted in ST235 
(complex B) or other VNTR types with integron II, and these were not linked in time 
and place to the ST233 isolates, suggesting a different genetic environment.  
A representative of ST235 carrying integron II (In559) was therefore investigated 
further using WGS, and the integron was located in an approximately 23-kb 
genomic island, as part of a double integron structure within a defective Tn6249-
like transposon. This genomic island was inserted within the glycerate kinase gene 
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of a PACS171b-like genomic island, which was in turn inserted within the endA 
chromosomal gene. This is similar to the genetic context of previously-reported 
transposons Tn6249 and Tn6160, both containing blaVIM-1 as part of a double 
integron structure, reported in P. aeruginosa isolates of ST235 and an unknown ST 
from Italy182 and Australia,207 respectively. Tn6162, containing a single In51 
integron, was also located in the same PACS171b-like genomic island in isolates 
from Australia and Uruguay.208 PCR analyses detected PACS171b-genomic-island-
like insertions in the chromosomal endA of 42 of the 44 MBL-positive ST235 isolates 
in our collection and insertions within the glycerate kinase gene of the PACS171b-
like genomic island were present in all but one of these 42. This suggests that 
transposons inserted within PACS171b-like genomic islands may represent a 
common platform, shared by many ST235 isolates, by which they can acquire new 
resistance genes. Nevertheless, MBL genes were reported in genomic islands 
inserted elsewhere in the genomes of ST235 isolates, for example blaIMP-1-
containing IS26-composite transposons were found inserted into the chromosomal 
hmgB or oprD genes,209,210 and a blaGES-5-containing integron, as part of transposon 
Tn6163, inserted into a different genomic island with a chromosomal insertion 
point close to the PA2583 gene.208  
A representative of ST111 carrying integron I (In59) was investigated by WGS, and 
again the integron was located on a genomic island, this time inserted within the 
PA2229 chromosomal gene and including a region with 99% identity to Tn4661, a 
Tn4561-like replicative transposon. Sequences identical to Tn4661 have also been 
reported in the P. aeruginosa plasmid Rms148199 and on the PAGI-4 genomic island 
of P. aeruginosa strain C.211 In our ST111 representative the genomic island, 
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including the Tn21-like transposon with integron I (In59), was flanked by the Tn4661 
inverted repeats, suggesting that the entire structure could be moved by the action 
of the transposon. However we only saw integron I (In59) in ST111 strains and it is 
only rarely reported in strains of other types (nevertheless including those 
belonging to STs 277, 244, 253 and 773 in several Greek hospitals, where In59-
encoding ST111 representatives were more prevalent122) suggesting that Tn4661-
mediated transposition of this integron, if it occurs, is uncommon. A PCR designed 
to amplify the junctions of the genomic island and link to it with the chromosome 
revealed that all but one of our 65 ST111 isolates had a similar Tn4661-like insertion 
in the PA2229 gene; amplicons were obtained for one (8 isolates) or both (56 
isolates) junctions of the identified genomic island with the chromosome, even in 
isolates carrying diverse integrons. This implies that integrons contained within 
Tn4661-like transposon structures inserted at this location in ST111 genomes could 
act as a lineage-specific platform for the acquisition of diverse resistance genes 
including blaVIM or blaIMP. 
In summary, ‘high-risk clones’ carrying particular integron types, for example ST111 
with In59 and ST233 with In559, were prevalent MBL-producing P. aeruginosa in the 
UK and appear to have become widespread internationally. Despite this, a variety of 
integron structures, including those with different 3’ structures, were seen amongst 
most of the ‘high-risk clones’ in our collection (STs 111, 654, 235 and 357) and were 
reported elsewhere.68,122,137 Genomic islands were identified and these contained 
integrons In59 (integron I) and In559 (integron II) in ST111 and ST235 
representatives, respectively. Lineage-specific genomic island insertions were seen 
in most isolates belonging to ST111 and ST235 strains, and were reported 
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elsewhere, although carrying different integron structures to those found here. 
Carriage of these shared island structures may predispose the lineages to the 
acquisition of diverse resistance genes. WGS methods, which are becoming 
increasingly available have the potential to provide increased discrimination 
between members of ‘high-risk clones’, including analysis of their resistance gene 
content and this will be explored in the following chapter. 
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5 Whole genome sequencing (WGS) for 
the analysis of ‘high-risk clones’ 
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5.1 Introduction 
Members of ‘high-risk clones’, such as P. aeruginosa ST111 and ST235, are often 
very similar or identical when analysed with conventional typing methods, including 
VNTR, even when isolated at diverse locations and times. It can therefore be 
difficult to determine whether repeated isolation of these types represent an 
outbreak or not, although this is critical to inform epidemiological investigations 
and to target effective interventions to limit their spread. Whole genome 
sequencing (WGS) is increasingly used in clinical microbiology and can provide the 
higher resolution when it is needed.  
  WGS for investigation of outbreaks 5.1.1
WGS, usually based on analysis of single nucleotide polymorphisms (SNPs) has been 
used to track outbreaks of numerous bacterial species, for example Mycobacterium 
tuberculosis,212 Staphylococcus aureus,213 Klebsiella pneumoniae,214 Salmonella 
enterica
215 and P. aeruginosa.216–218 These studies give insights into transmission 
events and potential sources and reservoirs of the bacteria. For example, 
retrospective WGS analysis was used to track an outbreak of KPC-producing K. 
pneumoniae belonging to the ST258 clone to presumptively identify likely 
transmission events.214 WGS was also used in near-real-time to identify the likely 
source of an ST253 P. aeruginosa outbreak in an Australian hospital as a sink in the 
neo-natal intensive care unit, thus informing infection control interventions.218 In 
addition, WGS has been used to study international members of ‘high-risk clones’, 
for example the E. coli ST131 clone,219 to understand better their global spread.   
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 Other applications of WGS 5.1.2
In addition to molecular epidemiology, WGS data can be used to investigate other 
aspects of the biology of the organism. For example, WGS studies have detected 
antibiotic resistance determinants in  P. aeruginosa,30 including acquired resistance 
genes. Similar studies have also been carried out on other bacterial species, 
including S. aureus220 and Enterobacteriaceae.221  
WGS data may also be used to seek specific features that may account for the 
apparent increased ability of some ‘high-risk clones’ to acquire and/or maintain 
resistance genes.  For example, Kos and colleagues recently reported that, among a 
collection of diverse P. aeruginosa genomes (including those belonging to STs 111 
and 235), those that commonly carried varied β-lactamase genes also lacked known 
clustered regularly interspersed short palindromic repeats (CRISPR), and did not 
encode any CRISPR-associated proteins (Cas).30 These CRISPR-Cas systems are 
bacterial adaptive immunity systems that defend bacteria against mobile genetic 
elements, including bacteriophage, plasmids and other horizontally-acquired 
DNA.222 Multi-drug resistant strains of enterococci have also been found to lack 
such defence systems.223 It is suggested that this lack of CRISPR-Cas systems, 
described more fully in the following section, may facilitate acquisition of new 
resistance genes via mobile genetic elements. 
 CRISPR–Cas adaptive immunity systems 5.1.3
CRISPR-Cas bacterial adaptive immunity systems are composed of CRISPR repeat 
arrays together with cas genes (figure 5.1). The CRISPR arrays consist of conserved 
repeat sequences, interspersed with unique spacer sequences, usually derived from 
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a mobile genetic element; the cas genes encode proteins involved in the action of 
the defence system.  
CRISPR-Cas function can be divided into three distinct stages: adaptation, 
expression and interference (figure 5.1).222,224 The first stage, adaptation, involves 
the introduction of new spacer sequences into the CRISPR array from a DNA 
element such as a bacteriophage (where the corresponding sequence is called a 
protospacer). During the expression stage a long primary transcript of the CRISPR 
repeat array is generated and processed into short CRISPR RNAs (crRNAs; also 
known as guide RNAs), each containing a single spacer sequence along with a 
portion of one or both of the flanking CRISPR repeats. In the final stage, 
interference, the crRNA together with Cas proteins form a complex that targets the 
foreign DNA containing the corresponding protospacer sequence (e.g. phage) and 
cleaves the DNA. 
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Figure 5.1: The three stages of CRISPR-Cas action. The CRISPR repeat region consists 
of a series of conserved repeat sequences (white boxes) interspersed with unique 
spacer sequences (coloured boxes labelled 1-6) and preceded by a leader sequence 
(grey box labelled L; includes a promoter sequence). CRISPR-associated (cas) gene 
arrays (blue arrows) are usually located adjacent to the CRISPR repeat region, and 
encode genes involved in the action of the defence system. CRISPR-Cas system 
action has three stages. During the first stage, adaptation, new spacer sequences 
are incorporated into the CRISPR array from the bacteriophage or other DNA 
element. During the second stage, expression, a long primary transcript is 
generated and processed into short CRISPR-RNAs (crRNAs) also known as guide 
RNAs, each containing a single spacer sequence. In the final interference stage a 
complex is formed of the crRNA and Cas proteins which specifically targets the 
corresponding protospacer sequence (from which the spacer sequence present in 
the crRNA was derived) and cleaves the foreign DNA. Figure adapted from 
Marraffini et al.222 
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Estimates based on available genome sequences suggest that CRISPR-Cas systems 
are present in around 40% of all bacterial genomes, with their prevalence varying 
from species to species.224 They can be classified into three main types (I-III), which 
differ in their cas gene content and the mechanisms by which they generate crRNA 
and target foreign DNA. While most characterised CRISPR-cas systems target DNA 
elements, as described above, a recent study suggests that a member of sub-type 
III-A found in Streptococcus thermophilus may target RNA bacteriophage.222,225 All 
types include cas1 and cas2 in their gene array while unique type-specific genes, 
cas3, cas9 and cas6, respectively, are associated with members of each of the three 
main types (I-III). The only CRISPR-Cas subtypes identified in P. aeruginosa genomes 
belong to the type I group,169 specifically subtypes I-E (previously known as 
Escherichia subtype) and I-F (previously known as Yersinia subtype), and these are 
described more fully in figure 5.2.  
Estimates suggest that CRISPR-Cas systems are present in 39-54% of P. aeruginosa 
strains with type I-F being more prevalent than type I-E. This conclusion is based on 
studies of clinical isolates from the USA, Lebanon and India where 39% of 
representatives from all three countries carried at least one CRISPR-Cas system 
(n=112, 6% type I-E, 33% type I-F)169 whilst 54% of isolates from cystic fibrosis 
patients in France carried at least one system (n=50, 12% type I-E, 48% type I-F).226 
However, as these isolates were from specific patient groups, or included countries 
where the prevalence of multi-drug resistant strains is extremely high (e.g. India), it 
is unclear how representative they are of the diversity generally seen in clinical 
settings. 
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Figure 5.2: (a) Structures of Type I-E (Escherichia subtype) and Type I-F (Yersinia 
subtype) CRISPR-Cas systems found in P. aeruginosa isolates. (b) Repeat sequences 
of the CRISPR arrays seen in the type I-E (E-CRISPR1/2) and type I-F (Y-CRISPR1/2) 
CRISPR-Cas systems in P. aeruginosa. Figure adapted from Cady et al.169 
 
  
182 
 
 Aims 5.1.4
The overall aim of this part of the study was to use WGS to investigate members of 
‘high-risk clones’ in our collection of MBL-producing P. aeruginosa. The study 
focused on isolates belonging to STs 111 and 235 (VNTR complexes A and B), as they 
are the two most-commonly-seen MBL-associated ‘high-risk clones’, both in this 
study and worldwide.  
Specific aims were (1) to investigate whether SNP analysis could be used to 
distinguish between closely-related P. aeruginosa isolates belonging to each of 
these ‘high-risk clones’ (2) to identify the resistance determinants present in these 
isolates and (3) to investigate whether members of these ‘high-risk clones’ carried 
CRISPR-Cas systems more or less often than isolates in our comparator collection 
from the BSAC Bacteraemia Surveillance Programme.  
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5.2 Methods 
 SNP analysis 5.2.1
SNP analysis was carried out by Anthony Underwood and Ali Al-Shahib (Applied 
Laboratory and Bioinformatics Unit, PHE) for the ST111 data or Michel Doumith 
(AMRHAI, PHE) for the ST235 data.  
Illumina sequencing was performed as described in Section 2.2.5. Fully finished 
reference genomes were chosen that were closely related to the clones studied: 
these comprised the ST146 LESB58 chromosome (GenBank accession number 
NC_011770.1) for the ST111 isolates, or the ST235 NCGM2.S1 chromosome 
(GenBank accession number AP012280) for the ST235 representatives.210 Trimmed 
fastq reads were mapped to the chosen reference strain using bwa-mem 0.7.5a, 
and variants were determined with GATK 2.6.5.227 In order to ensure that only high 
quality SNPs were retained, variants were parsed according to the following 
conditions:  
Depth of coverage (DP) ≥5,  
AD ratio (ratio between variant base and alternative bases) ≥ 0.8, 
Mapping Quality (MQ) ≥ 30, 
Ratio of reads with MQ=0 to total number of reads ≤ 0.05, 
Distance to nearest SNP >10  
All SNP positions that fulfilled these criteria in more than 90% of the samples were 
included in a multi-fasta file, where the sequence for each strain consisted of the 
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concatenated SNPs. The multi-fasta file was used as an input to generate a 
maximum likelihood (ML) tree using RAxML228 on the CIPRES portal229 with the 
following parameters: 
–m (substitutionModel) GTRCAT  
–b (bootstrapRandomNumberSeed) 12345  
–# (numberOfRuns) 100  
–c (numberOfCategories) 25  
SNP tree figures were generated using the EvolView online tool 
(http://www.evolgenius.info).230  
 Prediction of resistance determinants 5.2.2
Identification of resistance determinants was carried out by Michel Doumith 
(AMRHAI, PHE), using a database of reference sequences assembled to include 
acquired resistance genes, as well as chromosomal genes in which mutation is 
known to affect fluoroquinolone resistance (gyrA, gyrB, parC and parE). Acquired 
resistance gene sequences used were obtained from the Comprehensive Antibiotic 
Resistance Database (http://arpcard.mcmaster.ca) and the NCBI nucleotide 
database (http://www.ncbi.nlm.nih.gov/nuccore) using the accession numbers 
described by Zankari and colleagues.231 The gyrA, gyrB, parC and parE gene 
sequences were obtained from the P. aeruginosa PA01 complete genome sequence 
(GenBank accession number NC_002516). 
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Trimmed Illumina reads (fastq files) were mapped against this database using 
bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2), and Binary Alignment Map 
(BAM) and Variant Calling Format (VCF) files were produced with SAMtools 
(http://samtools.sourceforge.net). VCF files were parsed using a simple script that 
extracts, for each reference sequence with aligned reads, the number of sites 
covered by more than five reads and nucleotide alterations with respect to the 
reference sequence to calculate nucleotide identities. The presence of acquired 
resistance genes was determined with a stringent threshold of inclusion of >90% 
identity over the length of the reference sequence; except for β-lactamase variants 
where 100% identity was required, so as to identify specific alleles (e.g. blaVIM 
variants). For the gyrA, gyrB, parC and parE genes mutations were detected in the 
quinolone resistance determining regions (QRDR) as described by Kos et al;30 
corresponding to amino acid positions 83-87 (GyrA), 429-585 (GyrB), 82-84 (ParC) 
and 357-503 (ParE). 
 Detection of CRISPR-cas genes 5.2.3
Detection of CRISPR-cas genes from the WGS data was carried out by Michel 
Doumith (AMRHAI, PHE). Illumina reads were mapped, as described above for the 
resistance determinants, against sequences of sub-type I-E CRISPR-cas genes (cas2, 
cas1, cas6e/cse3, cas5, cas7, cse2 and cas3) from the RP73 P. aeruginosa complete 
genome sequence (GenBank accession: NC_021577) and sub-type I-F CRISPR-cas 
genes (cas1, cas3, csy1, csy2, csy3, csy4) from the PA14 P. aeruginosa complete 
genome sequence (GenBank accession: NC_008463).  
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CRISPR-cas genes specific to type I-E or type I-F systems were sought by PCR in BSAC 
Bacteraemia Surveillance Programme isolates from 2011 (see Section 2.1.2), using 
previously-described primers.169 Primers cse3_For and cse3_Rev were used to seek 
the cse3 gene (also known as cas6e) of type I-E CRISPR-Cas systems and csy1_FOR 
with csy1_REV to amplify the csy1 gene of type I-F CRISPR-Cas systems. Primer 
sequences are shown in table 2.1.  
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5.3 Results 
 WGS analysis of ST111 isolates 5.3.1
As described in Chapter 3, ST111 isolates were referred to AMRHAI from 15 London-
region laboratories between 2003 and 2012. We continued to receive MBL-
producing ST111 representatives from several London hospitals in 2013-2014 and 
there were concerns that this might reflect spread between hospital sites. Thus, a 
WGS investigation of this lineage was instigated in a collaboration between 
AMRHAI, the PHE Genomic Services and Development Unit, the PHE Applied 
Laboratory and Bioinformatics Unit, the PHE London regional laboratory and St 
George’s, University of London.232 A total of 120 ST111 P. aeruginosa isolates, 
submitted to AMRHAI between 2003 and 2014, were subjected to Illumina 
sequencing, as described in Section 2.2.5. Of these 120, 87 gave a sufficient mean 
depth of coverage (15x or greater) to be included in further analyses. 
Seventy-five of the 87 isolates were from patients. They included 51 of the 75 ST111 
representatives in the non-duplicate-patient MBL-producing isolate collection (see 
Section 2.1.1). The remaining 12/87 isolates were derived from environmental 
samples, collected by laboratories as part of their epidemiological investigations of 
outbreaks. The 87 isolates included those carrying blaVIM-(n=73), blaIMP-(n=5), 
blaNDM-(n=1), or both blaVIM- and blaIMP- (n=1) type MBLs and seven MBL-negative 
ST111 comparator strains, received by AMRHAI in 2011-2014.  
5.3.1.1 SNP analysis of the ST111 isolates 
SNP analysis was carried out as described in Section 5.2.1 using the ST146 LESB58 
reference strain (GenBank accession number NC011770), which is one of the most-
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closely-related organisms to ST111 for which a fully finished genome sequence is 
available. On analysis of the SNP data it was clear that the one blaNDM-carrying 
isolate was an outlier, having an average of 1,377 SNPs difference from any other 
isolate in the tree, so it was removed from a further SNP analysis. Among the 
remaining 86 isolates, regions of the reference that could be aligned against all 
sequenced genomes yielded 21,278 SNPs, with individual genomes differing at 0-
548 of these positions. The maximum likelihood tree resulting from this analysis is 
shown in figure 5.3.  
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Figure 5.3 (Previous page): Maximum likelihood tree based on SNP analysis of the 
86 ST111 representatives compared with the reference strain (ST146 LESB58); one 
outlying ST111 representative with blaNDM was excluded. Labels for individual nodes 
indicate information about each isolate in the format: date of isolation 
(month.year), VIM or IMP allele identified, patient (P), screening (S) or 
environmental (E) isolate number (followed by _1, _2, etc. for patients for which we 
received multiple isolates), referring hospital, and integron detected (integron I, or 
others (1-3) seen among ST111 isolates, as detailed in Chapter 4). Coloured 
branches and node labels represent the identified clusters (1-3); sub-clusters are 
also labelled. Coloured squares represent hospitals submitting more than one 
isolate, and coloured stars represent patients from whom multiple isolates were 
submitted. 
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5.3.1.1.1 Main clusters identified within ST111 
Several clusters and sub-clusters were identified among the 86 ST111 isolates 
(figure 5.3); these included cluster 1 (n=5, one laboratory), cluster 2 (n=11, four 
laboratories) and cluster 3 (n=50, ten laboratories). Variation within cluster 1, 2 and 
3 corresponded to 19, 6 and 181 SNPs, respectively. The remaining isolates were 
more diverse and included all five blaIMP-positive isolates and 6/7 of the MBL-
negative ST111 representatives, which were from four different hospitals (figure 
5.3).  
All five cluster 1 representatives were from Wales_1 and were referred between 
2010 and 2013. Isolates in cluster 2 (n=11) that differed by only six SNPs were 
referred over a 17-month period (2012-2014) and were mostly from London_9 (8 
isolates); single isolates were also submitted from three further London hospitals; 
One of these three isolates was collected at London_11 from a patient (P51) who 
had also attended London_9, but there were no known epidemiological links 
between London_9  and the other two patients, who attended London_25 or 
London_6. 
More than half (50/86) of the isolates belonged to cluster 3: these 50 comprised 40 
patient isolates and ten environmental isolates received between 2007 and 2014. 
Half (20 patient and 5 environmental) were from London_17 while the remaining 25 
isolates were referred by a further six London laboratories and three in South-East 
England. Two sub-clusters could be seen among these cluster 3 isolates.  
Sub-cluster 3a (n=13, 22 SNPs) included representatives referred mainly from 
London_26 (six patient and five environmental) but with an additional two isolates 
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from London_28, both from patients who were also hospitalised at London_26; 
these were mostly submitted in 2012-2013 but one London_26 isolate dated from 
2009.  
Sub-cluster 3b (n= 14, 20 SNPs) isolates were referred over a five-year period (2009-
2014); six were from London_17 and five from London_12, with single isolates from 
three other London or South-East England laboratories. This included a patient (P8) 
for which we had received two isolates from different laboratories (South East_10 
and London_17), but there were no known epidemiological links between 
London_17 and the isolates from other sites (South East_3, London_14 and 
London_12).  
5.3.1.1.2 Variation among ST111 isolates from single laboratories 
Where multiple ST111 isolates were received from the same laboratory they 
generally belonged to the same cluster or sub-cluster, for example those received 
from Wales_1 (n=5, cluster1), London_9 (n=7, cluster 2), London_17 (n=25, cluster 
3), London_26 (n=11, cluster 3a) and London_12 (n= 5, cluster 3b). However, there 
were exceptions where isolates from the same hospital were distant by SNP 
analysis, indicating independent acquisition of ST111 strains. These included 
representatives referred from London_28 (from 7 patients and 1 environmental) 
between 2005 and 2014, which were dispersed across the tree. Other examples are 
two isolates from London_7 (P19, 2010 and P49, 2013), which were on different 
long branches, and two representatives from London_6 (P60, 2013 and P10, 2009), 
which fell into clusters 2 and 3, respectively.   
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5.3.1.1.3 Variation among ST111 isolates from single patients 
Six patients had two MBL-producing representatives submitted to AMRHAI and 
isolates from the same patient consistently clustered together on the tree (figure 
5.3, table 5.1). For five of these six patients the two isolates were collected over 
short periods (up to 3 weeks), from different body sites, and differed by 0-1 SNPs. 
However, for one further patient (P8) two isolates were submitted four years apart 
and differed by 18 SNPs. The SNP tree indicated that the two isolates had a 
common ancestor not shared with any of the other ST111 isolates indicating that 
the strain had probably evolved within the patient.  
 
Table 5.1: Details of patients (n=6) from whom multiple ST111 P. aeruginosa 
isolates were submitted  
Patient Cluster No. of 
isolates 
Time period 
separating 
isolates 
Isolation sites Number of 
SNPs different 
P8 3b 2 4 years sputum, urine 18 
P42 3a 2 3 weeks sputum, unknown 0 
P43 2 2 3 days urine, blood 0 
P51 2 2 2 weeks unknown, sputum 0 
P52 3a 2 2 weeks urine, TIP 1 
P54 other 2 3 weeks urine, faeces 0 
TIP; trans-jugular intrahepatic portosystemic stent 
 
5.3.1.1.4 Comparison of sequence with VNTR data for ST111 isolates 
The most common VNTR type among the ST111 isolates was 11,3,4,3,2,2,5,4,7, seen 
in 57 of the 86 representatives; these 57 included most of the isolates that fell into 
SNP clusters 1, 2 and 3, and some of the MBL-negative strains. All of the blaIMP-
carrying representatives, spread over five years, had the same VNTR type 
(11,3,4,3,2,2,5,4,6) as did several MBL-negative isolates as well as two cluster 3a 
representatives from London_12. Those (n=5) with the profile 11,3,4,3,2,2,5,4,8 
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were from three different hospitals and all fell into cluster 3. Ten of the 13 isolates 
in cluster 3a had a consistent VNTR profile (11,3,4,3,2,2,6,4,7) and were all from 
patients hospitalised at London_26. The blaVIM-2-carrying isolate from patient P19, 
which was clearly different from the remaining 85/86 isolates included in the SNP 
tree had a unique VNTR profile (11,3,4,3,2,2,4,4,7) as did the NDM-producing 
outlier (11,3,4,3,2,2,6,4,13). 
5.3.1.2 Sequencing-based detection of resistance determinants in ST111 
isolates  
Resistance determinants were detected from the sequence data as described in 
Section 5.2.2. The intrinsic resistance genes blaOXA-50, blaPAO (ampC), aph(3’)-IIb and 
catB7 were identified in 85/87 isolates; the two remaining isolates had all these 
genes except catB7. gyrA, gyrB, parC and parE genes were detected too, but 
mutations in the QRDR of these genes could not be determined for most (69/87) 
ST111 genomes owing to insufficient depth of coverage of the region by the 
Illumina reads. A mutation affecting GyrA (83:T-I) was seen in all 18 isolates that 
could be analysed; this was also the most common mutation seen among 
fluoroquinolone-resistant P. aeruginosa isolates of diverse origin in a previous 
study.30  
The acquired resistance genes seen among the ST111 isolates are shown in figure 
5.4 and variously included MBL genes blaVIM-2, blaIMP-1, blaIMP-13 and blaIMP-18, in 
addition to those encoding other β-lactamases (blaPSE-1 and blaOXA-2), 
aminoglycoside-modifying enzymes (aacA4, aacA29, aac(3)-Ic and aadA2) and the 
class-1-integron-associated sulphonamide resistance cassette sul1.  
195 
 
 
196 
 
Figure 5.4 (previous page): Resistance determinants seen among the 86 ST111 
representatives. The maximum likelihood tree based on SNP analysis of the ST111 
isolates, as shown in figure 5.3. Labels for individual nodes indicate information 
about each isolate in the format: date of isolation (month.year), VIM or IMP allele 
identified, patient (P), screening (S) or environmental (E) isolate number (followed 
by _1, _2, etc. for patients for which we received multiple isolates), referring 
hospital, and integron detected (Integron I or others (1-3) seen among ST111 
isolates, as detailed in Chapter 4). Coloured branches and node labels represent the 
identified clusters (1-3); sub-clusters are also indicated. Coloured squares represent 
hospitals submitting more than one isolate, and coloured stars represent patients 
from whom multiple isolates were submitted.  Filled grey rectangles represent 
acquired resistance genes detected among the isolates while empty rectangles 
indicate that this resistance determinant was not detected in a particular isolate. 
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Most (74/87) isolates were found to harbour blaVIM-2, 72 of these 74 also had 
aacA29 (aacA29a and aacA29b differ by only four nucleotides and were not 
distinguished by the mapping script) and sul1. This result is consistent with the gene 
content of integron I (In59-like), which were amplified from all representatives of 
these isolates (Section 4.3.1). For a further isolate in cluster 3 blaVIM-2 and aacA29 
were detected but not sul1, despite the presence of integron I being confirmed by 
PCR. One integron I-carrying isolate (from patient P19, 2010, London_7) additionally 
had the aac(6’)-Ib, blaIMP-18 and blaOXA-2 genes (the blaIMP-18 gene had not initially 
been detected by PCR, but both the blaVIM and blaIMP genes were subsequently 
confirmed by PCR from a single colony pick). The representative was also the most 
distant, based on SNP analysis, from the other integron I-carrying isolates, none of 
which were referred from London_7. The final blaVIM-2-positive isolate (P49), among 
these 74 was most closely related to the five blaIMP-positive and six of the MBL-
negative strains had a different integron profile, designated other3 (determined by 
PCR as described in Section 4.2.1); an aac(3)-Ic gene was detected in this isolate in 
addition to the blaVIM-2 and sul1 genes. 
The 13 isolates that did not carry blaVIM-2 included seven that lacked MBLs, five with 
IMP-MBLs and one with NDM. One MBL-negative isolate belonged to cluster 3 but 
had only the aacA29 and sul1 genes; this isolate was also negative by PCR both for 
blaVIM and for any blaVIM-containing integron; it may have lost the blaVIM-2 gene 
cassette, consistently seen in all other cluster 3 isolates. Six further MBL-negative 
strains, from four different laboratories, with no known links between them, had 
the same acquired resistance gene content as each other, including aminoglycoside 
resistance genes aacA4, aadA2, the penicillinase blaPSE-1 and sul1; this is similar to 
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the gene content of an integron detected in a P. aeruginosa from an outbreak at a 
Spanish hospital,233 and it is possible that they are representatives of the PSE-1-
associated O12 strain commonly seen in Europe in the 1980s.119 The two IMP-13-
positive representatives, both from South_East_6 had similar resistance gene 
content to these six MBL-negative isolates, with which they shared a common 
ancestor, but with the addition of blaIMP-13. The remaining three IMP-positive 
representatives however carried aacA4 and sul1 genes in addition to blaIMP-1. The 
NDM-positive outlier (not included in figure 5.4) had blaNDM-1, blaVEB-1, aadA2, 
aph(3')-VIb, ant(2')-Ia and sul1 genes. 
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5.3.1.2.1 Comparison of genotypes with MIC data for ST111 isolates 
The 60/80 MBL-positive isolates for which MICs were available were resistant to the 
majority of tested antibiotics (table 5.2), including imipenem, meropenem and 
ciprofloxacin, but not colistin, to which all but one isolate remained susceptible, and 
aztreonam, to which most isolates were intermediate, based on EUCAST criteria.  
Surprisingly seven isolates (12%) remained susceptible to piperacillin-tazobactam, 
six of these carried blaVIM-2 and one blaIMP-1 and they were dispersed across the SNP 
tree. 
Greatest isolate-to-isolate variation in susceptibility was seen for the 
aminoglycoside antibiotics amikacin (23% susceptible or intermediate) and 
gentamicin (30% susceptible). All five IMP-producing isolates were susceptible or 
intermediate to amikacin despite carrying aacA4, which has been previously 
associated with resistance to amikacin.25 While most of the tested isolates carrying 
aacA29 variants (associated with resistance to amikacin and tobramycin, but not 
gentamicin)25,197 were resistant to all aminoglycosides, 17/62 remained susceptible 
or intermediate to amikacin and/or gentamicin. Notably this included all five 
London_12 isolates in cluster 3b, which were susceptible or intermediate to both 
amikacin and gentamicin (n=4) or amikacin only (n=1), and all tested isolates (9/11) 
in cluster 2 that remained susceptible to gentamicin.  
MIC data were available for three of the seven MBL-negative ST111 isolates, all 
carrying blaPSE-1, aacA4 and aadA2. All three remained sensitive to amikacin, 
ceftazidime and colistin, and were resistant to gentamicin, tobramycin and 
piperacillin-tazobactam, consistent with the previous report of an outbreak of a P. 
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aeruginosa strain with the same resistance gene content (blaPSE-1, aacA4 and 
aadA2).233 They were also consistently resistant to imipenem but had variable 
resistance to meropenem and ciprofloxacin, with resistance to these agents likely to 
be due to mutations rather than acquired resistance genes. 
 
Table 5.2: Antibiotic susceptibility of ST111 representatives subjected to WGS 
analysis (n=87) 
 MBL-positive (n=80) MBL-negative (n=7) 
Antibiotic S I R ND S I R ND 
Amikacin 8  6  46 20 2 1 0 4 
Gentamicin 18 - 42 20 0 - 3 4 
Tobramycin 3 - 57 20 0 - 3 4 
Piperacillin-
tazobactam  
7 - 53 20 0 - 3 4 
Ceftazidime 3 - 57 20 3 - 0 4 
Aztreonam 1 53 5 21 0 3 0 4 
Imipenem 0 0 60 20 0 0 3 4 
Meropenem 0 3 57 20 0 1 2 4 
Ciprofloxacin 1 0 59 20 0 1 2 4 
Colistin 59 - 1 20 3 - 0 4 
S, susceptible; I, intermediate; R; resistant, ND; not done 
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 WGS analysis of ST235 isolates 5.3.2
In order to assess diversity among MBL-producing ST235 isolates, 57 
representatives from 46 patients and 27 hospital laboratories were subjected to 
WGS. These isolates were received by AMRHAI between 2003 and 2012 and 
included 44 of the 52 MBL-producing ST235 P. aeruginosa isolates from the non-
duplicate-patient isolate set (see Section 2.1.1) along with 11 further MBL-
producing isolates from the same patients and two predominantly antibiotic 
susceptible MBL-negative comparators submitted to AMRHAI in 2012.We received 
no ST235 environmental isolates linked in time and place to any of the MBL-
producing isolates.  
Illumina sequencing was carried out as described in Section 2.2.5. As a result of the 
problems with low coverage that led to some of the ST111 isolates being excluded 
from later analyses (above), all ST235 isolates were sequenced twice and the 
resulting reads concatenated. This ensured that sufficient average genome 
coverage (>15x) was achieved for all isolates. 
5.3.2.1 SNP analysis of ST235 isolates 
SNP analysis was carried out as described in Section 5.2.1 using the ST235 reference 
strain NGCM2.S1 (GenBank accession number AP012280).210 Regions of the 
reference that could be aligned against all sequenced genomes identified 953 SNPs, 
with individual genomes differing at 0-548 of these positions. The SNP tree 
generated is shown in figure 5.5.
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Figure 5.5 (previous page): Maximum likelihood tree based on SNP analysis of the 
55 MBL-producing and 2 MBL-negative ST235 representatives compared with the 
reference strain (NCGM.S1). Labels for individual nodes indicate information about 
each isolate in the format: date of isolation (month.year), VIM or IMP allele 
identified, patient number (followed by 1, 2, etc. for patients where we received 
multiple isolates), referring hospital, and integron detected (major integrons I-VI as 
detailed in Chapter 4, or others (1-15) seen among ST235 isolates). Coloured 
branches and node labels represent the identified clusters (1-4). Coloured squares 
represent hospitals submitting more than one isolate, and coloured stars represent 
patients from whom multiple isolates were submitted, respectively.  
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5.3.2.1.1 Main clusters identified within ST235  
Four distinct clusters (designated clusters 1 - 4) were identified (figure 5.5). Isolates 
belonging to cluster 1 (n=14, 6 laboratories) were most tightly grouped, differing by 
56 SNPs, while those belonging to clusters 2 (n=14, 7 laboratories), 3 (n=15, 9 
laboratories) and 4 (n=5, 5 laboratories) were more diverse, varying by 146, 156 and 
90 SNPs, respectively. Seven MBL-producing isolates did not belong to any of these 
four identified clusters; these were from five patients and six laboratories and were 
diverse in terms of the SNP analysis, as were the reference (NCGM2.S1) and two 
MBL-negative ST235 strains. 
Cluster 1 isolates (n=14) were epidemiologically diverse, being received from six 
hospital laboratories across the UK between 2004 and 2012. The biggest 
contributors were Scotland_2 (6 isolates, 2008-2010) and London_13 (4 isolates, 
2004); single isolates were submitted from three further London laboratories and 
one in the West Midlands, each in a different year between 2006 and 2012.  
The 14 isolates belonging to cluster 2 were submitted from seven different 
laboratories in London and the south of England between 2004 and 2012. London_7 
was a major contributor, referring six isolates from three patients between 2008 
and 2010; all belonged to the same sub-cluster (2a), which also included an isolate 
referred from South West_1 in 2009 from the same patient (P16) as one of the 
London_7 isolates and a further isolate referred from London_24 in 2012. The 
remaining six cluster 2 isolates were submitted from five patients and four different 
laboratories between 2006 and 2010.  
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Cluster 3 isolates (n=15) were submitted from nine laboratories across the UK 
between 2003 and 2012, with some small sub-clusters, comprising isolates from 
two to three patients each, generally referred from the same laboratory. The five 
representatives in cluster 4 were also each referred from a different laboratory, in 
four different UK regions, between 2008 and 2012, each separated by at least five 
months.   
5.3.2.1.2 Variation among ST235 isolates from single laboratories 
In general, ST235 isolates submitted from the same hospital laboratory clustered 
together on the tree. Major exceptions were ten isolates submitted from London_7 
in 2005 to 2010, which variously belonged to cluster 2 (six isolates from three 
patients, 2007-2010), cluster 3 (one isolate, 2010), cluster 4 (one isolate, 2010) or 
did not fall into any of the main SNP clusters (2 isolates from different patients, 
2005 and 2009). Other exceptions included two isolates submitted from 
East_England_4 in 2009 and 2010, which belonged to cluster 3 or did not fall into 
any major SNP cluster, respectively, and two isolates from London_28 collected in 
2006 and 2004, which belonged to clusters 1 or 2, respectively.  
5.3.2.1.3 Variation among ST235 isolates from single patients 
Multiple isolates were submitted for ten patients. All these single-patient sets 
clustered on the SNP tree (figure 5.5; table 5.3). For most patients (8/10) two 
isolates were submitted 0-12 weeks apart and differed by 0-2 SNPs. For the two 
remaining patients, isolates were received over 12-18 month periods. Two isolates 
from one patient (P26) were received 18 months apart and differed by 2 SNPs. 
Three representatives were received from patient P16; the first was derived from a 
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tissue sample submitted by London_7 in 2008, while two further representatives, 
both from urine samples, but collected at two different hospitals (London_7 and 
South West_1) were received seven weeks apart approximately one year after the 
initial representative. These two later isolates differed by 4 SNPs from each other, 
and 13 and 15 SNPs, respectively, from the initial isolate from the same patient 
(table 5.4).  
 Table 5.3: Details of patients from whom multiple ST235 P. aeruginosa isolates 
were submitted (n=10) 
Patient Cluster No. of 
isolates 
Time period 
separating 
isolates 
Isolation sites Number of SNPs 
different 
P30 1 2 0 weeks unknown 0 
P31 2 2 0 weeks both blood 0 
P33 2 2 1 week both blood 0 
P16 2 3 1 year (P16_1 to 
P16_2) and 
 7 weeks (P16_2 
to P16_3) 
tissue, urine, 
urine 
13 (P16_1 and P16_2),   
4 (P16_2 and P16_3) 
and 
15 (P16_1 and P16_3) 
P12 2 2 1 week both blood 0 
P32 3 2 0 weeks PEG site, 
tracheostomy 
site 
1 
P1 3 2 12 weeks both sputum 1 
P13 3 2 12 weeks  both urine 0 
P26 3 2 18 months sputum, wound 2 
P4 Others 2 0 weeks both urine 2 
5.3.2.1.4 Comparison of sequence with VNTR data for ST235 isolates 
The most common VNTR type seen among the 57 ST235 isolates was 
13,3,6,4,5,1,9,2,8 (n=21, 38%) with representatives of this VNTR type dispersed 
across the SNP tree. Fourteen different VNTR types were seen among the remaining 
34 isolates, differing at the 7th (locus 207; 7, 8 or 10 repeats) and/or 9th loci (locus 
61; 9, 10, 11, 12 or 15 repeats), with one to seven isolates having each VNTR type.  
Representatives referred from the same hospital generally shared the same VNTR 
type in addition to clustering together on the SNP tree. The main exceptions were 
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the ten isolates received from London_7, which encompassed two different VNTR 
profiles, specifically 13,3,6,4,5,1,7,2,9 (n=7, SNP clusters 2 or 4), or 
13,3,6,4,5,1,8,2,10 (n=3, SNP cluster 3 or not belonging to main SNP clusters).  
5.3.2.2 Sequencing-based detection of resistance determinants in ST235 
isolates 
The intrinsic resistance genes blaOXA-50, blaPAO (ampC), aph(3’)-IIb and catB7 were 
identified in all 57 ST235 isolates. All 55 MBL-positive isolates also had a mutation in 
the QRDR of GyrA (83:T-I), as seen in ST111 representatives, while sub-clusters of 
the MBL-positive isolates had mutations in the QRDR of ParE; these were 457:S-G 
(all isolates in cluster 1), 419:D-N (two isolates from P1 in cluster 3) and 457:S-R (the 
isolate from patient P10, not in any of the main clusters). Neither of the MBL-
negative isolates had the GyrA (83:T-I) mutation seen in the MBL-producers, but 
one isolate did have a mutation in GyrB (466:S-F), also previously associated with 
fluoroquinolone resistance in P. aeruginosa.30 
Acquired resistance gene content varied greatly among the 55 MBL-positive 
isolates, consistent with the diverse integron contents seen in these representatives 
(Section 4.3.1; figure 5.6). Some clusters and sub-clusters shared similar gene 
content, as outlined below. Acquired genes detected included those conferring 
resistance to β-lactam antibiotics (including multiple MBL genes blaVIM-1, -2, -4, or -6 
or blaIMP-7, -14 or -26), aminoglycosides, tetracycline, trimethoprim, rifampicin and 
chloramphenicol. The sul1 gene, which is found in the classical 3’CS region of class 1 
integrons, was seen in all MBL-positive isolates but not in the two MBL-negative 
isolates. 
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Figure 5.6 (previous page): Maximum likelihood tree showing SNP analysis and 
resistance determinants for the 55 MBL-producing and 2 MBL-negative ST235 
isolates against the reference strain (NCGM.S1). Coloured branches represent the 
four clusters identified, as indicated. Labels for the individual nodes indicate 
information about the isolate in the format: date of isolation (month.year), VIM or 
IMP allele, patient number (followed by 1, 2, etc. for patients where we received 
multiple isolates), referring hospital, and integron detected (major integrons I-VI as 
detailed in Chapter 4, or others (1-15) seen among ST235 isolates). Coloured 
squares represent hospitals submitting more than one isolate, and coloured stars 
represent patients from whom multiple isolates were submitted, respectively.  
Filled grey rectangles represent acquired resistance genes detected among the 
isolates while empty rectangles indicate that this resistance determinant was not 
detected in a particular isolate. 
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All 14 cluster 1 isolates harboured blaVIM-2, aacCA5, aadA6 and dfrB5; these 14 
included all of the integron II (In559)-carrying ST235 isolates described in Section 
4.3.1. Four isolates in the cluster additionally carried the aac(3)-Ic gene and three 
had a variant of cmlA1.  
Isolates in clusters 2-4 had more varied acquired resistance gene content than those 
in cluster 1. Those belonging to cluster 2 variously carried blaVIM-1 (n=2), blaVIM-2 
(n=9), or blaVIM-6 (n=3) MBL genes and all also had the acquired resistance genes 
blaOXA-2 and aadA6. Sub-clusters shared additional genes including the β-lactamase 
determinants blaLCR-1, blaOXA-10 or blaVEB-9, and aminoglycoside resistance 
determinants, strB, ant(2”)-Ia or variants of aac(6’)-31 or aph(3’)-Vib.  Cluster 3 
(n=15) representatives carried either blaVIM-1 (n=10) or blaIMP-7 (n=5). Sub-clusters 
carried various additional resistance genes including blaPER-1, aac(3)-Ic, an aacA4 
variant, aadA2, aadA1, aadA6, aph(3’)-XV,  strB, and/or variants of catB10 or cmlA1. 
Representatives in cluster 4 (n=5) carried the MBL genes blaVIM-2 (n=3), blaVIM-6 (n=1) 
or blaIMP-14 (n=1) with variable additional resistance genes including blaOXA-10, a 
blaVEB-1 variant, blaVEB-9, aadA6, aacCA5, ant(2’)-Ia, a aph(3’)-Vib variant, tet(G) 
and/or dfrB5. In the remaining seven MBL-producing isolates diverse resistance 
genes were variously seen including blaVIM-2, blaVIM-4,  blaIMP-26, blaPSE-1, blaOXA-35, 
aadA6, aac(6')-Ib variant, aph(3')-VIb variant, arr7, aac(6')-v1 and/or dfrB5.  
5.3.2.2.1 Comparison of genotypes with MIC data for ST235 isolates 
All 55 MBL-producing ST235 P. aeruginosa isolates were resistant to most of the 
tested antibiotics (table 5.4); major exceptions being aztreonam, to which 64% of 
tested isolates were intermediate, and colistin, to which all isolates remained 
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susceptible. All 55 isolates were resistant to imipenem and meropenem, as well as 
ceftazidime, consistent with the presence of an MBL gene. Ciprofloxacin resistance 
was also seen in all these MBL-positive isolates, consistent with the GyrA (83:T-I) 
mutation. Five isolates (9%) remained susceptible to piperacillin-tazobactam; these 
carried blaIMP-7, blaIMP-14, blaIMP-26 or blaVIM-2 MBL genes. All isolates were resistant to 
the aminoglycosides gentamicin and tobramycin, but variable resistance was seen 
to amikacin to which 16/55 (29%) remained susceptible (n=5) or intermediate 
(n=11); this is despite 11 of these 16 isolates carrying variants of aacA4 or aac(6’)-31 
genes, which (if strongly expressed) are usually associated with amikacin 
resistance.25  
The two MBL-negative ST235 isolates were widely susceptible to tested antibiotics, 
exceptions being aztreonam (both isolates intermediate), meropenem (one isolate 
intermediate), and ciprofloxacin (one isolate resistant); the ciprofloxacin-resistant 
isolate had a mutation in gyrB (466:S-F), while the elevated meropenem MIC was 
likely due to mutations leading to reduced efflux and/or overproduction of the 
chromosomally-encoded AmpC β-lactamase.   
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Table 5.4: Antibiotic susceptibility of ST235 representatives subjected to WGS 
analysis 
 MBL-positive (n=55) MBL-negative (n=2) 
Antibiotic S I R NT S I R NT 
Amikacin 5 11 39 0 2 0 0 0 
Gentamicin 0 - 55 0 2 - 0 0 
Tobramycin 0 - 54 1 2 - 0 0 
Piperacillin-
tazobactam  
5 - 50 1 2 - 0 0 
Ceftazidime 0 - 54 1 2 - 0 0 
Aztreonam 0 34 19 2 0 2 0 0 
Imipenem 0 0 55 0 2 0 0 0 
Meropenem 0 0 55 0 1 1 0 0 
Ciprofloxacin 0 0 55 0 1 0 1 0 
Colistin 54 - 0 1 2 - 0 0 
S, susceptible; I, intermediate; R; resistant, NT; not tested 
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 WGS analysis of representatives of other ‘high-risk clones’ 5.3.3
Single representatives of ST233 (Paer_LW_109), ST357 (Paer_LW_197), ST654 
(Paer_LW_121) and ST773 (Paer_LW_167) were also sequenced. All carried the 
intrinsic resistance genes blaOXA-50, blaPAO (ampC), aph(3’)-IIb and catB7. Their 
acquired resistance gene content, shown in table 5.5, was variable; all 
representatives had blaVIM-2 and carried additional acquired resistance genes 
including those encoding resistance to β-lactams and aminoglycosides. All four 
representatives also had the GyrA (83:T-I) chromosomal mutation seen in ST111 
and ST235 isolates, with the ST773 representative having an additional mutation 
(457:S-T) in the QRDR of ParE (table 5.5). All four isolates were resistant to all tested 
antibiotics except for colistin, to which all remained susceptible, and aztreonam to 
which the ST773 isolate was intermediate.  
Table 5.5: Resistance determinants seen in single sequenced isolates belonging to 
ST233, ST357, ST654 and ST773 
Antibiotic ST233 ST357 ST654 ST773 
β-lactams blaOXA-1 
blaVIM-2 
blaOXA-10 
blaVIM-2 
blaVEB-1[v] 
blaVIM-2  
blaPME-1 
blaOXA-10 
blaVIM-2 
aminoglycosides aac(3)-Id[v] 
aadA2 
aadA3[v] 
aadA1* 
ant(2'')-Ia 
aph(3')-VIb[v] 
strB 
aac(6')-Ib[v] 
aadA1* 
 
trimethoprim dfrB5 dfrB2[v] - dfrB2[v] 
tetracycline tet(G) tet(A) tet(G)  
tet(A)[v] 
 
chloramphenicol cmlA1[v] 
 
- - cmlA1[v] 
sulphonamides sul1 sul1 sul1 sul1 
rifampicin - - - arr-2 
fluoroquinolones GyrA[83:T-I] 
 
GyrA[83:T-I] GyrA[83:T-I] GyrA[83:T-I] 
ParE[457:S-T] 
[v] indicates a variant of the given resistance gene 
* indicates that only fragment of the gene was detected 
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 Detection of CRISPR-cas genes 5.3.4
Illumina reads were mapped against type I-E and type I-F CRISPR-cas genes, as 
described in Section 5.2.3. For the 87 ST111 isolates, and 57 ST235 isolates 
(including MBL-positive and MBL-negative representatives) subjected to Illumina 
sequencing none of the reads mapped to any of the type I-E or type I-F CRISPR-cas 
genes. 
The single MBL-producing representatives of ST233 and ST357 had all seven type I-F 
CRISPR-cas genes (cas1, cas3, csy1, csy2, csy3, csy4); the ST773 representative had 
all six type I-E genes (cas2, cas1, cas6e/cse3, cas5, cas7, cse2 and cas3), and the 
representative of ST654 had all genes of both type I-E and type I-F CRISPR-Cas 
systems. The identified CRISPR-cas genes shared 99-100% nucleotide identity with 
the type I-E and type I-F genes from the RP73 (GenBank accession NC_021577) and 
PA14 (GenBank accession NC_008563) P. aeruginosa genomes, respectively, except 
for the cse1, cse2 and cas3 genes of the type I-E CRISPR-Cas system in the ST773 
representative, which shared 93% nucleotide identity with the reference sequences. 
To estimate the prevalence of these CRISPR-Cas systems in clinical P. aeruginosa, 
we screened 50 representatives randomly selected from the 209 isolates submitted 
as part of the BSAC Bacteraemia Surveillance Programme, 2011 (see also Sections 
2.1.2 and 3.3.3). These isolates were largely antibiotic susceptible and were diverse 
by VNTR typing, with few belonging to ‘high-risk clones’ (ST233, n=1 or ST235, n=2). 
Two PCRs were undertaken, targeting either the cse3 gene of type I-E, or the csy1 
gene of type I-F CRISPR-Cas systems, respectively, as described in section 5.2.3. 
Figure 5.7 shows the distribution of the detected genes among the 50 isolates. Ten 
215 
 
isolates (20%) yielded an amplicon using primers targeting the cse3 gene, indicating 
that they harboured a type I-E CRISPR-Cas system. A further 14 isolates (28%) were 
positive using primers targeting the csy1 gene, indicating that they carried a type I-F 
CRISPR-Cas system. One further isolate was positive for both PCRs, indicating that it 
had both type I-E and type I-F CRISPR-Cas systems. The remaining 25 isolates were 
negative by both PCRs. 
 
Figure 5.7: CRISPR-Cas systems detected among P .aeruginosa isolates from the 
BSAC Bacteraemia Resistance Surveillance Programme for 2011. The minimum 
spanning tree is based on clustering at the first eight VNTR loci for P. aeruginosa 
isolates. Coloured circles indicate whether genes representative of the CRISPR-Cas 
systems were detected by PCR for the 50 tested isolates, white circles indicate 
isolates that were not tested. The diameter of the circle is relative to the number of 
isolates with that VNTR profile. Grey shading indicates complexes. Thick solid lines 
represent single locus variants while thin solid lines and dotted lines represent 
multi-locus variants. Isolates corresponding to previously reported clones as 
described by Martin et al.115 are indicated and had the following VNTR profiles; 
Clusters A (8,3,4,5,2,3,5,2,x), D (10,3,5,5,4,1,3,x,x,), E (11,4,5,2,2,1,x,2,x) and H 
(12,5,1,5,2,2,x,x,x), Clone C (11,6,2,2,1,3,7/8,2/3,x), and PA14 (12,2,1,5,5,2,x,5,x). 
Two novel clusters are indicated with VNTR profiles 12,5,5,5,4,3,7,6,x and 
12,8,2,2,4,3,5,1,x respectively. See also figure 3.6. 
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5.4 Discussion 
SNP analysis was able to discriminate among members of the ST111 and ST235 
lineages, and revealed several different clusters and sub-clusters among 
representatives of both STs. These data, together with the epidemiological 
information indicate that separate introductions of these ‘high-risk clones’ had 
occurred in UK hospitals. However there was also evidence of spread within and 
between hospitals, indicated by closely related SNP clusters. The SNP analysis was 
consistent with VNTR and available epidemiological data, but provided 
discrimination between isolates that were identical by VNTR. 
Previous work (Chapter 3) had shown that the ST111 isolates shared the same or 
very similar VNTR types, dominated by large numbers of isolates from a few 
hospitals including London_17, London_9 and London_26, and with the majority 
carrying integron I (In59-like integrons), with blaVIM-2 and aacA29a and aacA29b 
genes. Some probable sub-clusters had already been identified based on a 
combination of the epidemiological and VNTR data, for example, ST111 isolates 
referred from London_26 (cluster 3a) all had a distinct VNTR type 
(11,3,4,3,2,2,6,4,7) and this was confirmed as a tight cluster by the SNP analysis. 
The WGS data however also allowed further subdivision of many isolates with 
identical VNTR types. In particular it confirmed that blaIMP-carrying and MBL-
negative ST111 representatives were only distantly related to those carrying blaVIM-2 
as part of integron I.   
The ST235 P. aeruginosa strains were more diverse than ST111 isolates in terms of 
VNTR typing; they also (unlike the vast majority of the ST111 isolates) had MBL-
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containing integrons of different sizes, carried various blaVIM and blaIMP MBL alleles, 
and were isolated at many different times and places, with representatives received 
from no more than seven patients at a single site. This diversity was confirmed by 
the large variation seen between most isolates by SNP analysis and the huge range 
of acquired resistance genes present, suggesting that ST235 strains have repeatedly 
acquired different MBL genes.  
P. aeruginosa strains can cause prolonged outbreaks, suggesting that there are 
hidden environmental reservoirs, acting as sources of infection.18,218 A notable 
example here is the previously discussed (Sections 3.4 and 4.4) nine-year 
persistence of a ST111 strain at London_17, which was attributed to contamination 
of the waste-water system.157 There was considerable sequence diversity among 
isolates received from London_17 (up to 35 SNPs between isolates) consistent with 
repeated patient infections from a wider environmental source, with a diverse 
ST111 population. Environmental isolates were also studied here from outbreaks of 
ST111 organisms at London_9 and London_26 and these clustered closely with 
patient representatives from the same hospital. However, as with the London_17 
environmental isolates, they were generally cultured from hospital sinks and sink 
drains, and so it is unclear whether these represent sources of infection or 
environmental contamination from the patients.  
Aside from environmental reservoirs, it is also possible that long-term 
asymptomatic colonisation of patients could be a hidden reservoir of these 
organisms. P. aeruginosa is not thought to be a member of the normal human flora, 
with any colonisation being only transient (with the exception of patients with 
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chronic respiratory colonisations, as is seen in cystic fibrosis). However, in this 
study, three patients appeared to carry the same ST235 or ST111 strain, closely 
related by SNP analysis, over periods of one to four years, although it also remains 
possible that these patients were re-infected with a very similar strain. Assuming 
that these three patients had become colonised, the inferred mutation rates were 
approximately 1.3, 4.5 or 13 SNPs/year; two of these were higher than a previous 
estimate of the mutation rate of P. aeruginosa (2.6 SNPs/year),234 but it still seems 
plausible that they resulted from a single colonisation event when considering the 
selection pressures that may be acting on bacteria adapting to the human host, and 
that patients could be initially colonised with a mixed population.  Any such long-
term colonisation could confound attempts to find epidemiological links between 
patients as a strain could be acquired and carried asymptomatically for a long time 
before it was detected. For example, in a three-year outbreak of IMP-8-producing 
ST308 P. aeruginosa at a German hospital,235 two closely-related strains, differing by 
only one SNP, were isolated from different patients in 2009 and 2011, respectively. 
The patients had consecutively stayed in the same room in 2009 and the authors 
suspected that the transfer of the strain had occurred in 2009, with the second 
patient remaining colonised over the following two years, only detected when the 
patient was re-admitted to the hospital in 2011.  
In addition to spread of ST111 and ST235 strains within a hospital, there was 
evidence of spread occurring between different hospital sites. For example, ST111 
cluster 3 isolates were received from multiple London and South East England 
hospitals. Although there were known patient transfers between some of these 
hospitals, for example between London_26 and London_28, and between London_9 
219 
 
and London_11, in many cases no epidemiological links were identified, albeit based 
on incomplete information about patient transfers, which are often not notified for 
isolates sent to the reference laboratory. 
In general, isolates that were referred from the same hospital clustered together by 
SNP analysis and shared similar resistance determinants, supporting the view that 
they were closely related. However, in a few cases the SNP analysis clearly indicated 
that representatives from the same hospital, which might otherwise have been 
considered part of the same outbreak, were genetically distinct. For example, four 
ST111 blaVIM-2-positive isolates received from London_28 during 2012 shared the 
same VNTR type or differed by one repeat at a single VNTR locus, but were 
dispersed across the SNP tree indicating that the infections were acquired from 
different sources. Another example concerned ten blaVIM-positive ST235 isolates 
submitted from seven patients at London_7 between 2007 and 2010. As discussed 
in Section 4.4, two different VNTR types and five different blaVIM-containing 
integron profiles were seen among these ten isolates leading us to suspect that they 
were likely from different sources. SNP analysis confirmed that these isolates were 
diverse, with four different sub-clusters, each from one to three patients spread 
across the SNP tree, and with each sub-cluster harbouring a distinct set of acquired 
resistance genes. They included three isolates received from different patients over 
a four-month period in 2010, with these belonging to clusters 2, 3 and 4; SNP 
analysis thus confirmed that these infections likely resulted from independent 
acquisitions of different ST235 strains rather than spread within the hospital.  
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The MBL-producing ST111 and ST235 isolates were resistant to the majority of 
antibiotics tested and the susceptibility patterns generally correlated with the 
presence of acquired genes for the β-lactam antibiotics, or (where these data were 
available) mutations affecting the GyrA, GyrB or ParE proteins, for ciprofloxacin. 
Resistance to aminoglycosides, particularly to amikacin and gentamicin, was more 
variable and was not completely explained by the presence of acquired resistance 
genes, as isolates carrying the same set of resistance determinants often had 
differing susceptibility patterns. For example ST111 isolates carrying integron I had 
variable susceptibility to gentamicin and amikacin. Where aminoglycoside 
resistance was present in the absence of any acquired genes known to confer such 
resistance it is likely that other factors are contributing to this variable 
aminoglycoside resistance, such as mutations affecting efflux, or cytoplasmic 
membrane transport.  On the other hand, isolates that retained susceptibility 
despite carrying genes known to confer resistance to a particular aminoglycoside 
(e.g. the 17/62 ST111 isolates carrying aacA29a/b as part of integron I that 
remained susceptible to amikacin), the acquired resistance genes may be poorly 
expressed.   
PCR analyses showed that 50% of tested isolates from the BSAC Bacteraemia 
Surveillance Programme (n=50) harboured at least one CRISPR-Cas system, which 
was in the same range as previous studies (39-54%).169,226 By contrast, type I-E or 
type I-F cas genes were not present in any of the 87 ST111 or 57 ST235 genome 
sequences, consistent with a previous study.30 It is possible that the lack of CRISPR-
Cas systems may contribute to the ability of ST111 and ST235 ‘high-risk clones’ to 
acquire new genetic material. However, as these CRISPR-Cas systems are only 
221 
 
present in around 50% of P. aeruginosa isolates generally, and since representatives 
of other ‘high-risk clones’ (STs 233, 357, 654 and 773) did carry them, additional 
factors must be involved in their clonal success and accumulation of resistance. 
CRISPR-Cas is just one of several known bacterial defence systems that may interact 
with each other to protect against exogenous DNA elements; these include 
restriction-modification, toxin-antitoxin, abortive-infection and phage-exclusion 
systems.236–238 More research is needed into the action of these systems, how they 
interact with mobile DNA elements, and whether they are less prevalent or act 
differently in ‘high-risk clones’.  
In summary, WGS analyses of isolates belonging to the ‘high-risk clones’ of ST111 or 
ST235 provided increased resolution between representatives of these lineages 
compared with VNTR and MLST. The analysis additionally allowed aspects of the 
bacterial biology to be explored, including the large diversity of resistance 
determinants seen among the isolates. Using WGS analysis in real-time will be 
useful to inform epidemiological investigations, particularly in helping to identify 
probable sources of infection so that hospitals and public health bodies can better 
target effective interventions to limit their spread. 
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6 Conclusions and future work 
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Increasing numbers of MBL-producing P. aeruginosa isolates were referred to 
AMRHAI from UK hospitals over recent years (figure 3.1). The aim of this work was 
to investigate the molecular epidemiology of these organisms and to elucidate to 
what extent their MBL genes may be transferred between strains.  It is important to 
have a better understanding of these multi-drug resistant organisms in order to 
identify effective infection prevention and control strategies to limit their future 
spread. The overall findings and implications of the research presented in this thesis 
will be discussed in this chapter, along with suggestions for future work. 
6.1 Main conclusions 
We found that internationally-recognised ‘high-risk clones’ (namely STs 111, 235, 
233, 357, 654 and 773) were important in the accumulation of MBL-producing P. 
aeruginosa in the UK, accounting for 86% of all such isolates referred to AMRHAI. 
This included isolates from 71 hospital laboratories, most of which did not have 
substantial outbreaks. Diverse ST and VNTR types were represented among the 
remaining 14% of MBL producers, indicating independent acquisition of MBLs by 
sporadic types. Whilst MBL-producing P. aeruginosa were rare at most of the 
referring laboratories, a few hospitals did have more persistent problems lasting up 
to nine years. These included long-term persistence of single strains at some 
hospitals, such as the nine-year ‘outbreak’ of an ST111 organism at London_17. 
Other laboratories referred isolates of diverse types, for example, London_7 
submitted 19 MBL-positive isolates over seven years belonging to STs 111, 235, 233 
and 654, indicating that independent introductions of MBL-producing strains had 
probably occurred.  
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Comparison with a collection of largely antibiotic-susceptible isolates from the BSAC 
Bacteraemia Surveillance Programme in 2011 indicated that these ‘high-risk clones’, 
though strongly represented among MBL producers, were not  prevalent generally 
among P. aeruginosa isolates from serious infections in the UK and Ireland. Rather, 
these lineages seem to represent a distinct subset of P. aeruginosa that are better 
able to acquire and/or maintain whatever resistance genes they may encounter. 
This view is supported by (1) the presence of various MBL genes, including different 
blaVIM and blaIMP alleles, in representatives of each high-risk lineage in this study 
and/or internationally, (2) the range of integron structures reported among most of 
the ‘high-risk clones’ in this study and/or internationally and (3) the varied acquired 
resistance genes detected among ST111 and particularly ST235 isolates by WGS.  
To better understand potential reasons underlying this increased ability to acquire 
and/or maintain resistance genes, the genetic context of the MBL genes were 
studied. The blaVIM and blaIMP genes were located within class 1 integrons (as is 
typical for these genes) and, in representatives of most of the common lineages, 
these integrons were chromosomally located. The genetic environment of blaVIM-2-
containing integrons was characterised fully for representatives of STs 111, 233 and 
235, and, in all cases, they were found within large chromosomally-located genomic 
islands. PCR indicated that most or all members of each lineage (STs 111, 233 or 
235) had insertions of a similar genomic island structure at the same genome 
position, even when the organisms carried different integrons. This observation 
suggests that members of the ‘high-risk clones’ may share stable lineage-specific 
chromosomally-located genetic platforms that can acquire varied resistance genes, 
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via the class 1 integrons that each genomic island encodes. This feature is likely to 
contribute to the success of these lineages in acquiring diverse resistance genes.  
Another feature suggested to contribute to the success of ‘high-risk clones’30,223 is 
the absence of bacterial defence systems against exogenous DNA, such as CRISPR-
Cas, leading to increased invasion by foreign DNA elements such as plasmids and 
bacteriophage. This theory was explored here, and the CRISPR-Cas systems 
previously described in P. aeruginosa were found to be absent from ST111 and 
ST235 representatives, indicating that this could be a factor in the success of these 
particular clones. However, CRISPR-Cas systems were present in only around 50% of 
P. aeruginosa in our BSAC Bacteraemia Surveillance Programme comparator 
collection from 2011, and were present in the other ‘high-risk clones’ (STs 233, 357, 
654 and 773). These observations suggest that the lack of CRISPR-Cas is unlikely to 
be a major determinant of all ‘high-risk clones’. 
Finally, the use of WGS to discriminate among otherwise-indistinguishable members 
of ‘high-risk clones’, was explored. Increased discrimination was seen between 
members of the same ‘high-risk clone’ using WGS analyses and varied resistance 
determinants were identified. This method, together with existing epidemiological 
data, helped to identify cases of probable cross-transmission between hospitals, as 
well as strains that were likely acquired from independent sources at the same 
hospital. This kind of investigation applied in real-time is likely to aid outbreak 
investigations as well as long-term surveillance of multi-drug resistant organisms. 
For example, recent studies have used WGS to identify probable sources of P. 
aeruginosa infections in real-time in a newly-opened hospital,217 and to identify the 
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likely source of an Australian ST253 P. aeruginosa outbreak in a neo-natal intensive 
care unit as a sink,218 informing infection control interventions in near real-time.  
Better understanding of the way in which these organisms spread within and 
between hospitals, and how they acquire resistance genes, has implications for 
their control in hospitals. Where there is an environmental source, interventions to 
decontaminate, and prevent recolonisation of such reservoirs are necessary. This 
could include regular flushing of hospital taps, or the use of basins with back 
outlets, rather than the conventional bottom outlet, to minimise the creation of 
bacterial aerosols from the drain.239 On the other hand, repeated import of diverse 
strains would require early detection of such organisms, possibly by screening of 
patients considered to be at-risk; this could include patients known to have been 
previously colonised with MBL-producing P. aeruginosa or hospitalised where there 
are known problems, either in the UK, or abroad (e.g. in Russia, or India). 
6.2 Future work 
This work strongly suggests that ‘high-risk clones’ have an increased ability to 
acquire and/or maintain resistance genes. Future studies should be conducted to 
test this observation, for example by determining whether ‘high-risk clones’ have 
increased transformation of resistance genes, by conjugation or electroporation, 
compared to other P. aeruginosa strains, and/or whether they have higher levels of 
retention of such genes over time.  
In addition, the biological reasons for the ‘high-risk clones’ prevalence among multi-
drug resistant clones should be elucidated. This work suggests that ‘high-risk clones’ 
such as ST111, ST235 and ST233 may carry lineage-specific chromosomal platforms, 
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known as genomic islands, that enable them to capture diverse resistance 
elements, and this could be part of the reason for their success. Studies, including 
the work presented here, are only recently beginning to elucidate the genetic 
context of integrons within transposons, genomic islands and mobile genetic 
elements, either as part of plasmids or in the bacterial chromosome.89,147,181,182 
Long-read sequencing technologies such as MinION or PacBio should facilitate 
characterisation of resistance-associated genomic islands and their association with 
‘high-risk clones’.  
It remains possible that absence, modification or downregulation of systems that 
defend bacteria against exogenous DNA may contribute to the ability of ‘high-risk 
clones’ to acquire and maintain resistance genes. Although the absence of CRISPR-
Cas systems does not seem to be a common feature of all ‘high-risk clones’ in our 
collection, other bacterial defence systems against exogenous DNA, such as 
restriction-modification, toxin-antitoxin, abortive-infection, and phage-exclusion 
systems could be involved.236–238 Further study of the function, regulation, and 
interactions of these anti-DNA bacterial defence systems, as well as of their 
prevalence and distribution in P. aeruginosa (and specifically in ‘high-risk clones’) is 
needed to better understand the contribution they may make to the success of 
high-risk lineages. 
While previous work has identified phenotypic features including reduced motility, 
increased biofilm formation and reduced in vitro fitness in which ‘high-risk clones’ 
(STs 111, 175, and 235) may differ240 it is difficult to understand how these features 
might lead to increased acquired resistance. Further work is thus required to 
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elucidate the precise reasons why ‘high-risk clones’ are successful, which may differ 
from one lineage to another. Comparative genomics studies should help to identify 
particular genes that are specific to or absent in these ‘high-risk clones’ compared 
with other P. aeruginosa strains and should be facilitated by the increasing 
availability of WGS sequencing data for diverse P. aeruginosa. Transcriptomics 
methods such as RNASeq could also be used to determine whether there are any 
differences in gene expression in ‘high-risk clones’ compared with other lineages 
that do not commonly harbour resistance genes. One recent study using this 
approach revealed varied gene expression profiles among diverse K. pneumoniae 
isolates, including a specific transcription profile associated with the ST258 ‘high-
risk clone’.241   
Rapid tests, such as PCRs, to detect ‘high-risk clones’ may be useful in hospitals to 
quickly identify these potentially multi-drug resistant organisms in clinical and 
surveillance specimens, thereby allowing rapid implementation of appropriate 
infection control measures. This may be particularly useful in hospitals and regions 
where a particular clone is widespread, for example the VIM-2-producing ST111 
clone that persisted at London_17 over a nine years, in this work, or the ST235 
clone producing VIM-2 that is prevalent in Russia, Belarus and Kazakhstan.136 
MALDI-TOF was recently shown to have potential in distinguishing between 
different clones, including STs 111 and 235.242 In addition, WGS methods should 
facilitate the identification of specific genes associated with particular ‘high-risk 
clones’, and these could be used as PCR targets, facilitating detection.  
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Finally, more work is needed to better understand where the reservoirs of multi-
resistant P. aeruginosa lie in hospitals. These may include environmental 
contamination of plumbing systems and/or medical equipment (e.g. ventilators), or 
long-term colonisation of patients themselves. Real-time investigation of outbreaks 
using the increased resolution that is offered by WGS should help us to better 
understand these reservoirs, as well as the routes of transmission of P. aeruginosa 
between patients and environmental sources. This should enable early 
implementation of appropriate infection control measures in an outbreak situation. 
6.3 Summary 
Overall, this research has shown that ‘high-risk clones’ are important in the spread 
of MBL-producing P. aeruginosa in the UK. The success of these clones is likely to be 
due to multiple factors, which may include the association with particular genomic 
islands or the absence of host defence mechanisms against exogenous DNA 
elements. Future work should focus on further elucidating the reasons for the 
success of these clones, to better understand how to limit the spread of these 
multi-drug resistant organisms.   
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7 Abbreviations 
AAC; aminoglycoside acetyltransferase  
AIM; Adelaide Imipenemase 
AME; aminoglycoside-modifying enzyme 
AMRHAI; Antimicrobial Resistance and Healthcare-Associated Infections Reference 
Unit 
ANT; aminoglycoside nucleotidyltransferase 
APH; aminoglycoside phosphotransferase  
Arr; rifampicin ADP-ribosyltransferase 
BAM; binary alignment map 
BSAC; British Society for Antimicrobial Chemotherapy 
Cas; CRISPR-associated proteins 
cas; CRISPR-associated genes 
cat; chloramphenicol acetyltransferase 
cml; chromamphenicol efflux protein 
CRISPR; clustered regularly interspaced short palindromic repeats 
Dfr: dihydrofolate reductase  
ECDC; European Centre for Disease Prevention and Control 
ESBL; extended-spectrum β-lactamase 
FIM; Florence imipenemase  
GES; Guiana extended-spectrum (β-lactamase) 
GIM; German imipenemase 
ICE; integrative and conjugative elements 
IME; integrative and mobilisable elements 
IMP; imipenemase 
IS; insertion sequence 
ISCR; insertion sequence common regions 
KPC; Klebsiella pneumoniae carbapenemase  
LPS; lipopolysaccharide 
MBL; metallo-β-lactamase 
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MIC; minimum inhibitory concentration 
MLST; multi-locus sequence typing 
NDM; New Delhi metallo-β-lactamase 
OXA; oxacillin-hydrolysing (β-lactamase) 
PER; Pseudomonas extended resistance (β-lactamase) 
PFGE; pulsed-field gel electrophoresis 
PHE; Public Health England 
PSE; Pseudomonas-specific enzyme (β-lactamase) 
QRDR; quinolone resistance determining region 
SIM; Seoul imipenemase 
SNP; single nucleotide polymorphism 
SPM; Sao Paulo metallo-β-lactamase 
ST; sequence type 
TEM; Temoneira (β-lactamase) 
VCF; variant calling format 
VEB; Vietnam extended-spectrum β-lactamase 
VIM; Verona integron-encoded metallo-β-lactamase 
VNTR; variable number tandem repeat  
WGS; whole genome sequencing  
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